

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:41:48 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 22, 2020 2:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Erbeling, Emily (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

From: "Folkers, Greg (NIH/NIAID) [E]" (b) (6)
Date: February 18, 2020 at 3:07:21 PM EST
Subject: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

FOR IMMEDIATE RELEASE
February 18, 2020
Contact: ASPR Press Office
202-205-8117
asprmedia@hhs.gov

HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi. The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

"Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease," said BARDA Director Rick A. Bright, Ph.D. "Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks."

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing [manufacturing capacity](#) for recombinant influenza vaccine in the United States, in accordance with a [presidential executive order](#) to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government

launched a single point-of-entry [website](#) for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.

Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA). BARDA also opened an easy broad agency announcement, an [EZ-BAA](#), specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVE brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security. To learn more about preparing for and responding to public health emergencies, from new infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health emergency website, www.phe.gov. For more information on partnering with BARDA on developing medical countermeasures, visit www.medicalcountermeasures.gov, and for more on DRIVE, visit drive.hhs.gov.

###

Note: All HHS press releases, fact sheets and other news materials are available at <https://www.hhs.gov/news>.

Like [HHS on Facebook](#) [👉](#), follow HHS on Twitter [@HHSgov](#) [👉](#), and sign up for [HHS Email Updates](#).

Last revised: February 18, 2020

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:41:42 +0000
To: David Willman
Subject: FW: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

David:

See press release below regarding BARDA and Sanofi.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 22, 2020 2:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Erbeiding, Emily (NIH/NIAID) [E] (b) (6)
Subject: Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

From: "Folkers, Greg (NIH/NIAID) [E]" (b) (6) >
Date: February 18, 2020 at 3:07:21 PM EST
Subject: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

FOR IMMEDIATE RELEASE
February 18, 2020
Contact: ASPR Press Office
202-205-8117
asprmedia@hhs.gov

HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi. The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

"Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease," said BARDA Director Rick A. Bright, Ph.D. "Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks."

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing [manufacturing capacity](#) for recombinant influenza vaccine in the United States, in accordance with a [presidential executive order](#) to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in

development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government launched a single point-of-entry [website](#) for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.

Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA). BARDA also opened an easy broad agency announcement, an [EZ-BAA](#), specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

About HHS, ASPR, and BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVE brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security. To learn more about preparing for and responding to public health emergencies, from new infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health emergency website, www.phe.gov. For more information on partnering with BARDA on developing medical countermeasures, visit www.medicalcountermeasures.gov, and for more on DRIVE, visit drive.hhs.gov.

###

Note: All HHS press releases, fact sheets and other news materials are available at <https://www.hhs.gov/news>.

Like [HHS on Facebook](#) , follow HHS on Twitter [@HHSgov](#) , and sign up for [HHS Email Updates](#).

Last revised: February 18, 2020

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:39:17 +0000
To: Kevin Thurm
Subject: RE: Thanks

Kevin:

Many thanks for your kind note. Much appreciated. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kevin Thurm (b) (6) >
Sent: Saturday, February 22, 2020 12:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Thanks

Tony

Good afternoon.

Just wanted to write and say how much I deeply appreciate your on-going public service; you've made extraordinary contributions over the course of your career and, as I've watched you on TV in the context of the current public health threat of the coronavirus, I know you're continuing to do so...

No need to respond; you have a lot going on.

From one citizen and a former colleague, extending my thanks and deep appreciation.

Best wishes.

Kevin Thurm

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:36:40 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: For review: ASM presentation for 26Feb2020
Attachments: ASM Public and Scientific Affairs Committee Meeting 2nd FINAL for 26Feb2020.pptx

I mistakenly put it into my Documents. Here it is, and I will put it into the OD now

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 22, 2020 2:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: For review: ASM presentation for 26Feb2020

I don't see it in OD

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 22, 2020 1:49 PM
To: Schneider, Johanna (NIH/NIAID) [E] <(b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: For review: ASM presentation for 26Feb2020

This is now "2nd FINAL" in the OD folder. You just need to remove the instruction slides and do the required updates on several of the slides and then it is ready to go. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schneider, Johanna (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 4:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: For review: ASM presentation for 26Feb2020

Dr. Fauci,
Attached is the presentation to the American Society for Microbiology (ASM) Public and Scientific Affairs Committee on Wednesday Feb 26th.

The topics they have expressed interest in are:

- NIAID Budget Request FY2021
- Novel Coronavirus
- Progress on a Universal Flu Vaccine

The talk is 30 minutes plus 15-20 for discussion.

I've scheduled 30 minutes Monday morning at 10AM to review the slides with you as well.

The presentation has been uploaded to the shared drive. As indicated we will update the necessary slides on Monday afternoon before sending them to ASM on Tuesday.

Thanks,
Johanna

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 19:33:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: Question

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 22, 2020 2:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6) >
Subject: Re: Question

Hi Dr. Fauci,

This effort is completely driven by BARDA. DMID is not involved.

Cristina

On Feb 22, 2020, at 2:18 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Cristina:

What is the relationship that we (DMID/NIAID) has with Sanofi in the development of a coronavirus vaccine? Are we funding them? Do we

have any agreement with them to develop a coronavirus vaccine, or is it BARDA who is dealing with them?

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 18:32:37 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Nabel NAS nomination
Attachments: (b) (6) 2020 NAS Nomination - Section 44 - 02-22-2020.docx

Bob:

Here is (b) (6) NAS nomination. Let us touch bases on Monday to get it uploaded to the website.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:08:16 +0000
To: Marlene Colucci
Cc: David Rubenstein;Ginni Rometty;Donahoe, John
Subject: RE: Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!

Marlene: Thanks for the note. It was my pleasure, and I never miss an opportunity to interact with David. He is an incomparable interviewer.

Best,
Tony

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Friday, February 21, 2020 2:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: David Rubenstein (b) (6); Ginni Rometty (b) (6); Donahoe, John (b) (6)>
Subject: Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!

Dr. Fauci,

We wanted to send a quick note to thank you for joining us today. Your discussion with David was so interesting and well received.

The coronavirus alone was on the minds of so many CEOs as it impacts their supply chain.

David, it goes without saying that you are the best interviewer! You make everything substantive and entertaining.

Wishing everyone an enjoyable weekend!

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR



T: 202-298-7650
C: (b) (6)
F: 202-785-0296

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:06:21 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: CoVid-19 in Infants

Please handle.

----- Original Message -----

From: JF K [REDACTED] (b) (6) >
Sent: Friday, February 21, 2020 2:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: CoVid-19 In Infants

Dr. Fauci,

Infants and children infected with CoVid-19 seem to be an anomaly. Could it be as simple as childhood vaccinations? Are Chinese children vaccinated with anti malarial drugs such as Chloroquine phosphate, which is proving effective in older patients for CoVid-19?

If infants and children are not getting severe infections, why?

Jonathan F. King

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 14:00:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers (GFOLKERS@niaid.nih.gov)
Subject: FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

fyi

From: Kevin Bowen <kbowen@iasusa.org>
Sent: Friday, February 21, 2020 6:31 PM
To: Donna Jacobsen <djacobsen@iasusa.org>; Zunyou Wu (b) (6); Brooks, John T (CDC/DDID/NCHHSTP/DHPSE) (b) (6); Baric, Ralph (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Sharon Hillier PhD (b) (6); El-Sadr, Wafaa M. (b) (6); Schooley, Robert (b) (6); Schooley, Chip (b) (6); Eron, Joseph J Jr (b) (6); Genesis Regalado (b) (6); Baric, Toni C (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

Dear CROI Speakers and Moderators:

We would like to schedule a planning call for next week to COVID-19 session at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). Please submit your availability using the poll at <http://whenisgood.net/ksy42az>. The poll should automatically adjust to your local time zone, but you can adjust the setting using the "Select your location" dropdown if needed.

We will confirm the call as soon as possible.

Regards,

Kevin Bowen
Program Director
CROI Scientific Program and IAS-USA Production

From: Donna Jacobsen
Sent: Friday, February 21, 2020 1:37 PM
To: Zunyou Wu (b) (6); John T. Brooks MD (b) (6); Baric, Ralph S (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Sharon Hillier PhD (b) (6); El-Sadr, Wafaa M. (b) (6); Kevin Bowen <kbowen@iasusa.org>; Schooley, Robert (b) (6) 'Robert T. Schooley, MD (b) (6); Eron, Joseph J Jr (b) (6); Kevin Bowen <kbowen@iasusa.org>; Genesis Regalado <regalado@iasusa.org>; Baric, Toni C

(b) (6) >; Conrad, Patricia (NIH/NIAID) [E]

(b) (6) >

Subject: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Dear Drs Wu, Brooks, Baric, and Fauci:

It is more than incredibly impressive at how all of you, in just the past few days, have rearranged your schedules and agreed to participate in this special session in only about 2 weeks. We are all very grateful, and know this will be tremendously impactful for the CROI audience.

Below is the final list of presentations, although the order and titles may well change. We are hoping to have a conference call with the session liaisons and speakers next week if possible, to go over each of the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for availability for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it; things are moving quickly.

Many thanks again,

All of us at CROI

SPECIAL LUNCHTIME SESSION ON COVID 19

Tue, 3/10, 12:10 PM - 1:20 PM EASTERN DAYLIGHT TIME

Auditorium

Preliminary Session Agenda (Order and talk titles to be confirmed)

1. FOCUS ON THE EPIDEMIOLOGY OF COVID-19 AND EFFORTS IN CHINA
 - a. Ziyun Wu, Chinese Center for Disease Control, China
15 minute live video (Skype or Zoom) update from China
2. FOCUS ON THE GLOBAL EPIDEMIOLOGY OF COVID-19 AND EFFORTS TO CONTROL THE OUTBREAK
 - a. John Brooks, US Centers for Disease Control, USA
15 minute update
3. FOCUS ON THE VIROLOGY OF CORONAVIRUSES OVERALL, MOLECULAR ASPECTS OF TRANSMISSION TO HUMANS, PATHOGENESIS IN MICE MODELS AND PARALLELS IN HUMANS, ETC.
 - a. Ralph Baric, University of North Carolina, USA
25 minute lecture
4. FOCUS ON MIDDLE EASTERN EFFORTS TO STUDY NOVEL CORONAVIRUSES AND DEVELOP DIAGNOSTICS, THERAPEUTICS, AND VACCINES
 - a. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
15 minute recorded update

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:13:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Triple E letter

Let us discuss. Likely no.

-----Original Message-----

From: Bridbord, Ken (NIH/FIC) [V] (b) (6) >
Sent: Friday, February 21, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Marietta Ethier (b) (6); Emily Lane <ELane@ (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Triple E letter

Tony, my condominium community has established a program in which prominent members of the Washington area are invited to make presentations on subjects of great public interest. Shown in the email below is a description of this program. In this regard I have been asked to contact you to see, recognizing your incredibly busy schedule, if you would be interested and able to provide an update on the Coronavirus situation to our residents. Most likely you (b) (6) If you have a potential interest in sharing your great expertise on this subject with our residents could you please have your staff contact Emily Lane who is copied on this email to explore possible dates and times that would work for you. Thank you so much for your consideration of this request. Ken

On 2/21/20, 3:36 PM, "Emily Lane" <ELane@ (b) (6)> wrote:

Dear Ken,

The (b) (6) Committee greatly appreciates your willingness to approach Dr. Anthony Fauci on our behalf, asking him to address the residents of the (b) (6) on the Coronavirus. It would perhaps be helpful to Dr. Fauci, to explain who we are and what we do. (b) (6), (b) (6)

The (b) (6) Committee was formed recently to create and organize events to educate, enlighten and entertain members of the Somerset community. A few weeks ago (b) (6) spoke to a sold out crowd on impeachment. We've featured authors on a variety of topics; invited doctors with specialties of interest to our community organized trips to the Kennedy Center and theaters for attendance at ballets and plays and sponsored visits, led by experts, to various museums and the Library of Congress to view special exhibitions. An example of the latter is a tour of the Folger Library (b) (6). A presentation by Dr. Fauci on the coronavirus would be of great interest to our constituency who keep informed by reading both national and international journals. We are flexible on the date for such an appearance needing only a few days' notice to inform our residents.

I need not tell you that it would our great honor to welcome Dr. Fauci to the (b) (6).

Sincerely

[Redacted signature block]

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:08:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

I totally agree. I do not want to be on a "session planning" call. Please have Hilary do this as suggested by Patty since she is preparing the talk. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Friday, February 21, 2020 4:44 PM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Since this is a taping for his remarks – can hilary do this call since she is doing the slides? hate to waste ASF time on this with all our other moving parts....just a thought.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Friday, February 21, 2020 4:37 PM
To: Zunyou Wu (b) (6)>; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) (b) (6)>; Baric, Ralph (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Sharon Hillier PhD (b) (6)

(b) (6) El-Sadr, Wafaa M. (b) (6); Kevin Bowen
(b) (6); Schooley, Robert (b) (6); Schooley, Chip
>; Eron, Joseph J Jr >; Kevin Bowen
>; Genesis Regalado (b) (6); Baric, Toni C
(b) (6), Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Subject: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time
Importance: High

Dear Drs Wu, Brooks, Baric, and Fauci:

It is more than incredibly impressive at how all of you, in just the past few days, have rearranged your schedules and agreed to participate in this special session in only about 2 weeks. We are all very grateful, and know this will be tremendously impactful for the CROI audience.

Below is the final list of presentations, although the order and titles may well change. We are hoping to have a conference call with the session liaisons and speakers next week if possible, to go over each of the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for availability for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it; things are moving quickly.

Many thanks again,

All of us at CROI!

SPECIAL LUNCHTIME SESSION ON COVID-19
Tue, 3/10: 12:10 PM - 1:20 PM EASTERN DAYLIGHT TIME
Auditorium

Preliminary Session Agenda (Order and talk titles to be confirmed)

1. **FOCUS ON THE EPIDEMIOLOGY OF COVID-19 AND EFFORTS IN CHINA**
 - a. **Qiyun Wu**, Chinese Center for Disease Control, China
15-minute live video (Slip or Zoom) update from China
2. **FOCUS ON THE GLOBAL EPIDEMIOLOGY OF COVID-19 AND EFFORTS TO CONTROL THE OUTBREAK**
 - a. **John Brooks**, US Centers for Disease Control, USA
15-minute update
3. **FOCUS ON THE VIROLOGY OF CORONAVIRUSES OVERALL, MOLECULAR ASPECTS OF TRANSMISSION TO HUMANS, PATHOGENESIS IN MICE MODELS AND PARALLELS IN HUMANS, ETC**
 - a. **Ralph Baric**, University of North Carolina, USA
25-minute lecture
4. **FOCUS ON NIAID/NIH EFFORTS TO STUDY NOVEL CORONAVIRUSES AND DEVELOP DIAGNOSTICS, THERAPEUTICS, AND VACCINES**
 - a. **Anthony Fauci**, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA
15-minute recorded update

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 12:06:10 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: DEAR TONY: CORONAVIRUS

Please handle.

From: Dr. Michael Jacobs [REDACTED] (b) (6) >
Sent: Friday, February 21, 2020 6:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Alexander Tarakhovsky [REDACTED] (b) (6); Lockshin, Michael MD [REDACTED] (b) (6); Dr. Michael Jacobs [REDACTED] (b) (6) >
Subject: DEAR TONY: CORONAVIRUS

dear tony:

i am a cornell medical school cumc [REDACTED] (b) (6) graduate. i am associate professor of dermatology at weill-cornell in private practice. [REDACTED] (b) (6)
[REDACTED] alexander tarakhovsky is [REDACTED] (b) (6) and a professor at rockefeller university. he is a virologist.

we have been following the corona virus pandemic closely, and a few days ago became alarmed at the news that the chinese government is sterilizing their paper money from hubei province.

we think that there is a possibility that the virus was released from a lab in wuhan, the biotech area of china. we also think that the virus might be complexed with another organism, such as a yeast or fungus, to make it more sticky.

we would like to discuss this with you further. we feel that immediate action must be taken by united states scientists to try to neutralize this threat.

please contact alexander and me at your earliest convenience at above emails or my mobile [REDACTED] (b) (6) or office [REDACTED] (b) (6) michael lockshin gave me your email.

with kind regards

michael jacobs

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:49:36 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus
Attachments: Cai & Garen 1995.pdf, Cai & Garen 1996 .pdf, Cai & Garen 1997.pdf

Please handle. Thanks.

From: Garen, Alan [REDACTED] (b) (6) >
Sent: Friday, February 21, 2020 7:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Garen, Alan [REDACTED] (b) (6) >
Subject: coronavirus

Dear D. Fauci,

I want to suggest that NIAID arrange to collect serum samples from Coronavirus patients who have survived a major infection and probably have generated antiviral antibodies. My laboratory showed in the attached papers that such antibodies could be cloned from sera using a powerful technology called Phage Display. The project could be initiated in this country with as few as 2 patients.

Sincerely, Alan Garen, Yale University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:39:57 +0000
To: Antoniak, Cynthia (NBCUniversal, MSNBC)
Cc: Goldner, Shannah (NBCUniversal); Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: MSNBC Reconfirming

No problem. See you then.

From: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Sent: Saturday, February 22, 2020 6:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: MSNBC Reconfirming

If you could get there by 7:30am...that would be great!

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, February 22, 2020 6:38 AM
To: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: [EXTERNAL] RE: MSNBC Reconfirming

I have received this e-mail and confirm 7:45 AM hit. What time do you want me at the studio?

From: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Sent: Saturday, February 22, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: MSNBC Reconfirming

Good Morning Dr. Fauci,

I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori Coffin.

You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.

Topics:

-Coronavirus-infected Americans flown home against CDC advice

https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4fa9bac6674f_story.html

-Decision to quarantine cruise ship—was that a misstep?

-Long term effects of decision to bring U.S. passengers back

Please reply that you got this.
Thank you!
Cyndi

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 3:09 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: contact at the studio tomorrow/MSNBC intv

We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first thing in the morning.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 3:04 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Ok – I am adding Dr Fauci to this email - please confirm to both of us in the morning. Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 2:55 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: RE: contact at the studio tomorrow/MSNBC intv

We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be 7:35am but that is the hit time.

Cyndi will send it to you by 5am tomorrow.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Friday, February 21, 2020 2:48 PM
To: Goldner, Shannah (NBCUniversal) <shannah_goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Will you or Cyndi send exact hit time tonight? What is the approx. time we will get that?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah_goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:42 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>
Subject: RE: contact at the studio tomorrow/MSNBC intv

Thank you so much

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 10:35 AM
To: Goldner, Shannah (NBCUniversal) <shannah_goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Great – thanks.

Please just let us know the exact time and we will have him arrive 20 mins prior.

His cell is (b) (6) and mine is (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:29 AM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)
Subject: contact at the studio tomorrow/MSNBC intv
Importance: High

Patricia, hi,

The contact at the studio in the morning is Natalia Abrams. The number at the office is 202-885-4800. Also, Cyndi Antoniak will be in touch with you in the morning and send you an email about the segment and just to touch base. If you need to reach Cyndi before she reaches you, her number is 212-664-1450 and her email is Cynthia.antoniak@nbcuni.com.

Thank you so much for making the interview work out, we appreciate it.

Shannah

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Friday, February 21, 2020 9:06 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C]

(b) (6); Lavelle, Judith (NIH/NIAID) [E]

(b) (6)>

Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

Hi Shannah

Saturday Morning between 7:30 am ET – 8 am ET is best for Dr Fauci and will need to be from the NBC Studio at 4001 Nebraska Ave NW studio. He has a hard stop no later than 8:15 am. Please send us the onsite contact name and number and firm hit time when you can.

Thanks,
-patty

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Sent: Thursday, February 20, 2020 4:17 PM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrck, Elizabeth (NIH/NIAID) [C]

(b) (6)

Subject: RE: hi and request for Dr. Fauci this weekend on MSNBC

That's terrific and yes, that studio is best if he can join us. Thank you so much. Shannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Sent: Thursday, February 20, 2020 4:16 PM

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrck, Elizabeth (NIH/NIAID) [C]

(b) (6)

Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

I am sure we can make one of these work – will let you know tomorrow.
We would do from the NBC Nebraska Ave NW Studio.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Thursday, February 20, 2020 4:12 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)
Subject: hi and request for Dr. Fauci this weekend on MSNBC
Importance: High

Patricia, hi, I hope all is well with you.

Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus -

https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html

We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good for him, we'll make work.

Thank you so much for your help in this matter.

All the best,

Shannah

Shannah Goldner
MSNBC
W: 212-664-1289
C: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 11:39:06 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: MSNBC Reconfirming

I just did reconfirm with a copy to you. Did you not get it?

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 22, 2020 6:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: MSNBC Reconfirming

You need to respond to this. It's in your on box

Sent from my iPhone

Begin forwarded message:

From: "Antoniak, Cynthia (NBCUniversal, MSNBC)" <Cynthia.Antoniak@MSNBC.COM>
Date: February 22, 2020 at 5:49:00 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Cc: "Goldner, Shannah (NBCUniversal)" <shannah.goldner@nbcuni.com>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Subject: MSNBC Reconfirming

Good Morning Dr. Fauci,

I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori Coffin.

You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.

Topics:

-Coronavirus-infected Americans flown home against CDC advice

https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4foabac6674f_story.html

-Decision to quarantine cruise ship—was that a misstep?

-Long term effects of decision to bring U.S. passengers back

Please reply that you got this

Thank you!

Cyndi

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 3:09 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: contact at the studio tomorrow/MSNBC intv

We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first thing in the morning.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Friday, February 21, 2020 3:04 PM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Ok – I am adding Dr Fauci to this email - please confirm to both of us in the morning. Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 2:55 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: RE: contact at the studio tomorrow/MSNBC intv

We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be 7:35am but that is the hit time.
Cyndi will send it to you by 5am tomorrow.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Friday, February 21, 2020 2:48 PM

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Will you or Cyndi send exact hit time tonight? What is the approx. time we will get that?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:42 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Lavelle, Judith (NIH/NIAID) [E] (b) (6)
Subject: RE: contact at the studio tomorrow/MSNBC intv

Thank you so much

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 10:35 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)
Subject: [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Great – thanks.

Please just let us know the exact time and we will have him arrive 20 mins prior.

His cell is (b) (6) and mine is (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Sent: Friday, February 21, 2020 10:29 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Robinson, Whitney (NIH/NIAID) [C] (b) (6)>; Deatrck, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>
Subject: contact at the studio tomorrow/MSNBC intv
Importance: High

Patricia, hi,
The contact at the studio in the morning is Natalia Abrams. The number at the office is 202-885-4800.
Also, Cyndi Antoniak will be in touch with you in the morning and send you an email about the segment and just to touch base. If you need to reach Cyndi before she reaches you, her number is 212-664- 1450 and her email is Cynthia.antoniak@nbcuni.com .
Thank you so much for making the interview work out, we appreciate it.
Shannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 21, 2020 9:06 AM
To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>
Cc: Robinson, Whitney (NIH/NIAID) [C] <(b) (6)>; Deatrck, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Lavelle, Judith (NIH/NIAID) [E]

(b) (6)

Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

Hi Shannah

Saturday Morning between 7:30 am ET – 8 am ET is best for Dr Fauci and will need to be from the NBC Studio at 4001 Nebraska Ave NW studio. He has a hard stop no later than 8:15 am. Please send us the onsite contact name and number and firm hit time when you can.

Thanks,
-patty

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Sent: Thursday, February 20, 2020 4:17 PM

To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)

Subject: RE: hi and request for Dr. Fauci this weekend on MSNBC

That's terrific and yes, that studio is best if he can join us. Thank you so much. Shannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Sent: Thursday, February 20, 2020 4:16 PM

To: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth

(NIH/NIAID) [C] <[REDACTED]> (b) (6)

Subject: [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

I am sure we can make one of these work – will let you know tomorrow.

We would do from the NBC Nebraska Ave NW Studio.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>

Sent: Thursday, February 20, 2020 4:12 PM

To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED]> (b) (6)

Cc: Barasch, Kimberly (NIH/NIAID) [C] [REDACTED] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] <[REDACTED]> (b) (6)>

Subject: hi and request for Dr. Fauci this weekend on MSNBC

Importance: High

Patricia, hi, I hope all is well with you.

Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus - https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html

We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good for him, we'll make work.

Thank you so much for your help in this matter.

All the best,

Shannah

Shannah Goldner

MSNBC

W: 212-664-1289

C: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 22 Feb 2020 02:39:22 +0000
To: Morens, David (NIH/NIAID) [E]
Subject: FW: So what do you guys think ? (I no it's not influenza, but a lot of your 2007 conclusions seem very valid now...)

David:

Please respond to this person.

Thanks,

Tony

-----Original Message-----

From: [REDACTED] (b) (6)
Sent: Friday, February 21, 2020 9:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: So what do you guys think ? (I no it's not influenza, but a lot of your 2007 conclusions seem very valid now...)

Dear David Morens, dear Anthony Fauci,

I realise it is not an influenza virus, but the outlook of your 2007 paper ("The 1918 Influenza Pandemic: Insights for the 21st Century") seems to me to be very valid for the current coronavirus outbreak. Or put differently - your statements and concerns from then mostly coincide with my thinking and worries now... :(.

So a question - what is your thinking now? Are the hospitals you're affiliated with hiring additional staff (yet)? Any personal preparations?

Good luck to you and all the best for those close to you, kind regards, Sean Scherer

P.S. I guess part of the the reason I'm asking is, because I (a non-institutionally affiliated biologist), am in touch with the university-hospital here ([REDACTED] (b) (6) Germany), but my concerns are so far falling on deaf ears... But also just reading the paper and seeing others come to the same conclusions - albeit on more theoretical grounds and multiple years ago - made me want to reach out. Plus I guess I'm simply curious about what you think !

From: (b) (6)
Sent: Fri, 21 Feb 2020 14:38:56 -0500
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: Re: Work related question

You are correct. No chance that I would accept. Thanks

On Feb 21, 2020, at 2:23 PM, Billet, Courtney (NIH/NIAID) [E]
(b) (6) > wrote:

In the interest of full disclosure: Stephanie (b) (6) used to work here at HHS and is now a VP with the American College of Preventive Medicine. For the life of me I couldn't see you saying yes to a weekend trip to Denver in May, and I would hate to have them waste their time sending an invite when they could be pursuing someone more likely to accept. Hope this is OK.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Friday, February 21, 2020 2:18 PM
To: Stephanie Marshall (b) (6) >
Subject: RE: Work related question

Hi – good to hear from you! I hesitate to speak definitively for him and his scheduler, but to be perfectly honest I think it's really unlikely that'd he'd be able to accept a speaking invite for Denver. The schedule is insane for the foreseeable future and isn't letting up on the weekends. He's turning invitations down left and right, unfortunately – especially those involving travel

From: Stephanie Marshall (b) (6)
Sent: Friday, February 21, 2020 1:51 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Subject: Work related question

Hi Courtney,

I hope you're doing well despite the ongoing craziness whether it's coronavirus or politics. Yikes, these are unsettled times.

I have a quick question for you. Our annual meeting is May 14 - 17 in Denver. Many of the sessions are in place but there's talk about doing a session around

coronavirus and inviting Dr. Fauci as the speaker. The meeting is a Thursday through Sunday and they're looking at inviting him to speak potentially on Sunday morning. Is this something he would even consider and would he commit this far out given everything that's going on? Any quick thoughts you might have would be helpful.

Thank you, thank you! Have a great weekend.

Stephanie

From: (b) (6)
Sent: Fri, 21 Feb 2020 10:40:17 -0500
To: Collins, Francis (NIH/OD) [E]
Cc: Hallett, Adrienne (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]
Subject: Re: FYI on Senate staff visit

Thanks, Francis.

On Feb 21, 2020, at 10:30 AM, Collins, Francis (NIH/OD) [E]

<(b) (6)>

Hi Tony,

I got asked by Alex Keenan what the NIH needs for the coronavirus response. I said that this had been looked at with great care by you and your staff. If you are asking me for technical assistance, I said, we need about (b) (3) for FY20-21, and more in the long run.

ASFR was in the room but did not have a visible seizure.

Just thought you'd want to know before you meet with the staffers later today.

FC

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 14:31:08 +0000
To: Donna Jacobsen
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers
(b) (6); Marston, Hilary (NIH/NIAID) [E]
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. I will be able to provide a 15 minute video with slides that discusses the NIH/NIAID efforts to study the novel coronavirus and to develop countermeasures in the form of diagnostics, therapeutics, and vaccines. Your team can work with Patty Conrad, Hilary Marston and Greg Folkers on the logistics. In the meantime, we will prepare the video.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Thursday, February 20, 2020 8:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Dear Dr Fauci:

We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to 1:20 PM EDT on Tuesday, March 10 if you have that time available, or have you send in a video recorded presentation a day or 2 before that we can show at the session. Having some way to communicate the

high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content together.

We know this is likely not possible, with the very short notice and your even more tremendously busy schedule around all of this. But it's worth the ask.

Please let me know if you think either of these is possible. And Patty, sorry for butchering your email address earlier.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
Executive Manager, CROI
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>



About IAS-USA: Established in 1992, the IAS-USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Sent: Thursday, February 20, 2020 7:12 AM

To: Donna Jacobsen <djacobsen@iasusa.org>

Cc: (b) (6); Elaine J. Abrams, MD (b) (6);

Sharon Hillier PhD (b) (6); Hoxie, James

(b) (6); Benson, Connie (b) (6); Kevin Bowen

<kbowen@iasusa.org>

Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. Unfortunately, I need to be in Washington, DC on March 10, and so I will regrettably have to decline your kind invitation. Thank you for thinking of me.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>

Sent: Tuesday, February 18, 2020 8:09 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Cc: (b) (6); Elaine J. Abrams, MD (b) (6)

Sharon Hillier PhD (b) (6); Hoxie, James

(b) (6); Benson, Connie (b) (6); Kevin Bowen

<kbowen@iasusa.org>

Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being

one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at CROI

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>



About IAS-USA: Established in 1992, the IAS-USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 13:33:20 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: FDA Request
Attachments: FDA Clearance Letter.pdf, Nepal Corona Virus Paper.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)


The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeff Fischer (b) (6)
Sent: Friday, February 21, 2020 8:30 AM
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); Khabbaz, Rima (CDC/DDID/NCEZID/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Chris Helm (b) (6) >
Subject: FDA Request

Drs Messonnier, Khabbaz, and Fauci,

The Center for Devices and Radiological Health at the FDA suggested that we reach out to COVID-19 EUA developers to (b) (4)

(b) (4)



Respectfully,

Jeff

Jeff Fischer
President
Longhorn Vaccines and Diagnostics LLC
2 Bethesda Metro Center Suite 910
Bethesda, MD 20814

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 10:47:53 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Fwd:
Attachments: Notes for NIH.docx

Please handle.

From: RICK SAWAYA <(b) (6)>
Sent: Friday, February 21, 2020 1:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Cassetti, Cristina (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd:

2202020

Dr. Fauci:

This is Dr. Rick Sawaya :

Dr. Tom Betz is (b) (6) and his training is more in line with yours than mine. He submitted this mini-endorsement to you for me and my work. He has seen most of my works and the NIH data protocol from 2016-2017. I think his background gives credibility to my ideas and lends a public health opinion which I did not have until calling him.

Hope you enjoy this.

I have treated cancers, herpes, acne easily with this stuff and honestly and confidentially it will do anything but your income tax.

Thanks, Rick Sawaya M.D.

(b) (6)
call between 10am and 10pm EST,

----- Forwarded message -----

From: Tom Betz <(b) (6)>
Date: Thu, Feb 20, 2020 at 10:32 PM
Subject: Re:
To: RICK SAWAYA <(b) (6)>

Rick,

I am attaching suggested notes for NIH. They may think we're both crazy but I imagine you have already been down that road and I'm interested to see what happens. Hang in there,

Tom

On Tue, Feb 18, 2020 at 2:01 PM RICK SAWAYA [REDACTED] (b) (6) wrote:

THIS HAS THE CELL WITH LEARS SIGNATURE ABOVE IT
AND A CYSTEINE RANDOM DIAGRAM

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 02:42:07 +0000
To: NIAID OD AM
Subject: FW: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Let us discuss.

From: Donna Jacobsen <djacobsen@iasusa.org>
Sent: Thursday, February 20, 2020 8:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch
Importance: High

Dear Dr Fauci:

We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to 1:20 PM EDT on Tuesday, March 10 if you have that time available, or have you send in a video recorded presentation a day or 2 before that we can show at the session. Having some way to communicate the high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content together.

We know this is likely not possible, with the very short notice and your even more tremendously busy schedule around all of this. But it's worth the ask.

Please let me know if you think either of these is possible. And Patty, sorry for butchering your email address earlier.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
Executive Manager, CROI
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>



About IAS-USA: Established in 1992, the IAS-USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 20, 2020 7:12 AM
To: Donna Jacobsen <djacobsen@iasusa.org>
Cc: (b) (6); Elaine J. Abrams, MD (b) (6); Sharon Hillier PhD (b) (6); Hoxie, James (b) (6); Benson, Connie (b) (6); Kevin Bowen <kbowen@iasusa.org>
Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. Unfortunately, I need to be in Washington, DC on March 10, and so I will regrettably have to decline your kind invitation. Thank you for thinking of me.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Donna Jacobsen <djacobsen@iasusa.org>

Sent: Tuesday, February 18, 2020 8:09 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Cc: (b) (6) Elaine J. Abrams, MD (b) (6)

Sharon Hillier PhD (b) (6); Hoxie, James

(b) (6); Benson, Connie (b) (6); Kevin Bowen

<kbowen@iasusa.org>

Subject: RE: CROI COVID 19 Session; Tuesday March 10 lunch

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at CROI

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Stuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>





About IAS-USA: Established in 1992, the IAS-USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 01:47:03 +0000
To: McNeil Jr, Donald G
Subject: RE: question re the WashPost story

Donald:

You know that I always answer your calls and e-mails, but this one I want to stay away from.
Sorry.
Best,
Tony

From: McNeil Jr, Donald G <mcneil@nytimes.com>
Sent: Thursday, February 20, 2020 4:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: question re the WashPost story

Now that I've had a chance to read the whole story -- after editors finished whirling -- I see it also contains these grafs:

Are they accurate?

Thanks

During one call, the CDC's principal deputy director, **Anne Schuchat**, argued against taking the infected Americans on the plane, according to two participants. She noted the U.S. government had already told passengers they would not be evacuated with anyone who was infected or showed symptoms. She was also concerned about infection control. **Anthony Fauci**, head of the National Institute of Allergy and Infectious Diseases, who was also on the calls, **recalled** saying her points were valid and should be considered. But **Robert Kadlec**, assistant secretary for preparedness and response for the Department of Health and Human Services and a member of the coronavirus task force, pushed back: Officials had already prepared the plane to handle passengers who might develop symptoms on the long flight, he argued. The two Boeing 747s had 18 seats cordoned off with 10-foot-high plastic on all four sides. Infectious disease doctors would also be onboard.

On Thu, Feb 20, 2020 at 4:24 PM McNeil Jr, Donald G <mcneil@nytimes.com> wrote:

Hi, Tony:

The Washington Post has just put up a story saying that the 14 infected passengers on the buses containing 238 American passengers from the Diamond Princess were flown home AGAINST the CDC's advice. And that the States Department overruled the CDC on this.

Can you confirm whether that's true?

Thanks...
Donald

Story contains these crucial graf(s):

In Washington, where it was still Sunday afternoon, a fierce debate broke out: The State Department and a top Trump administration health official wanted to forge ahead. The infected passengers had no symptoms and could be segregated on the plane in a plastic-lined enclosure. But officials at the Centers for Disease Control and Prevention disagreed, contending they could still spread the virus. The CDC believed the 14 should not be flown back with uninfected passengers.

“It was like the worst nightmare,” said a senior U.S. official involved in the decision, speaking on the condition of anonymity to describe private conversations. “Quite frankly, the alternative could have been pulling grandma out in the pouring rain, and that would have been bad, too.”

--

Donald G. McNeil Jr.
Science Correspondent
The New York Times

Tel: +1 212 556 1142
mcneil@nytimes.com

Articles: <https://www.nytimes.com/by/donald-g-mcneil-jr>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 21 Feb 2020 00:13:55 +0000
To: Richard Allen Johnson
Subject: RE: 02.20.2020 Thursday

Dick:

Thanks for the note. Always good to hear from you.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Allen Johnson (b) (6)
Sent: Thursday, February 20, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Sandra Goldstein (b) (6)
Subject: 02.20.2020 Thursday

Hi, Tony,

(b) (6) this week.

We watched a life size ASF as you discussed and reassured us about Covid-19. You are simply the best. Were you running for president, I am sure that you would win the yote.

Don't forget our lunch in Boston.

Best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 23:48:29 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Urgent- Phone Interview Request on Coronavirus

Done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Qi Zhang <qizhang@caixin.com>
Sent: Thursday, February 20, 2020 3:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Urgent- Phone Interview Request on Coronavirus

Dear Dr. Fauci,

Good afternoon. I am Olivia Zhang with Caixin Media, which is the front-liner of the Coronavirus reporting in China. We spoke at the very beginning of the virus and I wanted to talk to you regarding the latest situation, especially from test, treatment point of view. I also left you a voice message. Feel free to call me via (b) (6) whenever you're free.

I look forward to hearing from you.

Best,
Olivia

Qi ZHANG (Olivia)
U.S. Correspondent
Caixin Media Company Limited

Email: qizhang@caixin.com

Mobile: + (b) (6)

Twitter: @zhang_qiii

www.caixin.com | caixinglobal.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 23:28:04 +0000
To: Achenbach, Joel
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

It is impossible to predict at this point if the current outbreak will progress to a true pandemic. The future of this outbreak and whether it will progress to a pandemic will be determined by two factors: 1) the degree to which China controls infections in China, which will ultimately impact how many infections leak out to other countries in the world. 2) The success or not of other countries that have received travel-related cases from China in preventing the development of sustained transmission of infections in their own country. If these other countries are successful in containing the transmissions, then a pandemic will be avoided. If a large number of countries are unsuccessful in preventing sustained multi-generation transmissions, then we could witness the next pandemic.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Achenbach, Joel <Joel.Achenbach@washpost.com>
Sent: Thursday, February 20, 2020 6:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

Oh....and...the big question: How likely is it that covid-19 will become a pandemic? Would love an on-the-record assessment. Thanks...joel

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, February 20, 2020 6:06 PM
To: Achenbach, Joel <Joel.Achenbach@washpost.com>
Subject: RE: quick question: when does an epidemic become a "pandemic" officially?

CAUTION: EXTERNAL SENDER

Joel:

There are many iterations of the definition of a “pandemic”. However, one that I use that is simple and understandable is as follows: An outbreak of a serious infectious disease with substantial global health consequences (usually one that has never before been experienced by the human population) that is transmitted readily from person to person and where there is sustained transmission (i.e. multiple generations of person to person to person) in multiple countries and regions of the world. In this regard, the coronavirus outbreak in China is an “epidemic” in China, but it is not yet a pandemic since there is not “sustained” person to person transmission throughout the world. There are infections in other countries (more than 25 countries), but these started as travel related cases from China and although there are several human to human infections in these other countries, these infections have not yet been “sustained”. If we start seeing sustained, multiple generations of transmissions in many countries throughout the world, then the outbreak will have progressed to fill the criteria of a true pandemic.

Hope that this is helpful.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Achenbach, Joel <Joel.Achenbach@washpost.com>

Sent: Thursday, February 20, 2020 5:51 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: quick question: when does an epidemic become a "pandemic" officially?

Dear Tony Fauci:

Hi! Busy times. Hope you are well. Can you explain to me how we will know if and when covid-19 has become pandemic, versus whatever you'd call the current situation? Just in general, what's the definition of a pandemic?

Thank you...best, Joel

(and thanks for calling me back last weekend, sorry I missed you)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 16:45:39 +0000
To: Michael Gerson
Subject: RE: Tony, I'm still working on this, but need your reaction
Attachments: Gerson with minor Fauci edits.docx

Mike:

Thanks for sending this. It looks good. I have copied it to a WORD document and have made some minor suggested edits for your consideration.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michael Gerson (b) (6) >
Sent: Thursday, February 20, 2020 11:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Tony, I'm still working on this, but need your reaction

Meanwhile, on the other side of the earth, there have been 73,000 cases of coronavirus and more than 2000 deaths. This leaves American health experts hoping that the number of infections has been dramatically underreported.

That is not a typo. If the current numbers are close to accurate, it indicates a coronavirus mortality rate upwards of 2 percent. The mortality rate for the seasonable flu is generally .1 percent. The mortality rate for pandemic flu is .3 percent. The particularly deadly flu pandemic of 1918 –

which took the lives of more than 100 million people around the world – had a mortality rate of 1.8 to 2 percent.

So, if 2000 deaths is the numerator, scientists hope that the denominator is actually much larger. And that is probable, given the likelihood that there are many more people who have the infection but don't know it, or are not showing symptoms.

The good news? The outbreak started in a single location and seems largely contained there. There have been several hundred cases in more than 25 countries outside of China. But the overwhelming majority have been travel related. The containment measures of Singapore, Hong Kong and Japan – which have the most cases – seem to have been successful. Of the 15 American cases (before the arrival of the cruise ship passengers), 13 are travel related. The two others are spouses of people in that group. We still have not seen widespread, sustained transmission from person to person outside of China.

The Chinese reaction to the virus has shown the weaknesses and advantages of authoritarianism. The immediate response of a system built on fear is to a problem like this one is denial and deception. No one wants to carry bad news. So local Chinese officials spent the first week of the outbreak – as the disease was spreading under the radar – insisting that the transmission of the virus was all animal to human.

But only in a society like China could you have the effective lockdown of 50 million people, including the entire city of Wuhan, to slow the spread of the disease. Public health officials in most places – who are required to balance health needs with civil liberties – would not even consider such a measure. Yet it appears to be working.

The danger? “All that is needed is for a few countries in the developing world that can't contain the coronavirus,” Tony Fauci told me. “This could be the second wave of the pandemic.”

Pandemic diseases tend to attack the weakest links – the most vulnerable health systems – in the global chain. If there is sustained transmission in those places, says Fauci, “even countries with best practices will suffer.” Countries in Africa are of particular concern. There are millions of Chinese in Africa, and many Africans study in China. Countries such as Ethiopia, Senegal and South Africa seem to be doing a good job at testing random samples for coronavirus in key cities. But Liberia? Guinea? Sierra Leone?

Seldom has there been a stronger argument for American global engagement to strengthen African health systems, which constitute part of own immune system against pandemics. Seldom has there been a better

argument to abandon “America First” posturing and to recognize that our own fate is closely tied to the fate of other nations.

Much about the future course of the disease depends on the answer to a scientific question: Is someone who has the virus but lacks symptoms – or has symptoms so mild they hardly notice – capable of transmitting the virus to others? “It looks like the answer is yes,” says Fauci. Which would make the virus far harder to control.

“We may find that the virus is highly transmissible, but less lethal than we thought in the beginning,” Fauci told me. In this case, the danger would be similar to a particularly bad influenza. And the outbreaks could be seasonal, like the flu as well. “I would not be surprised if that happened,” Fauci concluded.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 15:15:05 +0000
To: Casseti, Cristina (NIH/NIAID) [E]
Subject: FW: inquiry/suggestion re Corona virus->

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alan DiCara (b) (6)
Sent: Wednesday, February 19, 2020 8:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Subject: inquiry/suggestion re Corona virus->

2.19.2020

Dear Dr Fauci,

Thanks so much for being who you are and for dedicating your life to protecting all of us. I write because I saw your interview on PBS tonight and had a question pertaining to denominators and numerators. Please know that I profess absolutely no expertise in areas pertaining to biology nor medicine nor disease and while I understood and agree with your estimation that the fatality rate of the Corona virus to date may be somewhat inflated of the number of cases is understated, I have a related

question for you regarding info I was able to find at this site <https://www.worldometers.info/coronavirus/>

Regarding data this site reports, among many things, and as one scrolls down, that the 'number of active cases' reported today is 57,228 and the number of these that are 'serious or critical' is 12,064. In a worst case scenario, and taking the 12,064 as the numerator and dividing it by a denominator of 57,228, we get 21.08, or about 21%, much higher than the 1% based on total deaths over total cases so far. Of course this is not fair but my question is this: can we know **better** how many of the patients (cases) who are 'serious or critical' and still being treated will recover?

Thanks much for any reply-
Alan DiCara, Winsted, CT

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 12:39:25 +0000
To: David Katz
Subject: RE: CoronaVirus Epidemic -- a Thought

David:

Thanks for the note. I hope that all is well with you. Although allogeneic/semi-allogeneic blood transfusions could be an interesting approach to serious COVID-19 disease, there are a number of existing drugs such as remdesivir (nucleotide analogue) and Kaletra (protease inhibitor) that have some pre-clinical activity against the virus and these are now being tested in randomized clinical trials.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: David Katz (b) (6)
Sent: Wednesday, February 19, 2020 6:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: CoronaVirus Epidemic -- a Thought

Dear Tony,

It has been some time since we last spoke, but this current catastrophe has provoked my thinking about possible therapeutic interventions that could be immediately employed -- in advance of therapies/vaccines that will take

many months to create. And I need to share those thoughts with you.

My suggestion is to treat actively-infected, and acutely ill, patients (under carefully controlled procedures) with allogeneic/ semi-allogeneic blood transfusions. The resulting GVHD response should theoretically combat, and eradicate the viral infection.

I look forward to your thoughts on this suggestion.

With best wishes to you and your family,

David

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 10:51:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY

FYI

From: Amelie RIOUX (b) (6)>
Sent: Thursday, February 20, 2020 2:00 AM
To: As Sy (b) (6) >; Gro Harlem Brundtland <(b) (6)>; 'Dzau Victor' (b) (6); Chris Elias (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fore Henrietta (b) (6)>; Gao Fu (b) (6); Gashumba Diane (b) (6); Ilona Kickbusch (b) (6); Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)>; Skvortsova Veronika (b) (6)
Cc: (b) (6) Tore Godal (b) (6); Godal, Tore (b) (6)
Subject: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY
Importance: High

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board Members,

We would like to hold a teleconference of the Board **today, 20 February at 13:00 Geneva time.**

The agenda for the call would be as follows:

- Short update and stock taking on the coronavirus outbreak;
- Functioning of the Secretariat and improving effectiveness of the Board;
- Way forward

Please note that this call would be a **closed discussion, for Board members only.**

We would appreciate if you could confirm your participation to Amélie Rioux (at (b) (6))

We will share with you shortly the call-in details.

Thank you for your support and continued engagement. We look forward to the call.

With kind regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 03:43:40 +0000
To: Sharon Rockefeller
Subject: RE: This evening's broadcast

Thanks, Sharon. It is always a pleasure to be on the PBS NewsHour. They are high on honesty and integrity.
Best regards,
Tony

From: Sharon Rockefeller <srockefeller@weta.org>
Sent: Wednesday, February 19, 2020 8:33 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: This evening's broadcast

Dear Dr. Fauci,

Thank you, once again, for appearing on the PBS NewsHour and for treating so many Coronavirus patients. Your gift of calm and clear explanations to normal people is unparalleled. Please do not exhaust yourself as you help so many others. (b) (6)

Very sincerely,
Sharon

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 00:54:10 +0000
To: Crawford, Chase (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Haskins, Melinda (NIH/NIAID) [E]; Selgrade, Sara (NIH/NIAID) [E]
Subject: RE: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings
Attachments: Draft NIAID insert for COVID-19 hearings_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crawford, Chase (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 19, 2020 6:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Haskins, Melinda (NIH/NIAID) [E] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Subject: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings

Dr. Fauci:

In preparation for the upcoming COVID-19 hearings of the House Committee on Energy and Commerce Health Subcommittee and the Senate Committee on Health, Education, Labor and Pensions, we have drafted the attached NIAID insert for inclusion in the combined HHS statement for the record. The Department plans to use the same combined statement for both the House and Senate hearings.

The attached draft has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

The Department has asked to receive your statement by COB tomorrow, Feb. 20th.

Thank you for your help.

Chase

Chase Crawford, D.V.M., M.S.

Public Health Analyst

Legislative Affairs and Correspondence Management Branch

Office of Communications and Government Relations

NIAID/NIH/DHHS

Bldg. 31, Room 7A17, MSC 2520

Bethesda, MD 20892-2520

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 23:03:23 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: BioCentury coverage of mAbs to treat COVID-19

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Karen Tkach Tuzman <ktkach@biocentury.com>
Sent: Wednesday, February 19, 2020 5:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: BioCentury coverage of mAbs to treat COVID-19
Importance: High

Dear Dr. Fauci,

I hope all is well. BioCentury is doing a roundup of companies and institutions developing antibodies against the SARS-CoV-2 virus to treat patients with COVID-19. Since you told my colleague Steve Usdin NIAID is developing its own mAbs against the virus, we'd like to include information about that program in our roundup.

Would you or one of your colleagues be able to answer the following questions? Any information you could share by 5 PM Pacific Time on Thursday, Feb. 20 would be greatly appreciated.

1. Are your mAb candidates being developed against specific targets on SARS-CoV-2? If so, what are those targets?
2. What platforms or processes are you using to identify mAb candidates?
3. Do you have multiple mAb programs against SARS-CoV-2 proceeding in parallel, and if so, how are they distinguished?

4. What is that status of each of your mAb programs? For example, have you nominated any lead candidates, are you awaiting patient samples, etc.?
5. Do you have any metrics on lead candidates available yet, such as neutralization titers? If so, what are they?

All the best,
Karen

Karen Tkach Tuzman, Ph.D.
Head, Discovery & Preclinical Development
Associate Editor, BioCentury Inc.
650-595-5333 x 144 (office)
www.biocentury.com

Notice: This communication (including any attachments) constitutes an electronic communication within the meaning of the Electronic Communications Privacy Act, 18 USC 2510, and its disclosure is strictly limited to the recipient(s) intended by the sender of this message. This communication (including any attachments) contains proprietary information, is protected under U.S. and foreign copyright and other intellectual property law, and may contain confidential material for the sole use of the intended recipient. Any unauthorized review, use, disclosure, dissemination, copying or distribution of this communication (including any attachments), or any of their respective contents, is strictly prohibited. If you are not the intended recipient, please contact the sender by return email and destroy all copies of the original message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 20:27:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6)
Subject: FW: Invitation to Speak
Attachments: Invitation_Dr. Anthony Fauci.pdf

Patty/Greg:
Let us discuss.
ASF

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crow, Hilary <HCrow@USChamber.com>
Sent: Wednesday, February 19, 2020 12:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Invitation to Speak

Dear Dr. Fauci,

I'm writing to share the attached invitation with you to speak at the U.S. Chamber Foundation's program on March 10 on the future of medicine.

Our audience of CEOs, market leaders, and opinion leaders would be thrilled to learn more about your perspective on the future of medicine, current issues like the Coronavirus, and future challenges in health and medicine.

Please let me know if you have any questions. I'm happy to schedule a quick call to provide more detail over the phone with you or someone on your team.

I hope you will be able to join us.

Best,
Hilary

Hilary Crow

Executive Director, Programs

U.S. Chamber of Commerce Foundation

1615 H Street, NW | Washington, DC | 20062-2000

Office: 202.463.5710

Mobile: (b) (6)



U.S. Chamber of Commerce Foundation

www.uschamberfoundation.org



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 16:51:27 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Handley, Gray (NIH/NIAID) [E]
Subject: RE: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

If they accept two people, you should go with Gray. Obviously, you should make no commitments and when asked about policy issues, say that you will convey to me and we will get back to them.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 19, 2020 10:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Handley, Gray (NIH/NIAID) [E] (b) (6)
Subject: Re: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Have you had a chance to discuss this world bank conference? You, Cliff and Libby received invites. As Gray has mentioned, this is a pledging conference, so we will need to be prepared to address funding (the person that attends would need to be in sync with you on that). Obviously Cliff is on travel. Who would you like to have at the conference, if anyone?

-hilary

From: Anthony Fauci <[REDACTED]>
Date: Friday, February 14, 2020 at 9:25 PM
To: NIAID AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Let us discuss.

From: Feng Zhao <fzhao@worldbank.org>
Sent: Friday, February 14, 2020 5:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]>
Cc: [REDACTED]; Mukesh Chawla <mchawla@worldbank.org>; Rocio Schmunis <rschmunis@worldbank.org>; Adrienne Kate Mcmanus <amcmanus@worldbank.org>; Gabrielle Lynn Williams <gwilliams1@worldbank.org>; WB Health Events <wbhealthevents@worldbank.org>; Muhammad Ali Pate <mpate@worldbank.org>
Subject: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Dear Dr. Fauci,

On behalf of the World Bank health team, in coordination with the Coalition for Epidemic Preparedness Innovations (CEPI), it is our pleasure to invite you to a half-day consultation on **Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development**. The meeting is set to take place on **Thursday, February 20, 2020** from **9:30am to 1:30pm** at the **World Bank Offices in Washington DC** (located at 1818 H St NW) on **floor C2, conference room MC C2-125**.

As you know, the novel Coronavirus outbreak, which started in Wuhan, China, is evolving rapidly. As of today, the number of confirmed cases has increased significantly to over 60,000 and the virus has reached 25 countries. The outbreak, a Public Health Emergency of International Concern (PHEIC), poses a threat to countries worldwide, especially those with weak health systems and low levels of pandemic preparedness.

It is of urgent importance that we move quickly to finance the development of the appropriate countermeasures for a disease that risks becoming endemic across the globe. Two critical issues are necessary to address: i) immediate financing for the development and scale-up of a diversified portfolio of vaccines, and ii) financing the manufacturing and procurement of vaccine for global distribution.

To enhance our discussions we are working on a background paper which we will share along with an agenda at the earliest. Recognizing the short notice, we will provide remote connection details for those unable to travel for the meeting. A working lunch will also be provided.

We hope that you will be able to participate in this important meeting. Kindly confirm your participation to Ms. Gabrielle Williams, Health, Nutrition and Population Global Practice, World Bank (wbhealthevents@worldbank.org). Please do not hesitate to reach out with any questions.

Looking forward to your positive response.

Best regards,
Feng Zhao

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 16:16:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Potential Speaking Engagement: Winter 2021

Please RSVP sorry no. Too busy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Andrew Turley (b) (6)
Sent: Wednesday, February 19, 2020 10:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Andrew Turley (b) (6) >
Subject: Potential Speaking Engagement: Winter 2021

Dear Dr Fauci

I know things must be impossibly busy right now with the current coronavirus issues but wanted to touch base to see whether you may be interested in a speaking engagement next Spring as part of our

(b) (6)
(b) (6)

A bit about me: I am a (b) (6) Air Force Major General and retired SES from the Department of Defense.

(b) (6)

(b) (6) is an associate professor emeritus from the School of Medicine and Health Sciences at the George Washington University. We are both longtime admirers.

(b) (6) consists of people drawn from a wide variety of backgrounds, including doctors, lawyers and many from the senior tiers of the finance and corporate worlds up to and including former CEOs and other executives (and even a few retired senior government folks like me). It is an active, well-read and learned community with a keen interest in current events. As an example, we have a very active Foreign Policy Association chapter that always draws folks from across the spectrum of political and policy perspectives for interesting and well-informed discussions.

Our (b) (6) speaker series consists of presentations on a vast array of subjects, from literature and art to current events and public policy issues. Typically held on Tuesdays nights from December through April, these sessions consist of a presentation of an hour or so followed by Q&A and general discussion. We always draw standing room only crowds.

Recent and upcoming speakers have included:



The recent coronavirus outbreak has captured the interest of the nation and the world. Our folks would be extremely interested in how organizations such as NIH respond and address these incredible challenges. A presentation by you about your work on these issues, from your groundbreaking work on AIDS onward or any other topic of your choosing, would be absolutely the height of our season.

We pay transportation, lodging, an honorarium, and could even arrange for a round of golf at one of our outstanding golf courses! (Of equal importance is that we can offer you a brief respite from the cold of winter.). There are direct flights from Washington DC to West Palm Beach. We have openings in January, February and March 2021.

We would be deeply appreciative of your favorable consideration. Please feel free to contact me if I can answer any questions

F. ANDREW TURLEY

CELL: (b) (6)
HOME: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 14:42:50 +0000
To: Greg Folkers ([REDACTED]) (b) (6)
Subject: FW: Clip of Dr. Fauci on NPR

Good interview on NPR. Possible for Director's Page.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: ([REDACTED]) (b) (6)
FAX: (301) 496-4409
E-mail: ([REDACTED]) (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lindsey Beall <lbeall@scgcorp.com>
Sent: Wednesday, February 19, 2020 8:22 AM
To: Deatrick, Elizabeth (NIH/NIAID) [C] ([REDACTED]) (b) (6); Pekoc, Ken (NIH/NIAID) [E] ([REDACTED]) (b) (6); Conrad, Patricia (NIH/NIAID) [E] ([REDACTED]) (b) (6); Fauci, Anthony (NIH/NIAID) [E] ([REDACTED]) (b) (6); Doepel, Laurie (NIH/NIAID) [E] ([REDACTED]) (b) (6); Folkers, Greg (NIH/NIAID) [E] ([REDACTED]) (b) (6); Hoffman, Hillary (NIH/NIAID) [E] ([REDACTED]) (b) (6); Oplinger, Anne (NIH/NIAID) [E] ([REDACTED]) (b) (6); Rancourt, Anne (NIH/NIAID) [E] ([REDACTED]) (b) (6); Lavelle, Judith (NIH/NIAID) [E] ([REDACTED]) (b) (6); Leifman, Laura (NIH/NIAID) [E] ([REDACTED]) (b) (6); Stover, Kathy (NIH/NIAID) [E] ([REDACTED]) (b) (6); Routh, Jennifer (NIH/NIAID) [E] ([REDACTED]) (b) (6); NIAID OD AM <NIAIDODAM@niaid.nih.gov>; Awwad, David (NIH/NIAID) [C] ([REDACTED]) (b) (6)
Cc: Oswald, Maria <mosvald@scgcorp.com>; Fabry, Cynthia (NIH/NIAID) [E] ([REDACTED]) (b) (6); Meylin Correa <mcorrea@scgcorp.com>; Marcia Bache <mbache@scgcorp.com>; Megan Schartner <MSchartner@scgcorp.com>
Subject: Clip of Dr. Fauci on NPR

Good morning,

Below is a clip of Dr. Fauci discussing coronavirus on NPR's Morning Edition. This clip aired earlier this morning.

https://app.criticalmention.com/app/#/clip/public/1b0da123-0cd7-4012-90a6-b82d27c73191?show_sentiment=false

Thanks,

Lindsey

From: Critical Mention <do-not-reply@criticalmention.com>

Sent: Wednesday, February 19, 2020 8:18 AM

To: Lindsey Beall

Subject: Critical Mention: Megan Schartner has shared a Radio Mention with you



You're always on it with Critical Mention.

***Megan Schartner* has shared a Radio Mention with you!**

From Megan Schartner (mschartner@scgc.com)

[View Mention](#)

[No Program Name Available](#)



Radio

Program Name No Program Name Available

Source WLRNFM

Market DMA: 16 Miami, FL

Time Feb 19, 2020 8:07 AM EST

Clip Length 07:16.852

it's morning edition from n. p. r. news on david green in culver city california and a militant in washington d. c. good morning in china the death toll from the corona virus has hit two thousand world leaders in public health officials are trying to contain it but new infections keep showing up carl golden for example he was a passenger on the diamond princess that's the cruise ship where hundreds of people got the virus we took an aquatic clues to also alone what went wrong who knew we were going and the crew and beautiful omar here's how he ended up in omaha carl his wife jerry were quarantined on that ship for twelve days in a felt fine the whole time but then the gun on a flight back to the u. s. and carl started feeling sick or wind burke from japan to this day about two hours into the flight they woke up with a high fever after napping a little bit and the doctors on board confirmed the and then on the flight landed he tested positive for the coronavirus he's recovering now in a bio contain mean unit at the university of nebraska's medical center he's going to have to spend fourteen days there and isolation well you know working %hesitation %hesitation catering we've heard on a but one of the two days of the different doctors each day i

didn't have a clue but got a little cough still you can you might want to debate left me and i'm a little to keep but maybe also because of the jet lag in the travels and everything else on top of it no it doesn't feel any different than you know recuperating from a regular cold carl's wife jerry hasn't been diagnosed with the virus is she's being monitored in a different part of the hospital but their case is a good example of some things we know and some things we don't know about how this virus is spreading so we have called doctor anthony **fauci** he's director of the national institute of allergy and infectious diseases good morning sir good morning so carl coleman was fine all those days on the ship then he gets on a plane and he gets a fever what does that tell us about how this virus is spreading well the virus has the ability to bind it to certain cells in your body particularly in your lung so you can get anything from mild asymptomatic illness to a cough and a fever to some people about oh about twenty percent of the people come to the attention of medical than physicians in health care providers can get serious pneumonias requiring intensive care it sounds like this individual is on the %hesitation mild side of the illness because as he said it doesn't feel much more than just a common cold and as a matter of fact corona viruses in general prior to this all one of the causes of the common cold okay so what does that tell us i mean bleary often looking at the cases we're looking at a rising death toll which is tragic we look much less at the people like carly say you know my voice is raspy a had a fever had a cough the years a wide range of stuff symptoms with this virus did do do we know why some people seem to be doing okay and other people are getting hit really hard well whether a couple things about that for the first thing is that any any kind of viral infection or any pathogen infection there's always a wide range of responses in the sense almost like a bell shaped curve some people get no sim is at all and we do have a symptomatic corona virus infection with this particular episode and then there's the bulk of people who get some sort of symptoms and then a small percentage of people do really really very poorly now that relates to the ability of the body to handle the virus and the one thing we know when it's not unique to this virus is that the elderly those with underlying conditions like chronic heart disease lung disease diabetes obesity they tend to get more complications much more than for example and otherwise healthy individual and that's the reason why if you look at the death rate which is around two percent for this disease at this time it is disproportionately high are among the elderly and particularly those who have underlying conditions this is interesting question carlin is wave terry presumably they work together the entire time they were quarantined right and if he gets the virus she does not did she just get lucky do some people have some sort of immune undefended don't it's a combination that's a good question it's a combination of both there is no virus that has one hundred percent attack rate even the most of infectious of all viruses like measles doesn't get a hundred percent of of %hesitation vulnerable people but respiratory viruses particularly things like influenza or the corona virus the attack rate is burying percentage and it was if he was really likely that his wife i don't think she necessarily had any on the line immune protection though that's possible the maybe some cross reaction of immune protection with other %hesitation microbes that she came into contact with but in most likely is as you suggest the luck of the draw okay interesting

and they got to patching wondered if you could clear something up because we've been hearing reports about so called super spread ours these you who spread the virus to a very high a number of other people and it sounds like a scary thing but and I just under is this a real phenomenon there that there are people who give the virus to more people than most and why is that happening well it is certainly the phenomenon of the super spreading israel we story with sars back in two thousand two and two thousand in three and they're episodes already with this particular new corona virus and it's a combination of two things it's an individual whose either at a particular moment in time shedding a very large amount of virus which makes it much easier to infect a group of people who are around him but you also see it sometimes in the hospital setting when you have a number of health care providers taking care of someone and that person is shedding a lot of virus so the short answer to your question is there are super spread is and it's a real phenomenon okay okay what we would you say at this moment is the most important or the most pressing question about this virus that we don't have answers to yet well what we don't know for sure we know that there are people who are infected will without symptoms or very minimal symptoms they hardly notice they're infected well we don't know is the extent to which people who have no symptoms are spreading it so we do know that this can occur because we have anecdotal documented cases of people who do not have symptoms who actually have infected someone usually a family member but we don't know the extent to which this cars in the broad component of this outbreak doctor anthony **fauci** the director of the national institute of allergy and infectious diseases sir thanks for joining us it was a pleasure to be with you

Critical Mention allows users to search global TV, Radio, Online News & Blogs from the United States, Canada, and Europe, watch video, and view share coverage. Receive real-time email alerts, build reports, and analyze coverage through word clouds and graphs.

Want to learn more about Critical Mention? Sign up for a demo: [Sign Up](#)

Copyright © 2020 Critical Mention. All rights reserved.

Our mailing address is:
Critical Mention
521 5th Avenue
16th Fl
New York, NY 10175

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 13:03:08 +0000
To: bdoherly@mms.org
Cc: lbaden@nejm.org;Fauci, Anthony (NIH/NIAID) [E];Redfield, Robert R. (CDC/OD);Lane, Cliff (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E]
Subject: RE: New England Journal of Medicine Editorial
Attachments: H. Clifford Lane's ICMJE-2013 - For Coronavirus Editorial Fauci et al -.pdf

Briana:

Cliff Lane has separately sent his signed CTA. I am attaching his ICMJE Form. And so you should have all the forms for all 3 authors: Fauci, Lane, and Redfield. Please let me know if you have any questions.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Briana Doherty <onbehalf@manuscriptcentral.com>
Sent: Monday, February 10, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: lbaden@nejm.org
Subject: New England Journal of Medicine Editorial

Dear Dr. Fauci,

I am delighted that you have agreed to write a signed editorial to accompany the article on the initial estimates of key transmission parameters associated with nCoV-2019 virus by Li et al.

The general purpose of the Journal's editorials is to provide the reader with an authoritative interpretation or elaboration based on the substance of the article. Since this substance is usually not within the average reader's special competence, such readers will particularly benefit if the editorial avoids technical jargon, explains the article's contribution to a field of knowledge, and emphasizes, whenever possible, its clinical implications. The editorial commentary should not be concerned exclusively with the article in question but rather should use the article as a starting point for a more general discussion.

Because editorials involve interpretation and opinion, you and your potential coauthor must be free of significant relevant financial associations (including equity interest, regular consultancies, or major research support) with a company, or with a competing company, that stands to gain from the use of a product discussed in the editorial. Please contact me immediately if you are considering a coauthor, so I can ensure that your candidate meets our

criteria. Additional information about disclosure of financial and other associations appears below this letter.

Please bear in mind that your editorial represents your (and any coauthor's) personal opinion. The Journal does not include statements of grant or other support or acknowledgments with editorials.

Journal policy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each author before a manuscript can be accepted. Therefore, the enclosed form should be signed by all authors and faxed to (781) 207-6529.

Your editorial is due at the Journal on Monday, February 17, at the very latest if the deadline imposed by our printing schedule is to be met. If the editorial is to include a figure, please submit the figure at least one week before the due date for the editorial itself.

*** Additional information about preparing and submitting your editorial is given below; please read it carefully.

The editors must reserve the right to edit (or even reject) your editorial, but whether we use it or not, the Journal currently offers a modest stipend of \$300.

Thanks again for agreeing to write this editorial for the Journal. I look forward to receiving it.

Sincerely yours,

Lindsey R. Baden, M.D.
Deputy Editor

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

LENGTH OF YOUR EDITORIAL

NEJM editorials should not exceed two printed pages. This means that your word count before editing should not exceed 750 words (approximately 4500 characters). Note that we spell out trial names and most other abbreviations for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the text; the entire manuscript, including references, should be double-spaced.

REFERENCES

Cite no more than 10 references, including the article you are writing about. The average collection of 10 references requires about a quarter of a printed page.

TABLE OR FIGURE

A table or a figure in your editorial will require a reduction in the number of words; because figures and tables vary in size, you may be asked to shorten the text of your editorial during the production process. A quarter-page table roughly equals 250 words, and a half-page table roughly equals 500 words.

DISCLOSURES

When completing your disclosure form, please indicate, in the "Comments" field next to the type of relationship being disclosed, the amount (in U.S. dollars) of any support you have received. Please also indicate how much of this support has been received over the past 2 years. Please e-mail your completed disclosure form to editorial@nejm.org.

In the event of publication, each author's submitted disclosure form will be posted on the Web (with any dollar amounts redacted).

COPYRIGHT TRANSFER

Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 781-207-6529 as soon as possible.

TO SUBMIT YOUR EDITORIAL

*** It is important that you follow the instructions below to ensure that your article enters the correct queue. ***

When you are ready to submit your manuscript, please log in to the New England Journal of Medicine - Manuscript Central site (<http://mc05.manuscriptcentral.com/nejm>). Your case-sensitive USER ID is afauci@niaid.nih.gov. For security purposes, your password is not listed in this message. If you are unsure of your password, please visit <https://mc05.manuscriptcentral.com/nejm> and enter your e-mail address in the "Forgot Your Password?" field.

Once you are logged in, the Main Menu will be displayed. Please click on the Author Center, where you will find the manuscript listed under "Invited Manuscripts." You can click on the "Continue Submission" button to begin submitting your article.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 12:37:58 +0000
To: Jon LaPook
Subject: RE: Coronavirus

It means that you are an outstanding and committed journalist. 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Wednesday, February 19, 2020 7:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Coronavirus

Got it. What does it mean that I'm waking up thinking about coronavirus?
:)

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine

NYU Langone Health
Twitter @DrLaPook

On Feb 19, 2020, at 7:33 AM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) wrote:

Jon:

Your hypothesis is certainly possible, but I think unlikely. In a NEJM paper for which I have just written an editorial, there were 400+ patients and none younger than 15 years old. I am certain that children from birth to 15 years were exposed to and primed by coronaviruses multiple times and so if 2nd infection enhancement were an important issue, we should have seen it in children and adolescents 15 years old and younger. Just a thought, but anything is possible.

Best,
Tony

Anthony S. Fauci, MD
Director

National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)

Sent: Wednesday, February 19, 2020 7:26 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Coronavirus

Good morning, Tony,

I woke up thinking this: given the relative sparing of young people during the COVID-19 outbreak, could something similar to what happens with dengue be going on? Could a second coronavirus infection - albeit with a genetically different variant than the first - bring about worse disease than the first? And, since up to a third of the common cold is caused by a variant of coronavirus, could older people somehow have been primed by an earlier coronavirus infection?

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 03:41:52 +0000
To: Grigsby, Garrett (HHS/OS/OGA);Redfield, Robert R. (CDC/OD);Cetron, Marty (CDC/DDID/NCEZID/DGMQ)
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Todays report from Dr Iwata From Kobe univ on Diamond Princess SHIP COVID-19

Folks:

You should take a look at this video (see link). The person, who is a Japanese infectious diseases specialist, is a bit inarticulate in the beginning of the video, but he provides a vivid and disturbing description of the conditions on the Diamond Princess.

Tony

From: Larry Washburn <[REDACTED] (b) (6)>
Sent: Tuesday, February 18, 2020 9:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Hodes, Richard (NIH/NIA) [E] [REDACTED] (b) (6)
Subject: Todays report from Dr Iwata From Kobe univ on Diamond Princess SHIP COVID-19

Dr. Fauci,

I am living in Japan [REDACTED] (b) (6) and this morning I saw this video released by Dr. Kentaro Iwata a infectious disease control specialist

Please have somebody on your staff review this **ASAP** short description of Dr Iwata's 1 day visit on the ship. He has experience with Ebola, Sars etc. He describes an alarming condition that you and CDC must be aware of. Japan has no CDC and they tend to be very bureaucratic.

<https://www.youtube.com/watch?v=vtHYZkLuKcl&feature=youtu.be>

I apologize if you already have this information.

Respectfully

Larry Washburn [REDACTED] (b) (6) Living in Japan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 01:32:37 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: CROI COVID-19 Session; Tuesday March 10 lunch

I am not that excited about doing this. They have CDC doing the Epi, which is fun. They have Ralph Baric doing the virology, which I easily can do, and they have me talking about what NIAID is doing, which is important, but boring from a lecture standpoint.

Greg:

What say you?

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, February 18, 2020 8:22 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Fwd: CROI COVID-19 Session; Tuesday March 10 lunch

Sent from my iPhone

Begin forwarded message:

From: Donna Jacobsen <djacobsen@iasusa.org>
Date: February 18, 2020 at 8:18:06 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Elaine J. Abrams, MD" (b) (6), "Sharon Hillier PhD" (b) (6), "Hoxie, James" (b) (6) >, "Benson, Connie" (b) (6), "Kevin Bowen" (b) (6) >
<kbowen@iasusa.org>
Subject: RE: CROI COVID-19 Session; Tuesday March 10 lunch

(resending with Patty's correct email address)

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID-19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview of the epidemic (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that it is important that we address COVID 19 at CROI.

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr. Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen
Executive Director/President
International Antiviral (formerly AIDS) Society-USA
131 Steuart St, Ste 500
San Francisco, CA 94105
415-544-9400

<https://www.iasusa.org>



About IAS-USA: Established in 1992, the IAS-USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

Confidentiality Notice: This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 00:28:47 +0000
To: Retzlaff, Jon
Subject: RE: ACTION: Invitation to Provide Opening Remarks at the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)

Not interested right now. Too busy. Have Hugh or someone else do this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Retzlaff, Jon <jon.retzlaff@aacr.org>
Sent: Sunday, February 16, 2020 6:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: ACTION: Invitation to Provide Opening Remarks at the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)

Dear Dr. Fauci,

It's pretty clear that you have been ridiculously busy over the past month+ serving as our nation's top infectious disease doctor! Thanks so much for your leadership and dedication, Dr. Fauci!

I'm actually reaching out to you on a topic other than the coronavirus, as I am writing on behalf of the co-chairs for an important NIH-American Association for Cancer Research (AACR) conference (**the NIH-AACR Cancer, Autoimmunity, and Immunology Conference**) that will be taking place on March 23-24, 2020, on the NIH campus (in the Masur Auditorium in the NIH Clinical Center).

The co-chairs would like to invite you to be the opening speaker on Monday, March 23rd. Dr. Sharpless will be the opening speaker on Tuesday, March 24th. Please see the attached draft agenda.

Now in its third year, the Cancer, Autoimmunity, and Immunology Conference focuses on: 1) understanding the biology of immune-related adverse events which have occurred in cancer patients treated with immunotherapies and how that might inform the study of autoimmune disease, and 2) defining the potential for the study of autoimmune disease to lead to greater understanding of the treatment and management of immune-related adverse events during and following cancer therapies. The goal of this interdisciplinary conference is to bring together people who might not typically interact to promote cross-fertilization for the betterment of both research and clinical care, which is why there are four NIH ICs very much involved in the Conference, including: NCI, NIAID, NIAMS, and NIDDK.

Chairing this effort on behalf of the AACR is Julie R. Brahmer, MD, Johns Hopkins University. From the NIH, we have Elad Sharon, MD, MPH, NCI; Ravi Madan, MD, NCI; Connie Sommers, PhD, NCI; Howard Young, PhD, NCI; Katarzyna Bourcier, PhD, NCI; Marie Mancini, PhD, NIAMS; Annette Rothermel, PhD, NIAID; and Lisa Spain, PhD, NIDDK.

I know the diverse audience, including patients, researchers, clinicians, industry, regulators, and others, would be thrilled by your presence. Of course, we also know that you have participated in the previous two conference on this topic, which underscores why they would love to have you participate again!

Please let us know at your earliest convenience if you are interested and able to participate in the conference on Monday, March 23rd. If you have additional questions or concerns, you can contact me at jon.retzlaff@aacr.org or (b) (6)

Thanks again, Dr. Fauci, and I look forward to hearing from you!

Jon

Jon Retzlaff, MBA, MPA


CHIEF POLICY OFFICER
VICE PRESIDENT, SCIENCE POLICY AND GOVERNMENT AFFAIRS
Office of Science Policy and Government Affairs



American Association for Cancer Research
1401 H Street, NW, Suite 740 | Washington, DC 20005

202-898-6499 Direct | 202-765-1087 Fax | (b) (6) Cell

jon.retzlaff@aacr.org | www.AACR.org



Please note that this e-mail and any files transmitted with it may be privileged, confidential, and protected from disclosure under applicable law. This information is intended only for the person or entity to which it is addressed and may contain confidential or privileged material. Any review,

retransmission, dissemination, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 19 Feb 2020 00:23:40 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: New England Journal of Medicine - 20-02387

FYI. Just to keep an eye on this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: New England Journal of Medicine <onbehalf@manuscriptcentral.com>
Sent: Tuesday, February 18, 2020 10:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: New England Journal of Medicine - 20-02387

Dear Dr. Fauci,

Thank you for submitting your manuscript, "COVID-19 : Navigating the Uncharted" to the New England Journal of Medicine.

Your manuscript has been forwarded to members of our editorial staff, who will make an initial evaluation and decide whether it merits further consideration. You will be notified of the decision as soon as possible.

Your manuscript ID is 20-02387.

Please mention the above manuscript ID in all future correspondence or when calling the office for questions. If there are any changes in your street address or e-mail address, please log in to ScholarOne Manuscripts at <https://mc05.manuscriptcentral.com/nejm> and edit your user information as appropriate. You may also view the status of your manuscript at any time by checking For Authors section of the site.

We are undertaking evaluation of your manuscript with the understanding that neither the substance of the article nor the figures or tables have been published or will be submitted for publication elsewhere during the period of review.

Please provide the editors with copies of other manuscripts by you or your coauthors addressing similar or related research questions that are in preparation or under consideration at other journals. This does not apply to abstracts published in connection with scientific meetings or to news reports based on presentations at such meetings.

The Journal's policy is explained more fully at <http://www.nejm.org/page/author-center/editorial-policies>.

Please call us at 617-734-9800 if you have any questions.

Sincerely,

Eric J. Rubin, MD, PhD
Editor-in-Chief

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 23:57:32 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: draft response for NBC online

See my minor tweak

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 18, 2020 2:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: draft response for NBC online

Ok any edits? Pls advise

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 18, 2020 2:47 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6); OCPLPresTeam
<OCPLPresTeam@od.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: draft response for NBC online

Reporter: Jacqueline Stenson
Organization: NBC online
Phone #(s): (b) (6)
Subject: COVID-19

NBC online asked, "What is NIAID's position on whether the SARS-CoV-2 is transmissible in asymptomatic people?"

I would propose that we send a response to Jacqueline attributed to ASF:

Early case reports indicate in certain circumstances SARS-CoV-2 is transmissible in asymptomatic people. We do not know the extent to which asymptomatic transmission is impacting the outbreak. However, we know that people with symptoms are usually the main driver of outbreaks of other respiratory diseases.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 23:32:19 +0000
To: Dennis Golden
Cc: Monica A Golden
Subject: RE: Coronavirus

Denny and Monica:

Many thanks for your kind note. I hope that all is well with you.
Warm regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Dennis Golden <(b) (6)>
Sent: Tuesday, February 18, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Monica A Golden <(b) (6)>
Subject: Coronavirus

Tony,

Our thoughts and prayers are with you as you professionally address the horrid coronavirus transmission.

We salute you for not "sugarcoating" or trying to be "diplomatic" about the Diamond Princess Cruises ship quarantine process.

As always, you proved yourself to be a courageous, honest and ethical man. A man who has always done the right things.

We stand with you !

In Hoc Signo Vinces.

Denny and Monica Golden

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 22:06:38 +0000
To: Selgrade, Sara (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];NIAID OCGR Leg
Subject: RE: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings
Attachments: Draft_NIAID FY2021 Statement for the Record_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, February 18, 2020 4:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings

Dr. Fauci:

In preparation for the upcoming NIH budget hearings of the House and Senate Appropriations Subcommittees on Labor, HHS, Education, and Related Agencies, we have drafted the attached NIAID statement for the record, highlighting the topics that you previously selected.

We have a firm 3-page limit for the statement. It has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

NIH OLPA has asked to receive your statement by this Wednesday, Feb. 19th. Please let us know if you would like us to request additional time for your review, given competing priorities.

Thank you for your help.

Sara

Sara Selgrade, Ph.D.
Section Chief for Legislative Activities
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
NIAID/NIH/DHHS
Bldg. 31, Room 7A17, MSC 2520
Bethesda, MD 20892-2520
Phone: (b) (6)
(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:37:35 +0000
To: Venigalla B Rao
Cc: Casetti, Cristina (NIH/NIAID) [E]
Subject: RE: Wuhan coronavirus vaccine candidates

Rao:

Best to contact Cristina Casetti in DMID. I have copied her here.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Venigalla B Rao (b) (6)
Sent: Tuesday, February 18, 2020 9:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Wuhan coronavirus vaccine candidates

Dear Tony,

Good morning!

Sorry for taking your time at this very super busy time. Greatly appreciate your service and leadership!!

(b) (4)

(b) (4)

With best regards,
Rao

On Tue, May 23, 2017 at 11:03 AM Venigalla B Rao <(b) (6)> wrote:

Dear Tony,
Just a quick update.

(b) (4)

(b) (4). He has accepted both the papers and the

papers should come out back-to-back in Virology soon. I am attaching both the pdfs for your interest.

From scientific perspective, it is very satisfying to see that both the papers using completely different approaches arrived at the same virion capture model. That was not anticipated when we initiated the work 5-years ago because the reasons to develop these assays were very different. I have mentioned to Emerman to consider highlighting the papers in the journal issue, and that you and Jim might be willing to write a short piece but I have not heard about this.

With best regards,
Rao

On Mon, May 1, 2017 at 11:33 PM, Venigalla B Rao [redacted] (b) (6) wrote:

Dear Tony,

[redacted] (b) (4)

With best regards,
Rao

On Mon, May 1, 2017 at 9:40 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) wrote:

Rao:

Thanks for the note and for

[redacted] (b) (4) (b) (4)

Best regards,

Tony

From: Venigalla B Rao [mailto:[redacted] (b) (6)]
Sent: Thursday, April 27, 2017 8:24 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Arthos, James (NIH/NIAID) [E]; [redacted] (b) (6)
Subject: Request

Dear Dr. Fauci,

This is Venigalla Rao from The Catholic University of America, Washington, DC. I have communicated with you a couple of times in the past years for different reasons. Having been involved in administrative duties (miniscule compared to yours), I can only imagine the demands on your time. I make this request despite this trepidation and I hope that you understand.

(b) (4)



Thank you for consideration.

With best regards,

Rao

Dr. Venigalla B. Rao
Professor and Chairman
Department of Biology
The Catholic University of America
620 Michigan Ave., NE
Washington, DC, 20064

<http://faculty.cua.edu/rao/>

Phone: (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:12:48 +0000
To: Suzanne Peskin
Subject: RE: Visiting !

Suzanne:

Thanks for the note. I am very, very sorry, but I do not think that we will be able to connect on Sunday. The White House and HHS have me going 24/7 including Saturday and Sunday with the coronavirus crisis. I have seen my wife (b) (6) for a total of about 45 minutes over the past 10 days. Hopefully, we can do this at some other opportunity, but this is a very bad time. I hope that you understand.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Suzanne Peskin (b) (6)
Sent: Monday, February 17, 2020 9:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Visiting !

Hi Tony, I hope all is well with you and your family. I know you are busy these days with the Coronavirus, but was wondering if you're in town this weekend ! (b) (6) lives in DC and works for Maryland CASA as a legal fellow. I'm coming in Friday evening and was planning on taking her down memory lane. She has heard so much about (b) (6) that I would love to introduce you two. (b) (6) We are free most of Sunday if you're in town. It's been way too long. Would love to see you.

Let me know if that is at all possible.

Love,

Suzanne
Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 13:17:03 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: (b) (4) for coronavirus
Attachments: (b) (4)

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Li, Qiuhong (b) (6)
Sent: Tuesday, February 18, 2020 8:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: (b) (4) for coronavirus

Dear Dr. Fauci,
I'm writing to you to seek advice on potential collaborations with NIAID-funded facilities or other private sectors to (b) (4)

(b) (4)

(b) (4)

Please feel free to contact me if you have any questions.

Best regards,
Qihong

Qihong Li, Ph.D,
Dept. of Ophthalmology
University of Florida
Gainesville FL
32610-0284

Phone: (b) (6)

Email: (b) (6)

From: (b) (6)
Sent: Tue, 18 Feb 2020 07:00:32 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: Funds for CoV

Francis:

[Redacted] (b) (5)

Tony

On Feb 18, 2020, at 6:22 AM, Collins, Francis (NIH/OD) [E]

(b) (6) wrote:

Hi Tony,

Larry and I will have our regular meeting with the Secretary today. (b) (5)

[Redacted] (b) (5)

I will see you this afternoon for our regular catch up, unless other events in our intensely busy lives intervene.

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:15:14 +0000
To: Bernice Mika Huang
Subject: RE: Singapore Coronavirus Updates

Bernice:

Thank you for this important update of information.
Best regards,
Tony

From: Bernice Mika Huang [REDACTED] (b) (6)
Sent: Tuesday, February 18, 2020 4:40 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Singapore Coronavirus Updates

Dear Dr. Anthony Fauci,

I'm Bernice [REDACTED] (b) (6).

I had read your online discussion details on USA Today which says:

" Another thing that we don't know is why, with a respiratory-borne illness, are there virtually no children getting infected. I mean, there are no cases of kids less than 15 years old. Does that mean for some strange reason they're not getting infected, or the illness is so mild in children that we're not noticing it? It's very clear the median age is 56 or 59."

I thought it would be crucial to share updates on Singapore's coronavirus situation for your reference, because you are the expert who could help analyze the current situation. Till date, in Singapore [REDACTED] (b) (6) have two young children who are infected:

ONE YEAR OLD

"Case 76 is a one-year-old Singaporean who was among the group evacuated from Wuhan on Feb 9. The toddler was without symptoms when he boarded the flight back to Singapore. He was put under quarantine upon landing in Singapore, and was confirmed to be infected with COVID-19 on Sunday afternoon. Advertisement He is currently warded in an isolation room at KK Women's and Children's Hospital, said MOH." Quoted from <https://www.channelnewsasia.com/news/singapore/covid19-coronavirus-singapore-update-feb-17-12441176>

SIX-MONTH OLD

" COUPLE, BABY AND MAID INFECTED The 28-year-old mother - whose infection was announced on Tuesday - works at Yong Thai Hang, a health product shop that primarily serves Chinese tourists. Her husband, a 45-year-old Singaporean tested positive on Wednesday at about 2pm, and is currently warded in an isolation room at the National Centre for Infectious Diseases (NCID). Both have no recent travel history to China. The couple's child, a six-month-old boy, tested positive at the same time and is currently warded in an isolation room at KK Women's and Children's Hospital. The family's domestic helper was one of the confirmed cases on Tuesday. MOH said in an update on Thursday that the child

was not in any infant care facility and was cared for at home, prior to being admitted to the hospital.” -
Quoted from

<https://www.channelnewsasia.com/news/singapore/wuhan-virus-coronavirus-singapore-number-cases-12395978>

**Thanks, Best Regards & God Bless,
Bernice Huang**

(b) (6)

--
Best Regards, Bernice

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:12:55 +0000
To: Sheeley, Colin (NBCUniversal)
Subject: RE: NBC News Inquiry

I know that it is frustrating for you, but they still have not changed the official number, even though we know that it is certainly more than 44. Sorry.

From: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>
Sent: Tuesday, February 18, 2020 12:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal) <Gemma.DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>
Subject: RE: NBC News Inquiry

Thank you Tony,

We heard this evening that there were 169 new confirmed cases aboard the cruise ship. Do you know if this changes the "official public" number at all?

Thanks,
Colin

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 17, 2020 8:19 AM
To: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>
Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimirro, Gemma (NBCUniversal) <Gemma.DiCasimirro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>
Subject: [EXTERNAL] RE: NBC News Inquiry

Colin:

Thanks for the note. The number 44 is in flux. When I checked a couple of days ago, the "official public" number was 44. However, it was clear that there was likely more than that since the results of the tests were still coming back on some individuals. And so, it is a minimum of 44 infected from the cruise ship, but it is uncertain how many more than 44 are infected. I do not know where the Americans are staying

Best,
Tony

From: Sheeley, Colin (NBCUniversal) <Colin.Sheeley@nbcuni.com>

Sent: Monday, February 17, 2020 3:36 AM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Cc: Chirbas, Kurt (NBCUniversal) <Kurt.Chirbas@nbcuni.com>; Varela, Jay (NBCUniversal) <jay.varela@nbcuni.com>; Santana, Cristian (NBCUniversal) <Cristian.Santana@nbcuni.com>; Mitchell, Alexander (NBCUniversal) <Alexander.Mitchell@nbcuni.com>; DiCasimiro, Gemma (NBCUniversal) <Gemma.DiCasimiro@nbcuni.com>; Studley, Joe (NBCUniversal) <Joe.Studley@nbcuni.com>; Metsch, Abigail (NBCUniversal) <Abigail.Metsch@nbcuni.com>

Subject: NBC News Inquiry

Hi there,

I'm reaching out on behalf of NBC National News – would you be able to confirm that 44 Americans aboard the Diamond Princess cruises ship have tested positive for coronavirus?

Also, would you be able to say where the Americans are staying as they are being treated for the virus?

Please **REPLY ALL** with your response, or give us a call at (212) 664-5222.

Thank you,
Colin

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 11:08:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CNNi Interview Request: Anthony Fauci

Let us discuss.

From: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Sent: Tuesday, February 18, 2020 5:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Rodbeek, Rosanne <Rosanne.Rodbeek@turner.com>; Avramova, Nina (NE) <Nina.Avramova@turner.com>
Subject: CNNi Interview Request: Anthony Fauci

Dear Mr Fauci,

I hope this finds you well.

I'm writing to you from CNN International to see if you are available to join [Becky Anderson](#) on her prime time flagship show '[Connect the World](#)' for a live interview on today to discuss the coronavirus.

The show airs live between **10amET – 12pmET** – do you have any availability during these hours to come to a convenient bureau?

We really loved having you on the show last Sunday! As the director of the National Institute of Allergy and Infectious Diseases your insight is always great for our global audience.

Might it be possible to arrange something?

Background on CNN

- CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
- CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin America.
- In September 2019 [CNN.com](#) had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.

Best,

Joanna Hynds


Planning Desk

CNN International

+ 44 207 693 1640 (office)

+ (b) (6) (cell)

joanna.hynds@turner.com



Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 10:44:58 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Confirmation from CNN's New Day

OK. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, February 18, 2020 5:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: Confirmation from CNN's New Day

Firm hit for this morning in med arts studio at 715 am

Be in studio at 7 am

Sent from my iPhone

Begin forwarded message:

From: "Steinfeld, Alix" <Alix.Steinfeld@turner.com>
Date: February 18, 2020 at 5:13:08 AM EST
To: "Figliola, Mike" <Mike.Figliola@turner.com>, Jonathan Bennett
(b) (6) >
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >, "Daniels, Ronnel
(NIH/OD/ORS) [C]" (b) (6) "Ryland, Ken (NIH/OD/ORS) [E]"
(b) (6) >, "Jackson Farrar, Joy (NIH/OD/ORS) [E]"
(b) (6)
Subject: RE: Confirmation from CNN's New Day

Good Morning
We have DR. ANTHONY FAUCI on New Day
Hit Time; 715aEST
IFB: 212.275.9225
PL: 212.275.9325
CONTROL: 212-275-9053
PO: 660980
Thanks
Alix

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Tuesday, February 18, 2020 5:12 AM
To: Jonathan Bennett (b) (6) Steinfeld, Alix

<Alix.Steinfeld@turner.com>

Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Daniels, Ronnel (NIH/OD/ORS) [C] (b) (6)>; Ryland, Ken (NIH/OD/ORS) [E] (b) (6)>; Jackson Farrar, Joy (NIH/OD/ORS) [E] (b) (6)

Subject: RE: Confirmation from CNN's New Day

Importance: High

Adding Alix who has that info

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com



CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Jonathan Bennett (b) (6)

Sent: Tuesday, February 18, 2020 5:05 AM

To: Figliola, Mike <Mike.Figliola@turner.com>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Daniels, Ronnel (NIH/OD/ORS) [C] (b) (6); Ryland, Ken (NIH/OD/ORS) [E] (b) (6); Jackson Farrar, Joy (NIH/OD/ORS) [E] (b) (6)>

Subject: Re: Confirmation from CNN's New Day

Mike,

Received and noted. What are the control room and and IFB numbers?

Jonathan

On Tue, Feb 18, 2020, 3:14 AM Figliola, Mike <Mike.Figliola@turner.com> wrote:

Hi everyone,

This is Mike with CNN's New Day. Hope you are well.

This is to confirm Dr. Fauci will be a guest today, **Tuesday 02.18.20** at around **7am EST** to discuss:

7A:

Latest on Americans who tested positive after evacuation from cruise ship; What we know about how coronavirus spreads <https://www.cbsnews.com/news/transcript-dr-anthony-fauci-on-face-the-nation-february-16-2020/>

You will be **solo at 7am EST** for the segments.

Alisyn Camerota and Jim Sciutto, in for John Berman, will both be conducting today's interview.

Please arrive at the studio no later than **6:50am EST**.

Here is your studio confirmation:

STUDIO INFO 2013424

THIS INTERVIEW WILL B E FROM their NIH MED ARTS STUDIO with a direct IFB connection

Control Room numbers are 301-827-8478 and 8479

Encompass Booking and Circuit Number:

Booking: 1-800-243-1995

Circuit: 36TBGS104492

Our IFB: 301-496-1811 (we prefer to call into the station's IFB)

Video: 1080i - the audio is embedded.

Please confirm you have received this and are all set to go!

Best,

M

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com



CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 03:08:59 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject: RE: New Coronavirus Draft Messaging

Short and sweet. Looks fine. Thanks.

From: Holland, Steven (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 17, 2020 10:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: New Coronavirus Draft Messaging

Tony,

When you get a moment could I get your take on this most recent iteration. Apologies for the intrusions.

Thanks

Steve

—
Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
301-402-7684 voice
(b) (6) fax
(b) (6) email

Assistant lab: Eva Portillo
(b) (6) email
(b) (6) voice

Assistant to SD: Beth Schmidt
(b) (6)
(b) (6)

From: "Bailin, Heike (NIH/OD/ORS) [E]" (b) (6)>
Date: Monday, February 17, 2020 at 10:01 PM
To: "Moss, Bradley (NIH/OD/ORS) [E]" (b) (6)
Cc: "Gottesman, Michael (NIH/OD) [E]" (b) (6), Steven Holland
(b) (6), "Schmitt, James (NIH/OD/ORS) [E]"
(b) (6) "Johnson, Alfred (NIH/OD) [E]" (b) (6),
"Palmore, Tara (NIH/CC/OD) [E]" (b) (6)>, "McGowan, Colleen

(NIH/OD/ORS) [E]" [REDACTED] (b) (6), "Cullen, William (NIH/OD/ORS) [E]"
[REDACTED] (b) (6)>, "Newcomer, Derek (NIH/OD/ORS) [E]"
[REDACTED] (b) (6)>, "Tosten, Timothy (NIH/OD/ORS) [E]"
[REDACTED] (b) (6)

Subject: Re: New Coronavirus Draft Messaging

Brad- thank you. I liked much of what you did. And thanks to all who've commented and edited. Your points are well taken.

For the sake of clarity and effectively steering folks to OMS for the proposed ICP measures I favor focusing the message even more. Pease find attached OMS edits:

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 03:05:47 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID 19 Diamond Princess Patients Possible Transmission by Fomites
Attachments: SARS Transmission Fomites Temperature and Humidity Variables.pdf

Please have someone respond

From: Angela Moore <(b) (6)>
Sent: Monday, February 17, 2020 10:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: COVID 19 Diamond Princess Patients Possible Transmission by Fomites

I am a dermatologist but also a clinical researcher and scientist.
I was reading all of the news regarding concerns and questions on how the fellow patients are being infected.

A few questions arose, based on the NIH data on SARS Coronavirus, that has been much more studied, and most likely less virulent than the current COVID 19, which supposedly has HIV traits as well as traits to increase transmission.

I have wondered if COVID-19 is like Legionella, and possibly transmitted in the airborne water droplets in the air conditioning units of the Diamond Princess ship.

Even with the SARS Coronavirus, it was shown to be infective on fomites for up to 28 days unless 40 degrees Celsius and 80% humidity, when it was then inactivated in a few hours (see the attached article). I am wondering if the trays of food, after being passed to passengers on the ships, were then washed in suboptimal conditions (NOT at 40 degrees Celsius for several hours at 80% humidity)

I AM concerned, that based on the reinfection of those in Wuhan, China, after they returned home, on whether 14 days of quarantine is enough, based on the modeling and studies on the SARS Coronavirus, and whether 28 days of quarantine may actually be needed.

With the HIV virus component of COVID 19, one must also wonder if the T cells are being infected and passing the infection along within an infected patient. In the U.S., we may need to beware of blood transfusions from anyone infected, even asymptotically, with COVID 19.

I am sure that you have teams of clinicians and scientists working on this, and I don't know if any of the original scientists working on the SARS models are still around at Chapel Hill to perform these related studies and modeling.

Angela Moore

Angela Yen Moore, MD
Arlington Center for Dermatology
Arlington Research Center

711 East Lamar Blvd., Suite 200
Arlington, Texas 76011
phone 817-795-7546
fax 817-226-7546

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:48:13 +0000
To: bdoherly@mms.org
Cc: lbaden@nejm.org; Redfield, Robert R. (CDC/OD); (b) (6); Eisinger, Robert (NIH/NIAID) [E]; Greg Folkers ((b) (6)); Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: New England Journal of Medicine Editorial
Attachments: NEJM Editorial - Fauci et al - FINAL - 02-18-2020.docx

Briana and Lindsey:

As promised, I am attaching the invited Editorial related to the COVID-19 manuscript that we had discussed. Should I also submit it through the NEJM online website or will you take care of this? We will send in the COI and authorship forms in the next day or 2. Please let me know if you have any questions. Thank you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Briana Doherty <onbehalf@manuscriptcentral.com>
Sent: Monday, February 10, 2020 11:11 AM
To: Fauci, Anthony (NIH/NIAID) [E]; (b) (6)>
Cc: lbaden@nejm.org
Subject: New England Journal of Medicine Editorial

Dear Dr. Fauci,

I am delighted that you have agreed to write a signed editorial to accompany the article on the initial estimates of key transmission parameters associated with nCoV-2019 virus by Li et al.

The general purpose of the Journal's editorials is to provide the reader with an authoritative interpretation or elaboration based on the substance of the article. Since this substance is usually not within the average reader's special competence, such readers will particularly benefit if the editorial avoids technical jargon, explains the article's contribution to a field of knowledge, and emphasizes, whenever possible, its clinical implications. The editorial commentary should not be concerned exclusively with the article in question but rather should use the article as a starting point for a more general discussion.

Because editorials involve interpretation and opinion, you and your potential coauthor must be free of significant

relevant financial associations (including equity interest, regular consultancies, or major research support) with a company, or with a competing company, that stands to gain from the use of a product discussed in the editorial. Please contact me immediately if you are considering a coauthor, so I can ensure that your candidate meets our criteria. Additional information about disclosure of financial and other associations appears below this letter.

Please bear in mind that your editorial represents your (and any coauthor's) personal opinion. The Journal does not include statements of grant or other support or acknowledgments with editorials.

Journal policy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each author before a manuscript can be accepted. Therefore, the enclosed form should be signed by all authors and faxed to (781) 207-6529.

Your editorial is due at the Journal on Monday, February 17, at the very latest if the deadline imposed by our printing schedule is to be met. If the editorial is to include a figure, please submit the figure at least one week before the due date for the editorial itself.

*** Additional information about preparing and submitting your editorial is given below; please read it carefully. ***

The editors must reserve the right to edit (or even reject) your editorial, but whether we use it or not, the Journal currently offers a modest stipend of \$300.

Thanks again for agreeing to write this editorial for the Journal. I look forward to receiving it.

Sincerely yours,

Lindsey R. Baden, M.D.
Deputy Editor

New England Journal of Medicine
10 Shattuck Street
Boston, MA 02115
(617) 734-9800
Fax: (617) 739-9864
<http://www.nejm.org>

LENGTH OF YOUR EDITORIAL

NEJM editorials should not exceed two printed pages. This means that your word count before editing should not exceed 750 words (approximately 4500 characters). Note that we spell out trial names and most other abbreviations for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the text; the entire manuscript, including references, should be double-spaced.

REFERENCES

Cite no more than 10 references, including the article you are writing about. The average collection of 10 references requires about a quarter of a printed page.

TABLE OR FIGURE

A table or a figure in your editorial will require a reduction in the number of words; because figures and tables vary in size, you may be asked to shorten the text of your editorial during the production process. A quarter-page table roughly equals 250 words, and a half-page table roughly equals 500 words.

DISCLOSURES

When completing your disclosure form, please indicate, in the "Comments" field next to the type of relationship being disclosed, the amount (in U.S. dollars) of any support you have received. Please also indicate how much of

this support has been received over the past 2 years. Please e-mail your completed disclosure form to editorial@nejm.org.

In the event of publication, each author's submitted disclosure form will be posted on the Web (with any dollar amounts redacted).

COPYRIGHT TRANSFER

Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 781-207-6529 as soon as possible.

TO SUBMIT YOUR EDITORIAL

*** It is important that you follow the instructions below to ensure that your article enters the correct queue. ***

When you are ready to submit your manuscript, please log in to the New England Journal of Medicine - Manuscript Central site (<http://mc05.manuscriptcentral.com/nejm>). Your case-sensitive USER ID is afauci@niaid.nih.gov. For security purposes, your password is not listed in this message. If you are unsure of your password, please visit <https://mc05.manuscriptcentral.com/nejm> and enter your e-mail address in the "Forgot Your Password?" field.

Once you are logged in, the Main Menu will be displayed. Please click on the Author Center, where you will find the manuscript listed under "Invited Manuscripts." You can click on the "Continue Submission" button to begin submitting your article.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:09:48 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Comments on Tedros

FYI

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 17, 2020 10:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Comments on Tedros

BTW, I just saw that you tried me earlier and I didn't respond. I was in Geneva and evidently didn't have service. Hope we can connect this time. Best number is my desk, +44 2035 251028. Thanks again, JL

From: John Lauerman (BLOOMBERG/ NEWSROOM:) At: 02/17/20 14:37:11
To: AFAUCI@NIAID.NIH.GOV
Subject: Comments on Tedros

Hi Dr. Fauci: I'm working on a story about WHO DG Tedros and the work that he's doing to contain the coronavirus epidemic. I'm planning on discussing a number of themes, including that responding to outbreaks has become the most visible job of the DG in the past couple of decades. I'd also like to explore the issue of how important it is that countries be as open as possible about disease outbreaks, and that it's the DG's job to encourage that and move countries toward greater transparency and participation in battling outbreaks. Would you care to comment on the job that Tedros is doing in these areas? Please give me a call at +44 2035 251028 or let me know when and at what number to call you. Thanks and regards, John Lauerman, Bloomberg News

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel: +44 (0) 2035 251028 cell (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:09:18 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Comments on Tedros

Please try to set up a call with John Lauerman.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Monday, February 17, 2020 9:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Comments on Tedros

Hi Dr. Fauci: I'm working on a story about WHO DG Tedros and the work that he's doing to contain the coronavirus epidemic. I'm planning on discussing a number of themes, including that responding to outbreaks has become the most visible job of the DG in the past couple of decades. I'd also like to explore the issue of how important it is that countries be as open as possible about disease outbreaks, and that it's the DG's job to encourage that and move countries toward greater transparency and participation in battling outbreaks. Would you care to comment on the job that Tedros is doing in these areas? Please give me a call at +44 2035 251028 or let me know when and at what number to call you. Thanks and regards, John Lauerman, Bloomberg News

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 02:02:35 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: [REDACTED] (b) (5)

Cristina:

[REDACTED] (b) (5)

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Mon, 17 Feb 2020 20:56:50 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: (b) (5) for SARS-CoV-2

(b) (5)

On Feb 17, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E]

(b) (6) wrote:

Hi Tony,

(b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 00:20:01 +0000
To: Townsend, Frances
Subject: RE: This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number...

Fran:

Thanks for the note. You certainly have covered a lot of ground with your questions. I look forward to seeing you tomorrow.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Townsend, Frances <FTownsend@MAFGRP.COM>
Sent: Monday, February 17, 2020 6:55 PM
To: (b) (6); Shuy, Bryan (OS/ASPR/IO) (b) (6)
Fauci, Anthony (NIH/NIAID) [E] (b) (6) Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Cc: Hanson, Elizabeth <ehanson@MAFGRP.COM>
Subject: This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number...

All. Below is an outline of questions for tomorrow at CFR. Sorry to get this to you late but it seems the news changes everyday. As you will see I focus mostly on coronavirus as I suspect that's where the interest will be but get to bio weapons toward the end.

I am happy to take additional questions or suggestions. These sessions go quickly and we have time for Q and A so I doubt I will get through it all but wanted you all to have something to look at.

Thanks again for doing this tomorrow.

Best
Fran

This ongoing 2019 novel coronavirus, or COVID-19, outbreak has a number of historic firsts. It's the largest quarantine in world history with China locking down over 60 million people. It's the first mass repatriation of American citizens into a quarantine, climbing over 1,000.

Let's start with some quick basics: what is coronavirus? How contagious? What is the morbidity rate?

How does it compare to SARs and MERs? More/less infectious? Lethal?

Just to put this in perspective every year here in the US we deal with the flu. How many Americans on average die each year from the flu?

But as I mentioned coronavirus has resulted in a number of historic firsts, talk about what you expect could be our scientific firsts and what roadblocks do those scientific firsts confront?

Over the years, global economic interdependence has grown in nearly every industrial sector, including health care. But that means our health care is also globally interdependent on other systems less equipped, less transparent and perhaps less responsible global actors.

China closed the wet market where the coronavirus outbreak began on 1/1, gene sequenced the virus on 1/9 so they could develop a diagnostic test but did not share the gene sequence with the global health community until 1/12.

How transparent and quick was the Chinese response? What should they have done that they failed to do? What were the consequences?

China now claims more than 70K infected and almost 1800 deaths from the virus. But it has been widely reported that the Chinese have underreported both numbers. What are countries' international obligations to report accurately? To whom? How do you know the numbers are accurate?

How does the current outbreak impact the domestic medical supply chain? What steps could or should we consider to enhance supply chain resilience?

What do the numbers suggest to you about what to expect regionally and worldwide? Have numbers peaked? Will they continue to rise? With the cruise ship there are now a total of 15 Americans infected. Do you expect additional cases? What scale? How prepared are we nationally? Locally?

Looking back over the roughly past decade, emerging infectious diseases played a recurring ominous theme. Be it from H1N1, to ebola, then Zika, and now the 2019 novel coronavirus, the threat is clearly not dissipating. When it comes to non-disease natural disasters, the Stafford Act provides a Disaster Relief Fund to enable immediate response. By comparison, there is a small Infectious Diseases Rapid Response Reserve Fund. Do we need a more Stafford Act-like mechanism to enable quicker response and research to these new threats? What other actions can we take to better prepare?

While often we see folks painting emerging infectious diseases and biodefense into separate categories, the truth is that there is significant crossover in terms of preparedness and research. Understanding that this is a sensitive topic, could you talk about how we should approach these risks in a comprehensive manner that can achieve public health and national security objectives concurrently?

I'd like to use this to transition to the topic of bio weapons which is what we originally planned to talk about. The landscape here has also transformed. When BioShield was written and the Strategic National Stockpile established we worried about State actors deploying banned weapons like smallpox, plague and hemorrhagic fever. And you

still must prepare against those things as well as new and emerging threats like the toxins we have seen deployed by Russia and North Korea in more targeted assassinations.

How do you stay ahead of these threats? Do we have the resources and surveillance that we need to stay ahead of the threat? And ensure the necessary vaccines and therapeutics?

The ebola outbreak may be an instructive example, it seems to be coming under some control despite the precarious security situation in the Democratic Republic of Congo. But the ongoing 2018 outbreak was the second largest in history following the 2013-2016 West African outbreak. As a result of these outbreaks, the United States government has pioneered new FDA-approved diagnostics and vaccines, with promising therapeutics seemingly around the approval corner too. What lessons can we draw from the ebola outbreaks? How do you work with and incentivize industry to develop what you need in the event of a catastrophic bio attack? And How do you make the best possible decisions about the stockpile?

I always worried that because we are global leaders if there was a bio attack or outbreak anywhere in the world, others would look to us and to our stockpile for the answer. Are our global allies doing enough to prepare against these threats--whether they be manmade or natural? Are they maintaining adequate stockpiles of medical countermeasures and research bases--and should they be?

Lastly (if we have time)...the FBI recently arrested a Harvard scientist for accepting undisclosed grant money from China for scientific research. It has now been reported that there are similar investigations at a number of US universities including Yale and MIT to name two and that the grant monies are in the billions. What are foreign governments looking for? Why in the US? Clearly a national security risk, is it a bio weapons concern?

DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the person(s) named in the message header to whom the email is addressed and may contain information that is confidential or legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, copying, or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately and permanently delete this e-mail message and any attachments (and any copies or printouts of the same).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:29:27 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: COVID-1
Attachments: letter to NIAID-ICIS.pdf

Please respond to them. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fitzgerald, Kate <Kate.Fitzgerald@umassmed.edu>
Sent: Monday, February 17, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Eleanor Fish <en.fish@utoronto.ca>
Subject: COVID-1

Dear Dr. Fauci,

On behalf of the International Cytokine and Interferon Society, please find attached a letter from us as clinicians and scientists committed to developing and implementing therapeutic interventions targeted against global viral infection outbreaks. We propose that high priority be given to evaluating the therapeutic antiviral activities of IFN- α / β (clinically approved formulations) against COVID-19 which poses a potential threat to global health. Further information is detailed in the attached. The ICIS would be happy to provide the scientific and clinical expertise for this program and welcome further discussion. In particular Dr. Eleanor Fish copied above has the track record and expertise in this area.

Sincerely,

Kate A. Fitzgerald | Professor of Medicine
President | International Cytokine and Interferon Society (ICIS)

www.cytokinesociety.org

Join us @ Cytokines 2020



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:22:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Happenings Radio Q+A...

Let us discuss. She called me up today and I told her to send me an e-mail since I was on a call. (b) (3)
For discussion.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: cassidy@happeningsmag.com <cassidy@happeningsmag.com>
Sent: Monday, February 17, 2020 3:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Happenings Radio Q+A...

Hi there,
This is Cassidy G-D from Happenings Magazine & Radio in Kenosha, WI- we ever so briefly spoke on the phone earlier today.

I was reaching out with the hope of getting you on our radio program for a 20-30 minute Q+A in which we would talk about the Coronavirus and more specifically the impact it is having on the Diamond Princess Cruise ship along with anything you would like to talk about regarding infectious diseases and or your position as director of the National Institute of Allergy and Infectious Diseases.

Please let me know if you have any interest in being on the air with us and I would be happy to provide further details. You can also get ahold of me by our office phone at 262-564-8800.

Hope you are well and I look forward to hearing back from you, Cassidy G-D

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 19:50:25 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Erbeling, Emily (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: BMGF

Cristina:

I just spoke with Chris Carp and Trevor Mundel of the BMGF and they want to try and coordinate some of the things that they and we are doing regarding COVID-19. I told them to give you a call to set up a teleconference to discuss respective R & D agendas of NIAID and BMGF.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:58:46 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Info from China

Please have someone respond to this person.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

—Original Message—

From: Jodie Dillman <(b) (6)>
Sent: Monday, February 17, 2020 12:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Info from China

Dear Dr. Fauci,

It is with trepidation that I reach out to you with information that has been shared with me regarding the real status of the Coronavirus in China. My information comes to me from a (b) (6) who has correspondence from a nurse in Harbin, China.

(b) (6) is here on an H1V visa, employed for the past several years at (b) (6) in the international student program. (b) (6)

(b) (6) I have no reason to doubt the authenticity of the correspondence that she shared with me.

This correspondence shows a lung X-ray, a glass container of bloody fluid removed from an infected lung, and a map of Harbin, China depicting many areas of the coronavirus outbreaks. The written correspondence reveals that the numbers being released of confirmed deaths is drastically low due to the spread being too fast to test. Deaths in hospital hallways and of medical staff is not being shared in order to prevent panic.

Protective gear is unavailable and the nurse writing the correspondence is fearful for her life. She states that there are five levels of screenings (tests?) before a person is reported as testing positive or of being infected with the virus. If someone dies before being confirmed, these suspected deaths are covered up and not reported. Reported numbers, even of confirmed cases are grossly undercounted.

I figure you and our government realize the information and numbers coming out of China are highly inaccurate, but this correspondence on (b) (6) confirms it. I felt it was only ethical and moral to report this, despite (b) (6) plea that the two people involved in the correspondence fear governmental retribution if it was discovered that they discussed or passed on this confidential information.

I report this and swear it to be true and confidential. I am trusting it will help in some way and not just stir panic.

Jolonda Dillman

(b) (6)

A large rectangular area of the document is completely redacted with a solid grey fill, obscuring all text and graphics that would otherwise be present.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:51:17 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: AI supplementation of influenza surveillance system for COVID-19 outbreak.

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ed Peshko <esp@hedviginc.com>
Sent: Monday, February 17, 2020 1:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: AI supplementation of influenza surveillance system for COVID-19 outbreak.

ps - feel free to contact me at this address, or my personal email address, that is (b) (6)

again, I have no dog in this fight aside from wanting to avoid a large scale pandemic worldwide.

And I'm sincerely hoping that we throw the rulebook out - and develop a new one - to deal with this the same way we did when we dealt with the 1918-1919 pandemic.

On Mon, Feb 17, 2020 at 10:09 AM Ed Peshko <esp@hedviginc.com> wrote:

Dr. Fauci,

Like you, I've been watching the COVID-19 outbreak with great alarm. Given the current data, I'm almost positive at this point that it will hit the US hard at some point and as a student of history that terrifies me.

So I'm hoping that your department has contacted the Bill and Melinda Gates foundation and see if you could make the following idea national or international. It is a supplemental health system based on AI and mobile technology and consists of two planks:

First:

- train an AI to be able to detect COVID-19 by measurements that can be done by cell phone (for example pictures of patients, recordings of patient's respiratory system)

Second:

- develop and release a smart-phone application that does the following:
 - turns on location tracking so health authorities can see where the cell phone owner is.
 - allows for people to upload health measurements from their cell phone.
 - keeps TRACK of where the cell phone owner is. If that person then tests positive for COVID later on, it can then automatically figure out all the contacts of that person for the last 14 days.
 - notifies those contacts that they have been in contact with someone with COVID-19, to isolate themselves and regularly test themselves.

The goal would be to prevent hundreds of thousands of people from descending on hospitals and overwhelming them, and to allow for the CDC or other medical personnel to go OUT and get them - or isolate them for treatment in their own homes - rather than having them come in and infect everybody.

Now this all hinges on the idea that AI could detect COVID-19 based on an audio recording or a simple picture and do it reliably, but I'm fairly sure that it can based of the peer-reviewed literature. It is not a difficult AI problem assuming that the microphone can pick up sounds well enough - if not, there are already integrated stethoscopes for cell phones that could be mass produced - and once developed to enough precision it could be deployed nationally or internationally fairly easily.

For all I know something like this is already in the works but I haven't heard of anything like it - apart from the chinese app which AFAICT does not use any AI but DOES allow for automatic contact tracing.

I sincerely hope this is already in the works. Ultimately it could be used both for detection and treatment - assuming the current antivirals work out they could be distributed to the same coordinates that positive diagnoses come in, perhaps by cheap drone so that nobody actually needs to be exposed to the virus to effect treatment.

Anyways, thanks for your time and efforts. Personally I'm a software developer but I'm hoping that perspective his helpful - for I view the fight against this virus as an INFORMATIONAL fight. It's like a fire-suppression system or food safety measures. Again, I have no clue whether or not this is already being done, and I apologize in advance if I'm missing something and this all seems obvious.

I just think that in this case it is prudent for us to be safe rather than sorry.

Thanks much,

Ed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 18:47:09 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: AI supplementation of influenza surveillance system for COVID-19 outbreak.

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ed Peshko <esp@hedviginc.com>
Sent: Monday, February 17, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: AI supplementation of influenza surveillance system for COVID-19 outbreak.

Dr. Fauci,

Like you, I've been watching the COVID-19 outbreak with great alarm. Given the current data, I'm almost positive at this point that it will hit the US hard at some point and as a student of history that terrifies me.

So I'm hoping that your department has contacted the Bill and Melinda Gates foundation and see if you could make the following idea national or international. It is a supplemental health system based on AI and mobile technology and consists of two planks:

First:

- train an AI to be able to detect COVID-19 by measurements that can be done by cell phone (for example pictures of patients, recordings of patient's respiratory system)

Second:

- develop and release a smart-phone application that does the following:

- turns on location tracking so health authorities can see where the cell phone owner is.
- allows for people to upload health measurements from their cell phone.
- keeps TRACK of where the cell phone owner is. If that person then tests positive for COVID later on, it can then automatically figure out all the contacts of that person for the last 14 days.
- notifies those contacts that they have been in contact with someone with COVID-19, to isolate themselves and regularly test themselves.

The goal would be to prevent hundreds of thousands of people from descending on hospitals and overwhelming them, and to allow for the CDC or other medical personnel to go OUT and get them - or isolate them for treatment in their own homes - rather than having them come in and infect everybody.

Now this all hinges on the idea that AI could detect COVID-19 based on an audio recording or a simple picture and do it reliably, but I'm fairly sure that it can based on the peer-reviewed literature. It is not a difficult AI problem assuming that the microphone can pick up sounds well enough - if not, there are already integrated stethoscopes for cell phones that could be mass produced - and once developed to enough precision it could be deployed nationally or internationally fairly easily.

For all I know something like this is already in the works but I haven't heard of anything like it - apart from the chinese app which AFAICT does not use any AI but DOES allow for automatic contact tracing.

I sincerely hope this is already in the works. Ultimately it could be used both for detection and treatment - assuming the current antivirals work out they could be distributed to the same coordinates that positive diagnoses come in, perhaps by cheap drone so that nobody actually needs to be exposed to the virus to effect treatment.

Anyways, thanks for your time and efforts. Personally I'm a software developer but I'm hoping that perspective is helpful - for I view the fight against this virus as an INFORMATIONAL fight. It's like a fire-suppression system or food safety measures. Again, I have no clue whether or not this is already being done, and I apologize in advance if I'm missing something and this all seems obvious.

I just think that in this case it is prudent for us to be safe rather than sorry.

Thanks much,

Ed

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 17:42:47 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: PBS NewsHour inquiry for today

FYI

Let us discuss after I get off the AMA call, which is going long

From: David Coles <dcoles@newshour.org>
Sent: Monday, February 17, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: PBS NewsHour inquiry for today

Dr. Fauci,

Might you be available to update our viewers on the latest developments in the coronavirus story today/tonight? We are particularly interested in getting your evaluation of the passengers who have been released from two cruise ships. The first, in Yokohama, Japan, where over 300 Americans released from the ship have now arrived back in the US, to go into 14 days of quarantine. 14 of those people tested positive at some point after leaving the ship, but before they boarded the plane. The second ship we want to focus on is in Cambodia. Something in the neighborhood of 1,000 passengers released from that ship have been reported to be in some state of travel to their homes, presumably around the globe. One woman who made it as far as Malaysia tested positive there and is hospitalized in Kuala Lumpur. We do know that the CDC is working with WHO and the cruise ship line to track down those traveling people.

We would very much like to hear from you what level of concern we should have over those many hundreds of people traveling right now, how well quarantine works, how important it is to maintain it, etc. We would also like to touch on the methods of containment and treatment being done inside China and how well those methods have worked.

I realize it is a holiday, and that could complicate things. But please let me know whether you could consider this, Doctor, and we will begin to work out the logistics.

Thank you.

Very best regards,
Dave

David Coles
Deputy Senior Producer, National Affairs



703 998 2104

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 16:35:20 +0000
To: Smith, Steven
Subject: Re: i've been thinking about you
Attachments: image003.png

Steven:

Thanks for the note. Much appreciated. It has been 24/7 for me for the past 4 weeks. Hope that all is well with you.

Best,

Tony

On Feb 17, 2020, at 10:39 AM, Smith, Steven <Steven.Smith@[REDACTED]> wrote:

Having just come back from Australia where coronavirus is hands down a national emergency, I've been thinking about you again and all the good work you do to keep us safe.

I was with someone who's a diplomat with the Australian government who said "it's much, much worse than the Chinese would have you believe. Much worse." Melbourne and Sydney were deserted almost immediately of Chinese tourists and students. I luckily flew through DOHA.

Hang in there. It's always something.

Steven

Steven W. Smith [REDACTED]

(b) (6)
(b) (6)

<image003.png>

This message, including attachments, is confidential and may be privileged. If you received this in error, please notify me by reply email and delete this message.

[REDACTED] (b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 14:14:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Request from CNN's New Day
Attachments: image001.jpg

Thanks

On Feb 17, 2020, at 9:11 AM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) wrote:

Working on this from med arts for tomorrow as well. Just FYI

Sent from my iPhone

Begin forwarded message:

From: "Figliola, Mike" <Mike.Figliola@turner.com>
Date: February 17, 2020 at 8:42:38 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Subject: RE: Request from CNN's New Day

Copy will be back soonest

M

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please

immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED]>
Sent: Monday, February 17, 2020 8:42 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Between 7 am – 7:50 am ET

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Monday, February 17, 2020 8:40 AM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED]>
Subject: RE: Request from CNN's New Day

Working on timing – is there a preferred time?

Mike Figliola
Editorial Producer
CNN's New Day
<[REDACTED]>
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED]>
Sent: Monday, February 17, 2020 8:40 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: Re: Request from CNN's New Day

Would hit time be 1. The 7 am hour? Do I have exact time?

Sent from my iPhone

On Feb 17, 2020, at 4:16 AM, Figliola, Mike
<Mike.Figliola@turner.com> wrote:

Hi Patty,

Mike with cnn and new day here

Hope all is well

We are interested in checking Dr Fauci's availability for
Tuesday's show.

May you let me know if he is avail and what time frame works
best?

Topic is Coronavirus

Thanks!

M

Sent from my iPhone

On Jan 30, 2020, at 10:05 AM, Figliola, Mike
<Mike.Figliola@turner.com> wrote:

Hi Patty!

Morning

If we want Fauci for tomorrow, is he avail?

Barring maj breaking news we are not planning to
cancel

Thoughts?

M

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Figliola, Mike
Sent: Thursday, January 23, 2020 10:22 AM
To: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Subject: RE: Request from CNN's New Day

Copy thank you!

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)
mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission

and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Sent: Thursday, January 23, 2020 10:16 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Per our chat just now – can have him avail between 6 am – 8:15. Hard stop at 815 am ET

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious
Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Thursday, January 23, 2020 10:02 AM
To: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Subject: RE: Request from CNN's New Day

Ok – we wont know until 1030a meeting – is it ok to hold 6 and 7a until then?

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)

Sent: Thursday, January 23, 2020 10:00 AM

To: Figliola, Mike <Mike.Figliola@turner.com>

Subject: RE: Request from CNN's New Day

Sorry to be a pain-if you think it will be in the 6 am hour – we might need to use a different studio...if its in the 7 am hour we can use our remote studio...

Any thoughts as to which hour again, sorry

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious
Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03

Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>

Sent: Thursday, January 23, 2020 9:23 AM

To: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)>

Subject: RE: Request from CNN's New Day

Copy thank you

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Sent: Thursday, January 23, 2020 9:18 AM
To: Figliola, Mike <Mike.Figliola@turner.com>
Subject: RE: Request from CNN's New Day

Checking now for all times between 6-9 will let you know soonest

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious
Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Figliola, Mike <Mike.Figliola@turner.com>
Sent: Thursday, January 23, 2020 9:10 AM
To: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)
Subject: RE: Request from CNN's New Day

Hi again

Could be back half of 7am but if this gets much worse we may play it higher in the hour – is there any time that doesn't work?

Mike Figliola
Editorial Producer
CNN's New Day
(b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.

From: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)

Sent: Thursday, January 23, 2020 8:57 AM

To: Figliola, Mike <Mike.Figliola@turner.com>

Subject: FW: Request from CNN's New Day

Hi Mike – we can make this happen. The 7 am hour is best for us but will get back to you. do you have an idea of the hit time? need to make sure our nih studio is available.

thx

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious
Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Begin forwarded message:

From: "Figliola, Mike"
<Mike.Figliola@turner.com>
Date: January 23, 2020 at 8:36:15 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]"
(b) (6)
Subject: RE: Request from CNN's New Day

Hi everyone,

This is Mike with CNN's New Day

Hope you are well

We would like to invite Dr, Fauci back to the program to discuss coronavirus

Might he be available tomorrow

We air 6-9am and happy to provide car service to and from the studio wherever you are located. John Berman and Alisyn Camerota anchor from NY.

Thoughts?

best,

M

Mike Figliola

Editorial Producer

CNN's New Day

(b) (6)

mike.figliola@turner.com

<image001.jpg>

CONFIDENTIALITY NOTICE: This e-mail transmission, and any documents, files or previous e-mail messages attached to it, may contain confidential information that is legally privileged. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in or attached to this message is STRICTLY PROHIBITED. If you have received this transmission in error, please immediately notify us by reply e-mail at mike.figliola@turner.com or by telephone at (917) 670-9410, and destroy the original transmission and its attachments without reading them or saving them to disk. Thank you.



NIH-00184



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 13:50:10 +0000
To: Natalie Rahhal
Cc: Kadlec, Robert (OS/ASPR/IO)
Subject: FW: Comments re: 14 US passengers with coronavirus and updates

Natalie:

I sent the incorrect e-mail address for Dr. Kadlec. Here is the correct one.
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, February 17, 2020 8:47 AM
To: Natalie Rahhal <(b) (6)>
Cc: <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Comments re: 14 US passengers with coronavirus and updates

Natalie:

Thank you for your note. Dr. Robert Kadlec, the Assistant Secretary for Preparedness and Response (ASPR) at HHS could either answer this question or point you in the direction of someone who could. I am copying him on this e-mail.
Best regards,
Tony

From: Natalie Rahhal <(b) (6)>
Sent: Monday, February 17, 2020 8:28 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Comments re: 14 US passengers with coronavirus and updates

Hi Dr Fauci,

I hope this note finds you well and that you've gotten a little rest over the weekend, during what I'm sure is an inordinately busy time. Would you be able to elaborate on the measures taken to keep the 14 US evacuees who have coronavirus from infecting others on board the plane? I know that remdesivir, under compassionate use, was given to at least the first American coronavirus patient, and last week NIH researchers published results early that it had preventive effects for macaques exposed to MERS. Has the US considered using this drug to protect those exposed to but not yet infected with coronavirus?

Thank you,

Natalie A Rahhal
Acting US Health Editor

Daily **Mail**.com

Daily Mail Online | 51 Astor Place, 9th floor, New York NY 10003

Tel: +1 212 402 9086

Mobile: (b) (6)

Twitter: <https://twitter.com/natalier78?lang=en>

Email: Natalie.rahhal@mailonline.com

Disclaimer

This e-mail and any attached files are intended for the named addressee only. It contains information, which may be confidential and legally privileged and also protected by copyright. Unless you are the named addressee (or authorised to receive for the addressee) you may not copy or use it, or disclose it to anyone else. If you received it in error please notify the sender immediately and then delete it from your system. Associated Newspapers Ltd. Registered Office: Northcliffe House, 2 Derry St, Kensington, London, W8 5TT. Registered No 84121 England.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 13:24:34 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: ASF ----- attached for your review is draft abstract for Florence vaccine meeting
Attachments: Keystone abstract --transforming vaccinology -- 3-16-2020 - with minor Fauci edits.docx

Greg:

This looks great. I have made some minor edits that are tracked in the document. Please accept these and then it is ready to go. Thanks.

Best,

Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 12, 2020 1:47 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Subject: ASF ----- attached for your review is draft abstract for Florence vaccine meeting

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 22:28:19 +0000
To: Jon LaPook
Subject: RE: Coronavirus

Jon:

I have no idea what this guy is talking about. I have never said the R0 was close to 5 or 6. The R0 is about 2.0 to 2.2. Also, the situation is as we have discussed on several occasions. In the USA, the travel restrictions seem to be working with only 15 cases in the USA (13 travel and 2 spouses). But, as I have said, this could change. If we get substantial sustained transmission in a number of countries throughout the world, including the developing world, then sooner or later there will be significant leakage of infected individuals into the USA since you cannot restrict incoming travel from the whole world. The way we might be able to avoid a real global pandemic is if the non-China countries can contain the infections in their respective countries before there is widely distributed sustained transmissions. Once widely distributed sustained transmissions happen, a global pandemic is inevitable. What would a global pandemic mean? It depends on the true rates of morbidity and mortality. The currently reported mortality of COVID-19 is about 2%. However, there are several folds more cases than are coming to the official attention of health authorities, i.e. asymptomatic or minimally symptomatic infections. If you count these, the denominator gets much larger and the case fatality rate could drop to 1% or even 0.5 % or less. If that is the case, then this could be a very severe seasonal flu (0.2% to 0.4%; regular seasonal flu is 0.1%) or a typical pandemic like 1957 or 1968 (0.5% -0.9 %). We are not sure where it is going to land.

Hope this is helpful.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6) >
Sent: Sunday, February 16, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus

Hi Tony,

I thought you would be interested to see a text (below my email) I just got from a very smart Wall Street guy who has been filling me in on reaction there. I've been doing my best on air to put the current situation in perspective - communicating that the risk in the U.S. is still relatively low while letting viewers know the situation is fluid and could change. How would you sum up where we are now?

Thanks,
Jon

TEXT I JUST RECEIVED:

"Doc, total panic mode setting in . Tony Fauci talking R nought at closer to 5 or 6. Good biotech guys saying it might not die down in April. People talking about 60% of us will get it ; unstoppable in Africa. I can't scare people but this is really bad. I hate bothering you on this but I know I need to take my cue from what you will say on CBS"

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 21:16:02 +0000
To: Lucassen, Elisabeth B
Subject: RE: Coronavirus patient--secure

Elisabeth:

Do you have time for a quick phone call?

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lucassen, Elisabeth B <Elisabeth.Lucassen@providence.org>
Sent: Friday, February 14, 2020 1:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Coronavirus patient--secure
Importance: High

Dear Dr. Fauci,

(b) (6)

(b) (6). Any input would be most appreciated. Many thanks in advance!

Sincerely,
Elisabeth Lucassen

This message is intended for the sole use of the addressee, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the addressee you are hereby notified that you may not use, copy, disclose, or distribute to anyone the message or any information contained in the message. If you have received this message in error, please immediately advise the sender by reply email and delete this message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:40:58 +0000
To: Redfield, Robert R. (CDC/OD)
Cc: Greg Folkers (b) (6)
Attachments: nejmoa2001316.pdf, NEJM Editorial - Fauci et al - clean with Fauci edits accepted.docx

Bob:

As per our discussion, I am attaching the Editorial together with the NEJM paper upon which the editorial is based. Please take a look and give your approval. Of course if you have any comments or edits, they are most welcome. As mentioned, the NEJM wants the manuscript by COB tomorrow (Monday).

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:20:29 +0000
To: Arthos, James (NIH/NIAID) [E]
Subject: RE: one on one

No problem. I am drowning in coronavirus and our meeting likely would have wound up being cancelled anyway. Hopefully, we will soon get back to some sort of normality in our meetings. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Arthos, James (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 16, 2020 2:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: one on one

Hi Tony,

I'm very sorry to bother you when you are so busy. Regarding this Tuesday, we are on your schedule for a one on one and unit head meeting. something came up last minute and I am going to be away from Tuesday through Friday, so I won't be able to make either. Sorry for the late notice.

Jim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 20:17:53 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: NEJM Editorial - Fauci et al - clean wuth additional Fauci edits - 02-15-2020.docx, NEJM Editorial - Fauci et al - clean with Fauci edits accepted.docx

Cliff;

I am attaching 2 documents: 1) The revised manuscript that Greg worked on in which I have added a number of tracked changes including deleting a substantial amount to get it between 800 and 900 words; and 2) A clean version where I have accepted all the tracked changes (Greg's and mine). Right now I like it the way it is and would not change it much if at all. What it needs now is references. Greg will take a shot at adding the references. If you have references, please send them to Greg and me. In the meantime, I will send it without references to Bob Redfield for his review/approval. Let us discuss by phone if you wish.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 19:19:00 +0000
To: Greg Folkers (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: NEJM Editorial - Fauci et al - clean wuth additional Fauci edits - 02-15-2020.docx, NEJM Editorial - Fauci et al - clean with Fauci edits accepted.docx

Greg;

I am attaching 2 documents: 1) The revised manuscript that you sent to me in which I have added a number of tracked changes including deleting a substantial amount to get it between 800 and 900 words; and 2) A clean version where I have accepted all the tracked changes (yours and mine. Right now I like it the way it is and would not change it much if at all. What it needs now is references. Can you add up to 10 references? It might be easier for you to do that rather than Cliff. If not, I will send to Cliff and see if he can do it. In the meantime, I will send it without references to Bob Redfield for his review/approval. Let us discuss by phone if you wish.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 16 Feb 2020 12:12:58 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19 therapy

Please handle.

----- Original Message -----

From: Cesare Cocchi [REDACTED] (b) (6) >
Sent: Sunday, February 16, 2020 5:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: COVID-19 therapy

Dear Doctor Fauci,

I am a pediatrician from [REDACTED] (b) (6) (IT).

I was wondering if high doses of vitamin A have been tried in the therapy of COVID-19.

Do you remember the cases of viral pneumonia due to measles that take place in African infants in the late seventies. It seemed to work.

Many sorry to bother you.

Have a good job!

Best regards

Cesare Cocchi MD

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 22:21:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: To VIMA newspaper-Greece-interview request-coronavirus

FYI

-----Original Message-----

From: Θεοδώρα Τσώλη <ttsoli@tovima.gr>
Sent: Saturday, February 15, 2020 4:22 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: To VIMA newspaper-Greece-interview request-coronavirus

Hallo

My name is Theodora Tsoli and I am a science editor for the greek newspaper To VIMA (www.tovims.gr) one of the biggest Sunday papers in my country. I would like to have, if possible, a telephone interview with dr Fauci on the coronavirus outbreak for next Sunday's paper. If he won't be able to speak, could I send questions to which he could answer?

Looking forward to your reply

Thank you in advance

Theodora Tsoli

Στάλθηκε από το iPhone μου

Σημαντικό: Παρακαλώ δείτε την δήλωση αποποίησης ευθυνών <www.alteregomedia.org/disclaimer.html>
Important: Please read our disclaimer <www.alteregomedia.org/disclaimer.html>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:26:27 +0000
To: Folkers, Greg (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject: RE: ASF RE: Dr. Fauci video request: Public Service Recognition Week
Attachments: ASF public service recognition - with tracked edits -05-05-2020.docx



See minor tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 6:16 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Awwad, David (NIH/NIAID) [C] (b) (6) >
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF RE: Dr. Fauci video request: Public Service Recognition Week

ASF –

Here is a short script for Public Service Recognition Week. We agreed to do a short video
ASF – can u tweak as needed?
David, could u record in some format that is easy? Cell phone or other I just learned they want by COB tomorrow

<< File: ASF public service recognition.docx >>

From: Seigfreid, Kim (NIH/OD) [E] (b) (6)>
Sent: Monday, April 27, 2020 4:30 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] (b) (6)>; Polimeni, Lydia (NIH/OD) [E] (b) (6)
Subject: Dr. Fauci video request: Public Service Recognition Week

Hi there,

Please see below. HHS is taking over the Partnership for Public Service IG account next week for Public Service Recognition Week. They asked if Dr. Fauci would be willing to do a short 30-second or less pre-recorded video thanking public servants for their work. It would be featured during the takeover, and also on NIH's other sm handles next week. It can be taken on a cell phone as sm does not require higher resolution. Let me know if you would like to accept or decline the request.

Many thanks,
Kim

Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: (b) (6)
(b) (6)

From: Muhammad, Janell (HHS/ASPA) <(b) (6)>
Sent: Monday, April 27, 2020 4:10 PM
To: Seigfreid, Kim (NIH/OD) [E] (b) (6)>; Channer, Amber (OS/OASH) (b) (6)>; Foster, Timothy (OS/ASPA) (b) (6)>
Cc: Palczewski, Andrew (HHS/ASPA) <(b) (6)>; Pratt, Michael (OS/ASPA) <(b) (6)>; Sherman, Jennifer (HHS/OASH) (b) (6)
Wilker, Michael (HHS/ASPA) (b) (6); Dine, Brooke (HHS/ASPA) (b) (6)
Subject: Public Service Recognition Week

Hello All,

Hope everyone is holding up well!

OHR is taking over the Partnership for Public Service (PPS) Instagram account during Public Service Recognition Week (May 3-9, 2020). The OHR team has reached out about wanting to develop a senior leader "mashup" video —perhaps including the DepSec. T

They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and the SG doing a pre-recorded video thanking public servants for their work.

I wanted to gather the troops so we can identify what all is being planned for this week of recognition and provide a POC for OHR if the request is feasible.

Happy to set up a call, if that is needed to discuss further.

Thanks,
Janell

Janell Muhammad

ASPA Digital Engagement (Team Lead)

U.S. Department of Health and Human Services

Email: (b) (6)

Office: (b) (6)

iPhone: (b) (6)

[HHS on Facebook](#) | [HHS on Twitter](#) | [HHS Latino](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:05:41 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study

See my minor change of my comment in red.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the ACTT 2 COVID-19 treatment trial (remdesivir and baricitinib). Below is your draft quote:

“We now have solid data showing that remdesivir diminishes to a modest degree the time to recovery for people hospitalized with COVID-19,” said NIAID Director Anthony S. Fauci, M.D. “ACTT 2 will examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients, including improving mortality outcomes.”

The trial may start enrollment tomorrow.

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:00:53 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19, (b) (4)
Attachments: Birman_Fauci_Azar_Adams_Hahn_letter_May_05_2020.docx

Please take a look at this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: (b) (4)
Sent: Tuesday, May 5, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Azar, Alex M. (b) (6); Adams, Jerome M <(b) (6)>; Hahn, Stephen (FDA) (b) (6)
Subject: RE: COVID-19, (b) (4)

Dr. Anthony S. Fauci, M.D.
Director, NIAID
Mr. Alex M. Azar II
Secretary, HHS
Dr. Jerome M. Adams, M.D.
Surgeon General, HHS
Dr. Stephen M. Hahn, M.D.
Commissioner of FDA, HHS

Dear Dr. Fauci,
Dear Mr. Azar,
Dear Dr. Adams,
Dear Dr. Hahn,

(b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 21:17:33 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Erbeiding, Emily (NIH/NIAID) [E]; Dieffenbach, Carl (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Graham, Barney (NIH/VRC) [E]; Marovich, Mary (NIH/NIAID) [E]
Subject: RE: D614G mutation paper

Thanks, John. [REDACTED] (b) (5)

[REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6) >
Sent: Tuesday, May 5, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); Erbeiding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] [REDACTED] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6); Graham, Barney (NIH/VRC) [E] [REDACTED] (b) (6) >; Marovich, Mary (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: D614G mutation paper

Tony,

David Montefiori will be on CNN tonight related to this paper – and story in in major newspapers. I spoke with David to get some advance info. The paper is out in BioRxiv.
Few key points

John

Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2

Korber B¹, Fischer WM¹, Gnanakaran S¹, Yoon H¹, Theiler J¹, Abfalterer W¹, Foley B¹, Giorgi EE¹, Bhattacharya T¹, Parker MD³, Partridge DG⁴, Evans CM⁴, de Silva TI^{4,5}, on behalf of the Sheffield COVID-19 Genomics Group⁶, LaBranche CC², and Montefiori DC²

Summary

We have developed an analysis pipeline to facilitate real-time mutation tracking in SARS-CoV-2, focusing initially on the Spike (S) protein because it mediates infection of human cells and is the target of most vaccine strategies and antibody-based therapeutics. To date we have identified fourteen mutations in Spike that are accumulating. Mutations are considered in a broader phylogenetic context, geographically, and over time, to provide an early warning system to reveal mutations that may confer selective advantages in transmission or resistance to interventions. Each one is evaluated for evidence of positive selection, and the implications of the mutation are explored through structural modeling. The mutation Spike D614G is of urgent concern; it began spreading in Europe in early February, and when introduced to new regions it rapidly becomes the dominant form. Also, we present evidence of recombination between locally circulating strains, indicative of multiple strain infections. These findings have important implications for SARS-CoV-2 transmission, pathogenesis and immune interventions.

From: David Montefiori, Ph.D. [REDACTED] (b) (6)

Sent: Tuesday, May 5, 2020 1:23 PM

To: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6)

Subject: RE: D614G

John,

I thought you should know that the D614G story is getting a lot of press attention today. A story came out in the LA Times this morning that probably started it all. It will likely be on CNN tonight, and maybe other networks.

Just a heads-up.

David

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 20:43:39 +0000
To: Billet, Courtney (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
Attachments: Script to honor Avi Schiffmann - 05-05-2020.docx

Here is my tracked version of the Schiffmann script.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, May 5, 2020 3:06 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

OK – so this is the ask from the Webby awards: a short recorded video message. They have sent a proposed script below -- just an example – obviously we're free to change it. Avi is a pretty extraordinary kid. 17 years old!

Here is the site he created, back in early January. He's aggregating data from WHO, CDC, and other sources: <https://ncov2019.live/>

NBC Today story: <https://www.today.com/parents/17-year-old-built-website-track-coronavirus-t175245>

New Yorker article about him: <https://www.newyorker.com/magazine/2020/03/30/the-high-schooler-who-became-a-covid-19-watchdog>

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Tuesday, May 5, 2020 2:32 PM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Courtney,

This would be a pre-recorded message with Dr Fauci solo. He would set up Avi's award and help to celebrate his Webby moment for him. Avi will be sending us his 5 word Webby speech which will then follow Dr. Fauci's intro. Below is a draft of the introduction for him, let us know if he would like to make any edits/changes. I've also attached the format for taping on his phone/computer. Please let me know if you need any additional information and hoping we can make it work.

Thank you so much

Best

Lesley

DR. FAUCI:

I'm Dr. Anthony Fauci. Unfortunately, you've seen a lot of me lately. But thankfully, I'm here to present some good news and I'm excited for the opportunity to shine some light on one of the many young people who have stepped up and helped us throughout a difficult time.

The 24th Annual Webby Awards would like to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world.

As we collectively navigate the severe impact of COVID-19, including the difficult, but critical calls for nationwide social distancing, the internet has become the lifeblood of people looking for accurate information about the novel coronavirus and the necessary steps to combat it.

Since launching the site on December 29th, Schiffmann's tracking tool has been an invaluable resource that sounded the alarm on the virus and its spread, notably calling attention to its severity long before many global officials.

At a time when the spread of misinformation can be so detrimental to our efforts, the site has provided over 600 million visitors with accurate real-time data. Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and the importance of measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating an essential website to provide real-time data about the virus to people everywhere, it is my great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year.



On May 5, 2020, at 10:31 AM, Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6) wrote:

Lesley – we’ve been discussing this. Can you tell us exactly what would be involved in this? How many minutes would you be looking for Dr. Fauci to speak? Would this be pre-recorded, with Dr. Fauci solo? Or would it be done as a Zoom or something like that, with an interaction between Dr. Fauci and Avi?

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Monday, May 4, 2020 5:31 PM
To: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Lesley – thanks so much for reaching out. Avi is so impressive! I am connecting you with Dr. Fauci’s assistant and scheduler, Patty Conrad, for follow-up.

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Monday, May 4, 2020 5:10 PM
To: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Fwd: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Courtney,

Hope you are staying well during these uncertain times. I am a Talent Producer for The Webby Awards and had reached out to Dr. Fauci regarding being involved in our “virtual” internet celebration which will showcase the artists, organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

Avi Schiffman is being celebrated as our Person of the Year and we would be honored if Dr Fauci would “virtually” present him his honor. The official letter is below and would love to discuss in more detail when you have a chance to review.

Thank you

Best

Lesley

Begin forwarded message:

From: Lesley Cahill Roy <lesley@lesleycahillroy.com>
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
Date: May 1, 2020 at 12:13:10 PM EDT
To: (b) (6)

Hi Dr Fauci

I just wanted to follow up on below regarding Avi and The Webby Awards. Would be wonderful if you could be a part of this moment for him.

Thanks so much

Lesley

On Apr 20, 2020, at 1:57 PM,
lesley@lesleycahillroy.com <lesley@lesleycahillroy.com> wrote:

<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>

Dear Dr. Fauci,

I hope you and the family are all safe and healthy during these challenging times. Hailed by The New York Times as "the Internet's highest honor," The Webby Awards has been the premiere award for online excellence for over two decades, honoring the companies and people who have critically shaped digital technology and culture.

This year, due to the impact of the coronavirus The Webby Awards are moving their renowned award show to an online experience. On May 19th, 2020, the 24th Annual Webby Awards will bring together Webby Winners from around the world in an Internet Celebration which will showcase the artists,

organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world. We would be honored if Dr. Fauci would “virtually” present Avi with his award.

As we collectively navigate the severe impact of COVID-19 on the world and late calls for nation-wide social distancing, the Internet has become the lifeblood for people looking for accurate information about the novel coronavirus. Since launching the site on December 29th, Avi Schiffmann’s tracking site was a necessary tool that sounded the alarm on the novel coronavirus and its spread, notably calling attention to its severity long before many global officials. By providing over 100 million visitors with real-time data on the virus’ spread, Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating a website to provide real-time data about the virus to people everywhere, it is our great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The celebration will highlight the important work Avi and his fellow winners are doing, and will mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci’s presenter speech could be recorded on his phone and we can send you through a script for him to review, edit and details for format and deadline.

This year’s Webby Awards will also take action, the impact of COVID-19 and government responses around the world, has brought the importance of voting into sharp focus. The Webby Awards has partnered with Vote.or and aim to check the voter registration status of 1 million voters in the United States, promoting the importance of voting to help ensure voter turnout this November is the highest it has ever been. This partnership will integrate into all elements of this year’s online celebration.

Our thoughts are with all of you in this difficult time.

Best

Lesley Cahill Roy

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 19:49:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW:

unlikely

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Konstantin Vulkov <kv@egoist.bg>
Sent: Tuesday, May 5, 2020 3:42 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: NIAID Ocpstoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)
Subject:

Dear Sir/Madam,

My name is Konstantin Vulkov and I am Program director of the biggest Bulgarian private radio station, Darik radio (www.darikradio.bg). This is a news/talk radio station. I am a regular contributor to Bulgarian National TV as well as several online and print publications, editor-in-chief of egoist.bg as well as editor-in-chief of the biannual Darik-owned publication called Dolce Far Niente.

I am a document photographer as well, focusing mainly on portraits.

I am covering the coronavirus pandemic extensively - visiting COVID-19 units across the country, making my daily radio programme "Mind games", writing stories for our websites www.darikradio.bg, www.dnews.bg and egoist.bg.

It would be an honour if I can make a short telephone interview with Mr. Anthony S. Fauci, M.D.

Please let me know if I can call and make the interview. I promise I won't take more than 10 minutes of Mr. Fauci's time.

Your help is much appreciated.

Best,

Konstantin

Konstantin Vulkov
Program Director
Darik Radio
82, Dondukov blvd.
Sofia 1504
Bulgaria

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 19:48:10 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: AUSTRIA - Try to support - COVID 19 - Strategy

Looks fine.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, May 5, 2020 3:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: AUSTRIA - Try to support - COVID 19 - Strategy

Dr. Fauci,

I will respond. Here is what I propose to say (in addition to thanking him). Let me know if you'd change anything:



Sincerely,

Andrea

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, May 5, 2020 at 10:40 AM
To: "Lerner, Andrea (NIH/NIAID) [E]" (b) (6)
Subject: Fwd: AUSTRIA - Try to support - COVID 19 - Strategy

Not a crazy note. Please respond on my behalf. Thanks

Begin forwarded message:

From: (b) (6)
Date: May 5, 2020 at 8:19:48 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: AUSTRIA - Try to support - COVID 19 - Strategy

Dear – highly respected – Dr. Fauci

Why do I try to childishly support a respected expert and personally highly honored Gentleman like you – Dr. Fauci ?

Because for me – it is heartbreaking and unbelievably disturbing, what was and is going on in the course of the last 4 months in the USA.


I talk about the USA, that relieved my country - AUSTRIA - 75 years ago from the hell of the NAZI-Regime – with American Lives and Blood.

With all my respect, my hopes, my passion, my tears, my mourning – May Grace and Blessing be with You and the USA.



After running the numbers available on COVID 19 pandemic data – my experiences as an Economist led to following analysis and proposed strategy:

**COVID 19 is a true threat for humans >65 years of age with pre-existing illnesses,
 but nearly influenza-like for humans < 65 years of age and humans > 65 years of age without pre-existing illnesses**

AUSTRIA: Deaths by age



Deaths as of 100.000 inhabitants by age



**Germany – Death by age – men and women
 – mortality rate in %**

Comparison – Italy and China

Coronavirus Mehr Männer unter den Toten

Die Auswertung des Robert-Koch-Instituts (RKI) basiert auf mehr als 149.000 Coronavirus-Fällen in Deutschland. Unter den mehr als 5000 erlittenen Covid-19-Todesfällen finden sich über fast alle Altersgruppen hinweg auf jeden Fall mehr Männer als Frauen.




(Kumuliert versterbender Covid-19-Patienten nach Alter und Geschlecht; Altersgruppen-Einteilung des RKI Stand: 23. April 2020) n tv

Italien: mehr Covid-19-Tote als in China

Mortalitätsrate in Prozent der Erkrankten

Altersgruppen	ITALIEN	CHINA
0-9	0	0
10-19	0	0,2
20-29	0	0,2
30-39	0,3	0,2
40-49	0,4	0,4
50-59	1,0	1,3
60-69	3,5	3,6
70-79	12,8	8,0
≥ 80	20,2	14,8

Anteil der Verstorbenen über 80 Jahre



Proposed Strategy

1. Keep the virus 100% (totally) away from people older than 60 with pre-existing illnesses

Identify, Testing, Shelter, Preserve from contact with virus, Preserve from Hospitalization and ICU

2. **Minimize possible contact with virus for people older than 60 without pre-existing illnesses**

Identify, Testing, Partial Stay at Home, Social Distancing, , Preserve from Hospitalization and ICU

Once 1 and 2 are warranted:

3. **Handle the rest of the population with care, but keep them going and working – as you would do in an influenza-season**

The critical factor for further intervention is the capacity of the regionally available ICU-capacity

Interventions: Social Distancing, Masks, Testing, Tracing, Stay at home when ill, Quarantine at home when ill

Respectfully Yours
Gerald Glockenstein

Mag. Gerald Glockenstein

(b) (6)



From: (b) (6)
Sent: Tue, 5 May 2020 10:47:11 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: request of interview by Giuseppe Sarcina, corriere della Sera

Please try to get clearance. This is the top newspaper in Italy

Begin forwarded message:

From: Sarcina Giuseppe <gsarcina@res.it>
Date: May 5, 2020 at 8:03:29 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Re: request of interview by Giuseppe Sarcina, corriere della Sera

Inviato da iPhone

Dear Doc, Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera,
the main italian newspaper.
I understood that you are looking at the italian case with great
attention.
I wonder if you can grant me a short interview.
I have sent an email march 21. But then I saw that you spoke with an
other italian newspaper. So I would like to have a chance to have your
voice for our Readers as well. Corriere della Sera is a newspaper based
in Milano, Lombardy, The region most affected by the coronavirus.
Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

(b) (6)

Oggetto: request of interview by Giuseppe Sarcina, corriere della Sera

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera,
the main italian newspaper.
I understood that you are looking at the italian case with great
attention.
I wonder if you can grant me a short interview.
That would be really helpful for our readers
Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

From: [REDACTED] (b) (6)
Sent: Tue, 5 May 2020 10:43:37 -0400
To: NIAID OD AM
Subject: Fwd: Invitation to Participate in Book Project on COVID-19

Let us discuss. [REDACTED] (b) (6)

Begin forwarded message:

From: Dawinder Sidhu <dss@umbc.edu>
Date: May 5, 2020 at 8:14:12 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: Invitation to Participate in Book Project on COVID-19

Dr. Fauci,

I hope this email finds you well. I am a professor at the University of Maryland, an elected term member in the Council on Foreign Relations, and a former fellow at the Supreme Court of the United States.

I am writing because I am preparing a book, tentatively entitled "Rebuilding America: A Blueprint for Post-COVID-19 America," consisting of essays by leading figures on (1) how COVID-19 has impacted their particular field, and (2) how that field should be reimagined in light of the crisis. The essays will reconsider all sectors of society, including law, education, healthcare, fashion, music, etc., and collectively will be the first comprehensive guide for post-coronavirus reconstruction efforts.

I am very hopeful that you may be willing to contribute a short essay on how the current coronavirus has impacted public health policy, and how such policies can and should evolve moving forward.


Only 50 industry leaders are being asked to contribute. Commitments have been secured from an impressive group, including a retired four-star general and a preeminent constitutional scholar. I very much hope you will take part in this innovative project given your historic and unparalleled contributions to the public's understanding of the current crisis.

With respect to logistics, I am hoping to receive commitments from all authors this month, with essays due within one month, and with the

essays available through Amazon's expedited publishing platform roughly one month after that. Each essay should be no more than 1,000 words, and I may offer light edits for the author's final approval. A final note: all proceeds from the sale of the book will be donated.

I am very hopeful that you will give every serious consideration to this invitation, and will lend your voice towards reimagining and revitalizing a new America.

Best,
Dave

Dawinder S. Sidhu
University of Maryland
 (b) (6)

dss@umbc.edu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 13:00:29 +0000
To: Lipkin, Ian W.
Subject: RE: SARS-CoV-2

Thanks, Ian. I hope that you are well.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lipkin, Ian W. (b) (6)
Sent: Tuesday, May 5, 2020 8:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: SARS-CoV-2

Tony,

(b) (6) This prompted the letter I sent to him last evening to which he responded this morning. I don't expect a response but wanted to keep you updated. We deeply appreciate your efforts in steering and messaging.

All my best,
Ian

P.s. Skoll just invested \$5M in piloting the GIDEoN international capacity building and surveillance network that includes Cliff and others in your intramural team.

Begin forwarded message:

From: ZhuChen (b) (6) >
Subject: Re:SARS-CoV-2
Date: May 5, 2020 at 8:16:23 AM EDT
To: Lipkin, Ian W. (b) (6) >

Dear Ian,

Thank you for your email detailing the

(b) (4)

(b) (4)

(b) (4). I shall keep you informed of any

progress in the coming weeks.
Best,
Zhu

----- Original -----

From: "Lipkin, Ian W." (b) (6);
Date: Tue, May 5, 2020 06:06 AM
To: "ZhuChen" (b) (6) >;
Subject: SARS-CoV-2

Dear Zhu,

The COVID-19 pandemic poses an unprecedented threat not only to global public health but also to economic and political stability. Uncertainty about the origin of COVID-19 pandemic is causing friction worldwide, particularly between China and the United States. There is agreement that the causative agent, SARS-CoV-2 originated in a bat. There is also a high level of confidence that the virus was not deliberately modified in any laboratory. What we do not know is the answers to two questions: (1) whether a precursor virus circulated in the human population before it evolved to become a pandemic virus and (2) whether a precursor virus adapted to humans by first passing through another animal. (b) (4)

(b) (4)

With great affection,
Ian

W. Ian Lipkin, MD
John Snow Professor of Epidemiology and Director
Center for Infection and Immunity
Mailman School of Public Health

Professor of Pathology and Neurology
College of Physicians & Surgeons
Columbia University
722 West 168th Street, 17th Floor
New York, NY 10032

Voice: (b) (6)

Fax: (212) 342-9044

Email: (b) (6)

Administrative Coordinator
(b) (6)

www.cii.columbia.edu

Follow CII on Twitter: CII_Columbia | Facebook: CII.Columbia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 12:40:52 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: VP slides
Attachments: VP brief VRC 5may2020v2.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Monday, May 4, 2020 7:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: VP slides



Tony, here are slides, including changes we discussed. Patty and all have them.
John

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 12:06:24 +0000
To: Harris, Mary (NIH/NIAID) [E]
Subject: RE: Thank you , Dr. Fauci, Thank you so very much!

Mary:

Many thanks for your kind note. It is much appreciated. Stay well.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Mary (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 8:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank you , Dr. Fauci, Thank you so very much!

Dr. Fauci,

I wanted to personally thank you for being the voice of reason, security, comfort and insight. (b) (6)
(b) (6) As much as I miss being in the office, I am grateful to say my Director is Dr. Anthony Fauci and share with my family, friends, and church that if you said it, it's gospel. They can bank on it! You have given comfort to my family and myself. You will never know how much! I want you and those who in researchers who are hard at work without much rest but tons of sacrifice including that of your families to find a vaccine, give the Nation a sense of safety and security in this unprecedented time are greatly appreciated. My family, friend and myself are send our prayers for your continued strength. Thank you doesn't seem like enough. I couldn't be prouder to work at NIAID and specifically on the 7th floor of Building 31.

Simply Grateful,

Mary Harris
NIAID Travel Policy Specialist
NIAID Travel Card Coordinator

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 00:37:21 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: CORONA and BACTERIAL SUPERINFECTION
Attachments: 1918 influenza insight- fauci.pdf, ESP el arroz epidemol.pdf, Infection and Immunity-2015-Rynda-Apple-3764.full.pdf, JClinsightco-infection.pdf, lancet.png, Mail Esp.pdf, mail germany 1.pdf, piramide.png, PLEASE FORWARD THIS MESSAGE TO error.pdf, portugal.pdf, Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza - Dr Fauci.pdf, press usa.pdf, Recuperados.pdf, spanish flu 1918 - eng original.pdf, tyska pres mail.pdf, US error message.pdf, Us mail 0408.pdf, WHO-2019-nCoV-clinical-2020.4-eng.pdf, virus piramdie eng.png

Please take a look and decide. Thanks.

From: Ola Melhus [REDACTED] (b) (6)
Sent: Monday, May 4, 2020 12:25 PM
To: [REDACTED] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: CORONA and BACTERIAL SUPERINFECTION

Dear Doctors,

I don't know if you have got this information.

A truly deadly virus

cannot spread very far. Why? Because people quickly get sick and die. In other words, they cannot spread the virus further, which is a prerequisite for a large spread like corona. Covid-19 has spread throughout the world.

The premise is that it is not very dangerous, it causes mild symptoms for most people, many do not even notice that they were sick. But the virus has different phases in the body, after a while it goes into a resting phase, you feel better, but the virus is still present and can pass on. Covid-19 is an optimally developed virus that spreads rapidly around the world. But if it were really deadly, almost everyone would die.

So far in our 4 billion long history, there have been **no airborne** viruses or bacteria. Yes, in the hollywood movie "outbreak" there was, but it was a movie. Why hasn't it?

If it had existed, this planet would have been a dead planet without life. It would have killed all living. It is possible that there is somewhere else in the universe, but not here on planet Earth. Not now. Remember, this is not the first time a new virus is spreading in the world. What is happening now has happened earlier in our long history.

But people are die you say. Yes, but the virus don't kill them. The virus open a "door" in the cell wall thats allows for bacterias, how always are present, to invade the body and create an aggressiv bacterial superinfection. That's what kills them. See,

1. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease.




FIG 1 Common pathways of susceptibility to postinfluenza bacterial superinfections. Early after influenza virus infection, mice show reduced susceptibility to superinfection that is at least in part due to increased production of IL-13. This IL-13-rich environment does not permit IFN- γ production, allowing unaltered phagocytosis and clearance of bacteria. The role for either neutrophils or macrophages (phagocytes) in bacterial clearance early during influenza virus infection has not been fully investigated. Progression of influenza virus infection results in increased susceptibility to secondary infection. Type I IFN (or IL-27) signaling initiated in response to influenza virus infection results in downregulated production of IL-1 β and IL-23 and impaired type 17 immune responses. Inhibition of IL-17 and IL-22 reduces production of antimicrobial peptides. Type I IFN signaling also reduces levels of neutrophil chemoattractants Cxcl1 and Cxcl2 and can induce formation of NETs. IL-27 induced during influenza virus infection further suppresses IL-17 production but stimulates production of regulatory cytokine IL-10, which contributes to increased susceptibility to superinfection, presumably by alteration of the anti-influenza inflammatory response. IAV, influenza A virus infection.

and this reports:

2. Deaths from Bacterial Pneumonia during 1918-19 Influenza Pandemic

3. The 1918 Influenza Pandemic: Insights for the 21st Century

4. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness

5. Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment

6. Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness

How can this happen? How can the doctors be so blind. I have a theory about this and here it comes:

My (b)(6) was a psychologist. May she rest in peace in heaven.

It seems that the corona virus has affected the brain more in a certain group in society, namely politicians, doctors, journalists and other with power and positions in the society. The virus is not dangerous for this group, but it's opens a door in the brain's cell wall that allows it to enter the fear center of the brain.

This door has been closed for many years. We haven't had any major wars and nothing has threatened them. They have felt invulnerable. Convinced of their own superior ability and greatness. Not only can they control the people, they can now control the climate by turning the carbon dioxide tap. If they close it, the temperature drops, if they open it the temperature goes up. They don't know that the sun is 109 times as big as our planet. 109 times. It seems so small when we look up in the sky. They thought they could control everything.

Then came the VIRUS, they receive an abrupt awakening. They get scared. Politicians get sick and die. Doctors die. The brain is attacked by fear virus. They can no longer think clearly and logically. The panic is near, they are reminded of their own mortality. Just like a virus in a computer. It's slows it down and it becomes unusable. That's what happens when a fear virus attacks the brain.

Here where I live, there are panic over 1600 confirmed cases. The television is talking "infected persons" when there is "confirmed laboratory cases". It's two different things. Misleading the people. Why panic over 1 600 infected? Closing all not necessary business, all schools, all except for supermarket, gas station, banks. You can't go out after 5.00 pm. If you do, you get arrested.

Why? They are scared. Because the ruling class is afraid. Everyone with this masks. Doctors crying on television. The President with mask. They are scared. Doctors. Journalists. Polices.

2020. The year when the world got completely crazy.

You have an medical obligation to inform the world about the truth.

Kind regards,

Ola Melhus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 00:36:13 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Therapeutics and vax
Attachments: NIAID SARS-CoV-2 Tx and Vax overview.docx

Please print out and put in folder labelled "COVID-19 Therapeutics and Vaccines"

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Monday, May 4, 2020 12:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]
<(b) (6)>
Subject: Therapeutics and vax

For your Therapeutics discussion later today

From: (b) (6)
Sent: Mon, 4 May 2020 19:52:45 -0400
To: Troye, Olivia EDP/NSC
Cc: Hurst, Natalie R. EOP/OVP; Mascola, John (NIH/VRC) [E]; Graham, Barney (NIH/VRC) [E]; Francis Collins
Subject: Re: Email connecting us


Here they are. Thanks

On May 4, 2020, at 7:46 PM, Troye, Olivia EOP/NSC

(b) (6)

Hi Dr. Fauci,
Per our conversation, sending you a note. I'm copying Natalie who will help get them cleared in.
Thank you!
Olivia

Olivia Troye
Special Advisor to the Vice President for
Homeland Security, Counterterrorism, and North America
Office of the Vice President, National Security Affairs
White House Coronavirus Task Force
O: (b) (6) | M: (b) (6) (Does not receive texts)
(b) (6)





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 21:05:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

Please see me about this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Monday, May 4, 2020 11:18 AM
To: ICDDIR-L@LIST.NIH.GOV
Cc: Parker, Ashley (NIH/OD) [E] (b) (6); Wholley, David (FNIH) [T] (b) (6)>; Melencio, Cheryl (FNIH) [T] (b) (6)>
Subject: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

Dear Colleagues,

As you may be aware, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership has been moving forward rapidly to address the global pandemic. We held our initial ACTIV leadership meeting on April 3rd including, NIH, FDA, BARDA, EMA, and industry heads of research and development. Four working groups were formed out of this meeting to focus on preclinical therapeutics, clinical therapeutics, clinical trial capacity, and vaccines.

Although some ICs have representatives participating in the working groups, we recognize there is a need to keep everyone looped in to the various activities and progress of the partnership, particularly in view of all of the concurrent IC projects about COVID-19. The ACTIV working groups will be delivering their second report to the **ACTIV Leadership Group on Wednesday, May 6, from 3:30-5:00pm**. I am writing to invite the ICs to listen-in on this meeting. There will be a lot to cover during the meeting and the members of the Leadership Group will be asking the questions. But to give a chance for us NIHers to

discuss what has been presented, I am scheduling a separate ICD call for 5:05-5:30pm, immediately following the ACTIV leadership meeting.

If you are available to take part, please send your responses to David Wholley and Cheryl Melencio of FNIIH (cc'd here) by noon tomorrow, May 5th. Once you confirm your attendance, Cheryl will send you a calendar invite for both the ACTIV leadership meeting and the ICD follow-up call.

Best regards,
Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 15:28:08 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Need your help Covid-19 CAS-10685

I do not know this person. We should refer him to Brett Giroir.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Monday, May 4, 2020 10:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Need your help Covid-19 CAS-10685

Do you know this person?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Kara (NIH/NIAID) [E] (b) (6) >
Sent: Friday, May 1, 2020 8:38 AM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6) >
Cc: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Subject: FW: Need your help Covid-19 CAS-10685

Hi, Patty –

This individual states that he previously worked with Dr. Fauci and that he knows him. Please let me know if you would like Public Inquiries to handle.

Thanks,
Kara

From: Ray Rosa (b) (6) >
Sent: Thursday, April 30, 2020 5:58 PM
To: NIAID Ocpstoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Subject: Need your help Covid-19

I am working with a group of physicians whom need your guidance on Serum Covid-19 tests. I need someone to call me so I can ask specific questions. I worked with Dr Fauci back in 1998 when I was in the Air Force. So he does know me. Ray Rosa is the name. Can you please call me.

(b) (6) cell

Sent from AOL Mobile Mail
Get the new AOL app: mail.mobile.aol.com

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 14:00:23 +0000
To: NIAID OD AM
Subject: FW: inquiry

Another one that he will probably want to do.

From: Augustine M. K. Choi <[REDACTED]> (b) (6)
Sent: Monday, May 4, 2020 9:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED]> (b) (6) >
Subject: inquiry

Hi Tony,

I can only imagine your schedule. Thank you for all you are doing for the country in our fight against this virus.

Weill Cornell would like to invite you for a 3 min remarks to the Class of 2020 at their upcoming graduation if your schedule allows. The virtual graduation is on May 28th. We can tape your remarks at any time which fits your schedule, from now or up to right before May 28.

If you able to accept this invitation, please let me know. If not, totally understandable and we would love to have you back again after covid subsides.

Thanks again!

Augustine M.K. Choi, M.D.
Stephen and Suzanna Weis Dean, Weill Cornell Medicine
Provost for Medical Affairs, Cornell University

Weill Cornell Medicine
1300 York Avenue, Suite F-113 Box 83 | New York, NY 10065
Telephone: 212-746-6005
Fax: 212-746-8424
Email: amc2056@med.cornell.edu

From: Anthony Fauci <[REDACTED]> (b) (6)
Date: Monday, March 30, 2020 at 12:19 PM
To: Augustine Choi <[REDACTED]> (b) (6)
Subject: [EXTERNAL] RE: all wearing masks

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 12:28:04 +0000
To: Corey, Larry
Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

As an FYI for the 9:00 AM meeting.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dolsten, Mikael (b) (6) >
Sent: Monday, May 4, 2020 8:15 AM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Lowy, Douglas (NIH/NCI) [E] (b) (6) >; Jansen, Kathrin (b) (6) >
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis
Thanks for the response

We appreciate the federal initiative and opportunity to influence it's design . I know Kathrin Jansen (cc'd here) from PFE is working w the team on this.

(b) (4)
(b) (4) It's great to be collaborating w NIH-FDA for the best of our nation and global health .

In the master protocol , I hope the working committee is discussing (b) (3)
(b) (3)

(b) (5)

These are just two examples we can discuss on Wednesday in the leadership meeting if time permits .

(b) (5)

I look forward to the meeting

Best
Mikael
Sent from my iPhone

On May 4, 2020, at 04:26, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Hi Mikael,

Wow, sounds like you are making fantastic progress with the vaccine program, and we would certainly not want to do anything to slow you down! I understand that you are evaluating several mRNA formats with BioNTech. If one of those turned out to be ready for phase II/III in late June, we would be most interested in the possibility of including that in the master protocol. Please keep Tony and me in touch with Pfizer's progress, including which mRNA format you choose to move into advanced development.

Hope to hear your voice at the ACTIV Leadership Group meeting on Wednesday. There will be a lot to talk about!

Best, Francis

From: Dolsten, Mikael [REDACTED] (b) (6) >

Sent: Sunday, May 3, 2020 6:26 PM

To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below



I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E]

[REDACTED] (b) (6) > wrote:

Mats

Hi Mikael,

Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?

[REDACTED] (b) (4) – I trust that compound is on the list of therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing? They are supposed to put forward a tentative list for the Wednesday Leadership Group meeting. Ditto with the (b) (4) option!

Looking forward to catching up soon!

Best, Francis

From: Dolsten, Mikael [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 12:06 PM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

I trust you are well but likely working too many hours as we all experience in the difficult Covid times.

In the vaccine space we have progressed rapidly and are already in phase 1/2 studies dose escalation phase testing multiple format of mRNA vaccine . Key for us is [REDACTED] (b) (4) .

In the anti-viral areas we are [REDACTED] (b) (4)

[REDACTED]

We also want to start [REDACTED] (b) (4)

[REDACTED]

How are things going w ACTIV.
Any issues to discuss ?

I hope our PFE representatives in ACTIV are helping out well

Pls let me know if there is anything particular to discuss or I can help you with

Best personal regards
Mikael

Sent from my iPhone

On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E]
(b) (6) > wrote:

Hi Morten,

Thanks for your note. It would be great to have this connection – but let me suggest that you start with David Wholley (cc'd here), as he oversees all four of the ACTIV working groups. Joe is the program lead for the group on preclinical therapeutics/repurposing.

Best, Francis

From: Sogaard, Morten (b) (6)
Sent: Sunday, May 3, 2020 10:46 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Dolsten, Mikael (b) (6); Prof Trevor M Jones CBE FMedSci (b) (6) >; Sogaard, Morten (b) (6) >
Subject: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis,

I hope you are having a good weekend.

Quick question: Would you be OK if I/we reached out to Joe Menetski, who I understand leads many of the ACTIV efforts. We have come to know Joe very well as a great collaborator on the AMP gene therapy initiative and It would be very easy I think working informally with Joe to look a bit more under the hood and identify/ map opportunities for alignment with the other initiatives.

All the Best,
Morten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 10:53:14 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Subject: RE: EOP/OMB Alert: May Hearing Guidance

What does this mean for the May 12 Senate Hearing?

From: Haskins, Melinda (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Sent: Monday, May 4, 2020 6:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] <[REDACTED]> (b) (6)>
Subject: EOP/OMB Alert: May Hearing Guidance

I have highlighted in yellow the fundamentals of the OMB guidance below.

Melinda

From: Hallett, Adrienne (NIH/OD) [E] <[REDACTED]> (b) (6)>
Sent: Sunday, May 3, 2020 9:54 PM
To: OD-OLPA-Leg Contacts <OD-OLPA-LegContacts@OD.NIH.GOV>
Subject: Fwd: May Hearing Guidance


FYI. New OMB hearing guidance.

From: Yaworske, Jason A. EOP/OMB <[REDACTED]> (b) (6)>
Sent: Sunday, May 3, 2020 9:06 PM
Cc: Ueland, Eric M. EOP/WHO <[REDACTED]> (b) (6)>; Hodgson, Christopher (ovp.eop.gov) <[REDACTED]> (b) (6)
Subject: May Hearing Guidance
Importance: High

Agency legislative affairs teams,

(b)(5) - PCP





Thank you, and please let us know if you have any questions.

Jason

Jason Yaworske
Associate Director for Legislative Affairs
Office of Management and Budget

(b) (6) (a)

(b) (6) (c)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 00:50:18 +0000
To: Collins, Francis (NIH/OD) [E]; Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]; Parker, Ashley (NIH/OD) [E]
Subject: RE: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

We need to find out precisely what he is talking about when he says "vaccine formats" and "refined formats". I really do not know what he is talking about. (b) (4), (b) (5)

John/Cliff:

Let us discuss this at our morning meeting.

Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Sunday, May 3, 2020 8:03 PM
To: Mascola, John (NIH/VRC) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Parker, Ashley (NIH/OD) [E] (b) (6)
Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi John, Cliff, and Tony,

See note below, where Mikael Dolsten indicates Pfizer is planning to (b) (4). He intends to discuss our master protocol possibility with Kathrin Jensen. I am not quite sure what he means by "several vaccine formats".

Does this timetable sound realistic?

Any suggestion about a response?

Francis

From: Dolsten, Mikael (b) (6)
Sent: Sunday, May 3, 2020 6:26 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below



I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E] <[REDACTED]> (b) (6) wrote:
Mats

Hi Mikael,

Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?

(b) (4) - I trust that compound is on the list of therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing? They are supposed to put forward a tentative list for the Wednesday Leadership Group meeting. Ditto with the (b) (4) option!

Looking forward to catching up soon!

Best, Francis

From: Dolsten, Mikael (b) (6)
Sent: Sunday, May 3, 2020 12:06 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

I trust you are well but likely working too many hours as we all experience in the difficult Covid times.

In the vaccine space we (b) (4)
(b) (4)
(b) (4)

In the anti-viral areas we are (b) (4)
(b) (4)

(b) (4)

How are things going w ACTIV.
Any issues to discuss ?

I hope our PFE representatives in ACTIV are helping out well

Pls let me know if there is anything particular to discuss or I can help you with

Best personal regards
Mikael

Sent from my iPhone

On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) wrote:

Hi Morten,

Thanks for your note. It would be great to have this connection – but let me suggest that you start with David Wholley (cc'd here), as he oversees all four of the ACTIV working groups. Joe is the program lead for the group on preclinical therapeutics/repurposing.

Best, Francis

From: Sogaard, Morten [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 10:46 AM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >
Cc: Dolsten, Mikael [REDACTED] (b) (6); Prof Trevor M Jones CBE FMedSci [REDACTED] (b) (6); Sogaard, Morten [REDACTED] (b) (6)
Subject: DK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis,

I hope you are having a good weekend.

Quick question: Would you be OK if I/we reached out to Joe Menetski, who I understand leads many of the ACTIV efforts. We have come to know Joe very well as a great collaborator on the AMP gene therapy initiative and It would be very easy I think working informally with Joe to look a bit more under the hood and identify/ map opportunities for alignment with the other initiatives.

All the Best,
Morten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:45:43 +0000
To: Greg Folkers ([REDACTED] (b) (6)); Doepel, Laurie (NIH/NIAID) [E]
Subject: Pitt and INC
Attachments: Commencement Remarks, generic 30-sec for UPitt and UNC SOM, - FINAL - for 5-08-2020 (videos).docx

See attachment with remarks for UPitt and UNC . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:28:33 +0000
To: Greg Folkers (b) (6); Doepel, Laurie (NIH/NIAID) [E]
Subject: USUHS
Attachments: Commencement Remarks, USUHS 2-min -FINAL - for 5-16-2020 (Video).docx

See attachment with USUHS remarks . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:21:04 +0000
To: Greg Folkers (b) (6); Doepel, Laurie (NIH/NIAID) [E]
Subject: AMA
Attachments: Commencement Remarks, AMA 3-min - FINAL - for May 2020 (Video).docx

See attachment with AMA remarks . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 20:58:32 +0000
To: Doepel, Laurie (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: UCSF
Attachments: Commencement Remarks, UCSF SOM - FINAL - for May 2020 (Video).docx

Greg/Laurie:

I am attaching the UCSF 3 minute talk. I labeled it as "FINAL" and it is in the OD folder. However, I have left in the tracked changes for you to see what I did. Please accept the changes and then go over it one last time. I like it the way it is and so please no trivial corrections.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 20:11:08 +0000
To: Doepel, Laurie (NIH/NIAID) [E]; Greg Folkers ([REDACTED] (b) (6))
Subject: Holy Cross
Attachments: Commencement Remarks, Holy Cross - FINAL - for 05-22-2020 (video).docx

The Holy Cross video script is in the OD File marked as "FINAL". I have left the tracked changes showing so that you will know what I have done. Please accept the changes and take a final look. I am also attaching for your look.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 18:34:28 +0000
To: Tromberg, Bruce (NIH/NIBIB) [E]; 'Sharpless, Ned
(b) (6)'
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: 2 quick points

Thanks, Bruce.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tromberg, Bruce (NIH/NIBIB) [E] (b) (6)>
Sent: Sunday, May 3, 2020 2:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); 'Sharpless, Ned
(b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: Re: 2 quick points

Hi Tony,

Thanks! Hope you are doing well.

This is basically exactly what we are working to facilitate with our RADx and digital health (app) platform initiatives...greatly expanding testing and creating a digital backbone to provide people with ways to access tests and interpret results. For expanding testing platforms, see <https://www.nibib.nih.gov/news-events/newsroom/nih-mobilizes-national-innovation-initiative-covid-19-diagnostics>. We have >700 applications that have been started in just a few days. For the digital health (e.g. app) platform we've put a lot of thought into the design and are hoping a contractor will be able to launch a pilot study of healthcare workers soon. Ned and I plan on issuing additional calls in this area with multiple institutes as stakeholders in the coming weeks.

Best,
Bruce

Bruce J. Tromberg, Ph.D.

Director
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health
Building 31, Room 1C14
Bethesda, MD 20892-2281
(b) (6)
301-480-0679 - FAX
(b) (6)
<http://www.nibib.nih.gov>

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, May 3, 2020 at 1:55 PM
To: "Sharpless, Ned" (b) (6)
"Tromberg, Bruce (NIH/NIBIB) [E]" (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Subject: FW: 2 quick points

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen (b) (6)>
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview [REDACTED] (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland ([REDACTED] (b) (6) [REDACTED]). As his email says, [REDACTED] (b) (6) with Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 [REDACTED] (b) (6) [REDACTED]. It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out [REDACTED] (b) (6), and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:[REDACTED] (b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: [REDACTED] (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up [REDACTED] (b) (6) but I'm writing because it might yet bring at least the two of us together.

[REDACTED] (b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:56:39 +0000
To: NIAID OD AM
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

????? Who is this person?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Sunday, May 3, 2020 1:55 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Friday, May 1, 2020 12:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Dr Fauci

I just wanted to follow up on below regarding Avi and The Webby Awards. Would be wonderful if you could be a part of this moment for him.

Thanks so much

Lesley

On Apr 20, 2020, at 1:57 PM, lesley lesleycahillroy.com <lesley@lesleycahillroy.com> wrote:

<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>

Dear Dr. Fauci,

I hope you and the family are all safe and healthy during these challenging times. Hailed by The New York Times as "the Internet's highest honor," The Webby Awards has been the premiere award for online excellence for over two decades, honoring the companies and people who have critically shaped digital technology and culture.

This year, due to the impact of the coronavirus The Webby Awards are moving their renowned award show to an online experience. On May 19th, 2020, the 24th Annual Webby Awards will bring together Webby Winners from around the world in an Internet Celebration which will showcase the artists, organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world. We would be honored if Dr. Fauci would "virtually" present Avi with his award.

As we collectively navigate the severe impact of COVID-19 on the world and late calls for nation-wide social distancing, the Internet has become the lifeblood for people looking for accurate information about the novel coronavirus. Since launching the site on December 29th, Avi Schiffmann's tracking site was a necessary tool that sounded the alarm on the novel coronavirus and its spread, notably calling attention to its severity long before many global officials. By providing over 100 million visitors with real-time data on the virus' spread, Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating a website to provide real-time data about the virus to people everywhere, it is our great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The celebration will highlight the important work Avi and his fellow winners are doing, and will mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci's presenter speech could be recorded on his phone and we can send you through a script for him to review, edit and details for format and deadline.

This year's Webby Awards will also take action, the impact of COVID-19 and government responses around the world, has brought the importance of voting into sharp focus. The

Webby Awards has partnered with Vote.or and aim to check the voter registration status of 1 million voters in the United States, promoting the importance of voting to help ensure voter turnout this November is the highest it has ever been. This partnership will integrate into all elements of this year's online celebration.

Our thoughts are with all of you in this difficult time.

Best

Lesley Cahill Roy

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:55:14 +0000
To: 'Sharpless, Ned [REDACTED] (b) (6)'; Tromberg, Bruce (NIH/NIBIB) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 2 quick points
Attachments: covid contact tracing.pdf

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen [REDACTED] (b) (6)
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E]; [REDACTED] (b) (6) >
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview [REDACTED] (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland [REDACTED] (b) (6). As his email says [REDACTED] (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 [REDACTED] (b) (6). It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time

to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) (6) and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:(b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up (b) (6) but I'm writing because it might yet bring at least the two of us together.

(b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:53:55 +0000
To: Eric Ottesen
Subject: RE: 2 quick points

Eric:

Thanks for your note. No problem. I will forward this to people here at NIH who are pursuing such approaches. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen (b) (6) >
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland (b) (6). As his email says, (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 (b) (6). It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) (6), and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:(b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up (b) (6) but I'm writing because it might yet bring at least the two of us together.

(b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201
(b) (6)

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:52:37 +0000
To: NIAID OD AM
Subject: FW: INVITE- American College of Cardiology
Importance: High

From: Kim, Jonathan Ho-Youn (b) (6)
Sent: Friday, May 1, 2020 3:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Ryan Meyer (b) (6); Robyn Snyder (b) (6)
Subject: Re: INVITE- American College of Cardiology
Importance: High

Dr. Fauci- Of course, I appreciate how busy you are, so just reaching out again on behalf of the American College of Cardiology as noted below. We were hopeful we could steal just an hour of your time in June for an important discussion on COVID-19 and exercise training. This is part of a virtual agenda for one of our national conferences (Care of the Athletic Heart) with outreach around the world given this is a part of the ACC educational platform.

We hope this is something you have the bandwidth for, and simply appreciate your consideration. I hope to hear from you and thank you for all your service once again.

My best, Jonathan Kim

Jonathan H. Kim MD, MSc, FACC
Chief of Sports Cardiology
Department of Medicine, Division of Cardiology
Department of Orthopedics
Emory University
Adjunct Assistant Professor
Division of Applied Physiology
Georgia Institute of Technology
Team Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, Atlanta Braves, and Atlanta Dream
Office Phone: (b) (6)
Research Profile: <http://medicine.emory.edu/cardiology/emory-first-faculty-directory/profile.html?f=JKIM10>
Email (b) (6)

From: Kim, Jonathan Ho-Youn
Sent: Thursday, April 16, 2020 3:46 PM

To: [REDACTED] (b) (6)
Cc: Ryan Meyer [REDACTED] (b) (6); Rcbyn Snyder [REDACTED] (b) (6)
Subject: INVITE- American College of Cardiology

Dr. Fauci-

On behalf of the American College of Cardiology (ACC), first I would like to thank you for your tremendous service throughout your incredible career and certainly during these present and challenging times. We are indebted to your service and thankful everyday we have you to help guide public health measures through the COVID-19 pandemic.

I am a member of the Sports and Exercise Council for the ACC and the Course Chair for our annual ACC Care of the Athletic Heart Conference. Originally scheduled June 18-20, 2020 at ACC Heart House in Washington DC. I am also faculty at Emory University and direct our sports cardiology program in Atlanta.

Of course, we have made the difficult decision to cancel our live meeting in June, but myself along with the staff at ACC are working very hard transitioning the course to a virtual course and agenda. This course will be a much shorter version and the agenda will all be pre-recorded and distributed as a 'live simulated version' on June 20, 2020.

With the impact of COVID-19 on all aspects of life and society, in our academic world of sports cardiology, we are dealing with how COVID has impacted exercise and athletes. As you can imagine, there are a multitude of different issues and questions that colleagues are raising.

One new session for our virtual agenda that we think will generate a lot of interest and is of high importance will be a panel discussion on sports, exercise, and COVID-19. We would like to get additional expertise on the panel from the ID/public health and Sports Medicine arenas, in addition to sports cardiology. Of course, there is no one that carries the expertise you do from the ID and public health perspective and we would be extremely honored if you could be a part of this one session and join our faculty for the course.

Before getting into more details and a formal invite from the ACC, I wanted to first see if you had the bandwidth for this. Understanding you are as busy, if not busier, than anyone in the world right now. This session would be pre-recorded and we would certainly work to be flexible with anytime you had for this in early June to record.

I hope this is something that could work- again we would be honored to host you virtually.

Many thanks for considering, and hope to hear from you soon. Best, Jonathan Kim

Jonathan H. Kim MD, MSc, FACC
Chief of Sports Cardiology

Department of Medicine, Division of Cardiology

Department of Orthopedics

Emory University

Adjunct Assistant Professor

Division of Applied Physiology

Georgia Institute of Technology

Team Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, Atlanta Braves, and Atlanta Dream

Office Phone: (b) (6)

Research Profile: <http://medicine.emory.edu/cardiology/emory-first-faculty-directory/profile.html?f=JKIM10>

Email: (b) (6)

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:50:45 +0000
To: Jon LaPook
Subject: RE: Today's segment on CBS Sunday Morning

Jon:

Terrific piece on "No time to abandon science"! Keep up this great work. We need to stay on course.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Sunday, May 3, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Today's segment on CBS Sunday Morning

Dear Tony,

I hope (though would not bet my life that) you are getting at least a modicum of down time today.

Here's a link to the segment I told you about. No commercial!

<https://www.youtube.com/watch?v=0jCohlBICg0>


[<http://img.youtube.com/vi/0jCohlBICg0/0.jpg>]<<https://www.youtube.com/watch?v=0jCohlBICg0>>


Dr. Jon LaPook: No time to abandon science - YouTube<<https://www.youtube.com/watch?v=0jCohlBICg0>>
www.youtube.com

As we reach a point in the COVID-19 pandemic when some states are tempted to open sooner than health experts say they should, Dr. Jon LaPook notes that this ...

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS Evening News Professor of Medicine NYU Langone Health





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:23:12 +0000
To: Paola Dama
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: White House Coronavirus Task Force

Dr. Dama:

Thank you for your note. I am attaching a slide of the members of the USA Task Force and as you can see, Dr. Antonio Giordano is not a member.

Best regards,
A.S. Fauci

White House Coronavirus Task Force – Announced Jan. 29, 2020

Chair: VP Mike Pence

Response Coordinator: Deborah Birx

- | | |
|----------------------|---------------------|
| ■ Jerome Adams | ■ Stephen Hahn |
| ■ Alex Azar | ■ Derek Kan |
| ■ Stephen Biegun | ■ Larry Kudlow |
| ■ Robert Blair | ■ Chris Liddell |
| ■ Ben Carson | ■ Steven Mnuchin |
| ■ Ken Cuccinelli | ■ Robert O'Brien |
| ■ Kelvin Droegemeier | ■ Matthew Pottinger |
| ■ Anthony Fauci | ■ Robert Redfield |
| ■ Joe Grogan | ■ Joel Szabat |



- | |
|-----------------|
| ■ Seema Verma |
| ■ Robert Wilkie |

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paola Dama <(b) (6)>
Sent: Sunday, May 3, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: White House Coronavirus Task Force

Dear Dr. Fauci,

I hope to find you well with this email.
I take the liberty to write you because I have some concern about the misinformation that can discredit your task and honors.
On many occasions in tv and press, Antonio Giordano, Director of Sbarro Institute in Philadelphia, Keeps saying that he is a member of the USA Task Force.
I'm wondering if it's true.

I work in UK, but I'm originally from Naples (Italy).
I held my PhD in Carlo Croce's lab at OSU and I specialized in immunotherapy at University of Chicago.
Currently I'm a research fellow at University of Sussex.

I apologize if you find this email inopportune, the time is unfortunate, I grant you.
I don't like the idea that some people might take advantage of this very unpleasant moment for all the world.
So I wish that I made a mistake this time.

I'm also wondering if you are willing to release a brief interview.
I stand with you and USA that I miss very much

I really appreciate your time
Thank you
Kind Regards
Ciao ☺

Paola Dama, Ph D
Molecular Oncology and Pharmacology

University of Sussex
School of Life Sciences
John Maynard Smith (JMS) Building
Room 4B13
Falmer, Brighton BN1 9QG

cell. (b) (6) (Italia) / (b) (6) (USA)
(b) (6)

Email: (b) (6)
Skype: (b) (6)
website www.taskforcepandora.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 15:44:23 +0000
To: [REDACTED] (b) (6)
[REDACTED]
Subject: Great photo of Mommy and me in this article

<https://www.usatoday.com/story/news/nation/2020/05/03/coronavirus-white-house-expert-dr-anthony-fauci-americans-trust/3042991001/>

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6)
Sent: Sun, 3 May 2020 10:30:04 -0400
To: Collins, Francis (NIH/OD) [E]
Cc: Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]; Wholley, David (FNIH) [T]; Tabak, Lawrence (NIH/OD) [E]; Denny, Joshua (NIH/OD) [E]; Gebo, Kelly (NIH/OD) [G]; Lowy, Douglas (NIH/NCI) [E]; Devaney, Stephanie (NIH/OD) [E]; Adam, Stacey (FNIH) [T]; Santos, Michael (FNIH) [T]; Freire, Maria (FNIH) [T]
Subject: Re: crazy idea

[REDACTED] (b) (5)

On May 3, 2020, at 9:47 AM, Collins, Francis (NIH/OD) [E]
[REDACTED] (b) (6) wrote:

Hi John, Cliff, and Tony,

As we contemplate ways to stand up a master protocol that could enroll 50 – 100K participants in a multi-arm COVID-19 trial this summer, I wondered if [REDACTED] (b) (5)

[REDACTED]

See below - [REDACTED] (b) (5). What do you think?

Francis

From: Denny, Joshua (NIH/OD) [E] [REDACTED] (b) (6) >
Sent: Saturday, May 2, 2020 11:22 PM
To: Collins, Francis (NIH/OD) [E] <[REDACTED] (b) (6)>
Cc: Tabak, Lawrence (NIH/OD) [E] [REDACTED] (b) (6) >
Subject: Re: crazy idea

Hi Francis,

This is exciting to hear! Fabulous to hear we may be approaching such a trial. [REDACTED] (b) (5)

[REDACTED]

(b) (5)



Best,
Josh

Sent from my iPhone

On May 2, 2020, at 8:34 PM, Collins, Francis (NIH/OD) [E]

(b) (6) >wrote:


Hi Josh,

Developments over the last week (b) (5)

(b) (5)

(b) (5)

(b) (5)



Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 12:31:13 +0000
To: Handley, Gray (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: form Jorge Perez IPK Cuba

Thanks.

From: Handley, Gray (NIH/NIAID) [E] (b) (6)
Sent: Saturday, May 2, 2020 11:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: form Jorge Perez IPK Cuba

Will send a reply tomorrow morning.

I have spoken to State Department and have approved response. Someone will listen in.

Will copy you.

Gray

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, May 2, 2020 3:18 PM
To: Handley, Gray (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FW: form Jorge Perez IPK Cuba

Gray:

Would you please handle this.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any

other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pérez Avila, Jorge <(b) (6)>
Sent: Friday, May 1, 2020 12:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: form Jorge Perez IPK Cuba

Dear Dr. Fauci

Hello from Cuba.

Have been a long time we haven't been in touch.

Now the whole world is facing a new epidemic and in Cuba we are working in order to controlling. We will like to re-new our contact regarding this disease Covid 19, we prepare a telephone conference in order to exchange ideas to have a better understanding to control the epidemic. This conference will be held from Cuba next tuesday 05/05/2020 at 4:30pm Cuban time. In clouse I am sending the topics. We will like to have you and Dr. Handley in this activity if it is possible to attend this conference. If you are in agreement we will like to know by answering this email and them we will you any other detail.

If you have any other person to contact in order to participate will be helpfull for us.

Waiting for your answer.

Dr. Jorge Perez
IPK
Cuba

Preliminary program

Objectives:

- Updating COVID-19 situation at global, regional and mainly in Cuba and USA
- To sharing data of how our two countries are facing this emergency including research studies, etc

Topics for the discussion:

- The main strategies that both countries are developing to face COVID-19.
- Diagnostic strategy
- Clinical management in adults and children
- Innovative Cuban biotechnology products incorporated into the treatment models used in the different stages of treatment
- Some other research studies
- Discussion

Events and courses at the following address:

<http://Instituciones.sld.cu/ipk/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 20:17:31 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE:

Thanks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, May 2, 2020 4:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Erbeling, Emily (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE:

Hi,

I already reached out to Dr. Bolognesi and some of us in Program have a call scheduled with him to discuss this proposal.

I will let you know the outcome.

Kind regards,
Cristina

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, May 2, 2020 3:39 PM
To: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Cc: Erbeling, Emily (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE:
Importance: High

Cristina:

It would be a good idea for you to show this to a couple of other NIAID people for their opinion, and then out of courtesy to get back to Dr. Bolognesi one way or another.

Thanks,
Tony


Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, April 30, 2020 11:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6)>
Subject: RE:

Dear Dr. Fauci,

I reviewed this proposal (b) (3)
(b) (3), (b) (4)



(b) (5) informative
to discuss the project directly with them. Would you like for me to put together a small group at NIAID (with reps from DMID and DAIDS) to talk with Dr. Bolognesi and his colleagues?

Kind regards,

Cristina

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 30, 2020 7:58 PM
To: Cassetti, Cristina (NIH/NIAID) [E] <(b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] <(b) (6)>
Subject: FW:
Importance: High

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.

Thanks,

Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6)

Sent: Monday, April 27, 2020 6:09 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]

<(b) (6)>

Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." (b) (6)
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." (b) (6) >
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:08:58 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Please take a look at this and respond if appropriate.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Idonae Lovetrue (b) (6) >
Sent: Friday, May 1, 2020 2:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Beigel, John (NIH) [E] (b) (6); Booth, Mason (NIH/NIAID) [C]
(b) (6) Kim, Sonnie (NIH/NIAID) [E] (b) (6)
Subject: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Dear Dr. Fauci,

I'd like to share with you that the recent clinical trial results on remdesivir have validated our prediction of the remdesivir-specific post-treatment viral rebound in human COVID-19 patients. More details can be found in our official announcement <https://bit.ly/RRRemdesivir>.

This prediction of remdesivir's clinical efficacy on viral load made on Feb. 23 2020 (b) (6)

(b) (6)

(b) (6)

We appreciate and respect all the efforts you have made towards the COVID-19 pandemic.

Best regards,
Idonae

Idonae Lovetruie | CEO, Demiurge Technologies AG, Switzerland

www.demiurge.technology

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. While some information used on this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:00:06 +0000
To: Fetalvo, Ninio J. EOP/OVP
Subject: RE: Back to CMS

Ninio:

Thanks for all your good work in the White House. Stay safe and well.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fetalvo, Ninio J. EOP/OVP (b) (6)
Sent: Friday, May 1, 2020 3:12 PM
To: (b) (6); Fetalvo, Ninio (CMS/OC) (b) (6)
Subject: Back to CMS

All,

Today is my last day on detail to the Office of the Vice President. I am heading back to CMS to continue supporting the Trump Administration's response to the coronavirus. It has been an incredible honor serving the Vice President and the Coronavirus Task Force, and a pleasure working alongside all of you. I look forward to our ongoing work together.

Best,
Ninio

—
Ninio J.H. Fetalvo

Personal: (b) (6) | (b) (6)
CMS: (b) (6) | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:27:23 +0000
To: Johnson, Martin S. (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; NIAID OCGR Leg; McGowan, John J. (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Rotrosen, Daniel (NIH/NIAID) [E]; Crum, Wayne (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Gilles, Sharon (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Law, Kim (NIH/NIAID) [E]; Lee, Kun-Lin (NIH/NIAID) [E]; Bushar, Nicholas (NIH/NIAID) [E]; Schneider, Johanna (NIH/NIAID) [E]
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Thanks, Martin.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] (b) (6)
Sent: Friday, May 1, 2020 7:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] <wcrum@niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6)v>;

Schneider, Johanna (NIH/NIAID) [E] (b) (6)

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Tony,

YTD spending is \$110.8M, increasing \$24.1M from last week.

Spending driven by implementation of 3 epidemiological studies, ramp up of resources necessary for vaccine candidate testing and vaccine candidate development.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, April 24, 2020 7:11 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)

Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] <(b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)

Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Tony,

YTD spending is \$86.7M, an increase of \$8.3M from last week.

Spending driven by foundational research including the characterization of factors associated with severe disease, transmission dynamics, structural analysis of SARS-CoV-2 proteins. Small awards to support vaccine and therapeutic discovery.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, April 17, 2020 6:15 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel

(NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6)>;
Harper, Jill (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E]
<(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston,
Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
(b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon
(NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6)>;
Lee, Kun-Lin (NIH/NIAID) [E] <(b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]
(b) (6)>; Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/17/20

Tony,

YTD spending is \$78.4M, an increase of \$10.9M from last week including costs to evaluate therapeutics in humans and NHPs, manufacture of a prototype virus-like vaccine candidate developed by Taubenberger/Memoli, and spending to accelerate discovery of new therapeutics, vaccines and diagnostics.



Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 10, 2020 8:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/10/20

Tony,

YTD spending is \$67.5M, unchanged* from last week. A summary is attached.

I have also attached an updated budget plan reflecting our projected spending by research category by fiscal year. We are updating this weekly as we receive updates from the divisions on the timing of clinical trials, observational studies, natural history studies and research resource needs.

We will report mid-week on our YTD spending which will be in sync with the data the Dept. extracts.

Martin

-
- The reason that we have reported no weekly increase is to match our reported spending with the financial information that the Department is now extracting from our accounting system. We have always included spending from our regular appropriation, as directed by the Department. Now the guidance from the Dept. has been updated to report **only** spending from the supplemental COVID-19 appropriations.

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 3, 2020 8:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E]

(b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] <(b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] <(b) (6)>; Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>; Doepel, Laurie (NIH/NIAID) [E] <(b) (6)>; Gilles, Sharon (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Law, Kim (NIH/NIAID) [E] <(b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] <(b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] <(b) (6)>; Schneider, Johanna (NIH/NIAID) [E] <(b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/3/20

Tony,

YTD spending is \$67.5M , a weekly increase of \$45.9M mostly for initial funding for set-up of clinical trials for evaluation of remdesivir in patients with early disease stage and a placebo-controlled clinical trial of intravenous hyperimmune immunoglobulin (IVIG) in patients with COVID-19.

I've provided a summary spending plan the team worked on and a table for the \$1.532B that we have received in supplemental appropriations

- \$826M NIAID received 3/5/20 - the Coronavirus Preparedness and Response Supplemental Appropriations Act
- \$706M NIAID received 3/25/20 - the Coronavirus Aid, Relief, and Economic Security (CARES) Act

In the last document I've also included narrative summarizing activities funded by the \$249M Other NIH Institutes received in the CARES Act

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 27, 2020 7:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] <(b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Marston,

Hilary (NIH/NIAID) [E] <(b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
(b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon
(NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>;
Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>;
Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]
(b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/26/20

Tony,

YTD spending is \$21.6M , a weekly increase of \$4.0M for clinical trial site set-up for therapeutics, further vaccine development, small animal development, and therapeutic development (mAbs) and basic research.

Most of the \$50M-\$60M we listed last week we expect to be awarded before March 31. In many cases contractors have begun work without the award so as to not stall work.

Early next week I'll provide a summary spending plan for the additional \$706M that NIAID received in the supplemental appropriation signed by the President today.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 20, 2020 4:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E]
(b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
(NIH/NIAID) [E] (b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum,
Wayne (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E]
(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E]
(b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary
(NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>;
Doepel, Laurie (NIH/NIAID) [E] <(b) (6)>; Gilles, Sharon (NIH/NIAID) [E]
<(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy
(NIH/NIAID) [E] (b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin
(NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6)
Schneider, Johanna (NIH/NIAID) [E] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/19/20

Tony,

YTD spending is \$17.6M , a weekly increase of \$3.5M for clinical trial site set-up, therapeutic development (mAbs) and basic research.

We greatly appreciate all your hard work.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 13, 2020 6:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] - (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6); Erbeling, Emily (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/12/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$1.5M for a total YTD spending of \$14.1M.

The \$1.5M increase is for the following:

\$1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptable RCT of remdesivir.

\$0.4M supported data analysis of rhesus animal model and grant to gain understanding of the host pathways that regulate viral gene expression and viral subversion of the host immune system.

\$0.1M funded vaccine development at VRC and DIR



Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 6, 2020 5:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/5/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$0.2M for a total YTD spending of \$12.6M.

The \$0.2M increase is for vaccine candidate development at NIAID Intramural Labs including RML. Costs are mostly for staffing and overhead and include a preclinical immunogenicity

study designed to test the mRNA-1273 nCoV vaccine two-dose schedule in mice. The study will measure the immune response to this vaccine in an animal model in anticipation of clinical test in humans.



Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, February 28, 2020 11:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$2.3M for a total YTD spending of \$12.4M.

A recap of the \$2.3 million spent in the last week is as follows:

- \$1.9M to set-up a Phase I trial (45 subjects) of the VRC/Moderna mRNA platform candidate at Kaiser Permanente Washington Health Research Institute (One of the VTEUs)

- \$0.3M that supported University of Hong Kong researchers in the development of a RT-PCR test to detect SARSCoV2 from human samples. The group has now shared the tests and relevant reagents with over 30 labs globally to enable diagnosis of COVID-19.
- \$0.1M vaccine candidate development at NIAID Intramural Labs



Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, February 14, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6)
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending as of 2/13/20

Dr. Fauci,

Attached is a narrative we are updating weekly for NIAID's COVID-19 response.

The accompanying spreadsheet summarizes the figures and includes a summary of our supplemental request.

We'll provide an update by Thursday of next week.

Martin

Resource Planning and Mission Integration Branch (RPMIB) – NIAID

NIH Bldg. 31 Room 7A47

Tel: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:22:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: (b) (6)
Subject: RE: RE:

Zeke:

Thanks for your note. (b) (6) and I would love to get together with you all for dinner. Let us try to do so within a reasonably soon time frame.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: RE:

Email from Zeke Emanuel.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Emanuel, Ezekiel J <(b) (6)>
Sent: Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: <(b) (6)>
Subject: Re: RE:

Tony

You are national--international --treasure. And we are depending upon your sanity and smarts.

We can have you and (b) (6) over for dinner on the porch and order in from (b) (6) or something. Anytime you are ready.

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy <(b) (6)>

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: <(b) (6)>

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Friday, May 1, 2020 6:55 PM
To: Emanuel, Ezekiel J <(b) (6)>
Cc: <(b) (6)>
Subject: RE: RE:

Zeke:

Thanks for the note. Indeed, we do agree. (b) (6)

(b) (6) I look forward to chatting with you some time soon.

Best,

Tony

From: Emanuel, Ezekiel J <(b) (6)>

Sent: Thursday, April 30, 2020 6:37 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Subject: Re: RE:

Sorry for misreading what you said--I think maybe I overintepreted--lots of finance people called and seemed like I was a downer compared to you. But I think we agree.

Are you and (b) (6) doing okay?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Sent: Thursday, April 30, 2020 5:33 PM

To: Emanuel, Ezekiel J (b) (6)>

Subject: RE:

Zeke:

I did not "strongly" endorse it. I specifically said that it was not a knockout drug and was only a baby step in the direction of developing more and better drugs. I said that it was important because it proved in a well-powered, randomized, placebo-controlled clinical trial that one can suppress the virus enough to see a clinical effect, as modest as the effect was. I do not think I forced anything.

Happy to chat with you about it.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6) >
Sent: Thursday, April 30, 2020 2:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject:

Tony,

I hope you and (b) (6) are doing well. You are doing an amazing job under difficult circumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!

I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit forced?

My reading was the data were weak and in normal times for normal disease it is not enough to approve. And very unlikely to really impact COVID-19 disease pattern--regardless of supply issues.

Stay safe

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:00:31 +0000
To: Hurst, Natalie R. EOP/OVP
Subject: RE: Update - White House Coronavirus Task Force Meeting

Thanks, Natalie!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 17:57:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Greetings from India

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Prof. Chirantan Chatterjee <(b) (6)>
Sent: Saturday, May 2, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Deepak Bhatt Manager - Communications (b) (6)
Subject: Greetings from India

Dear Dr Fauci,

My greetings from India. I am a health economist and management professor at the Indian Institute of Management, Ahmedabad, India's premier management school. Also, i am a avid fan of your work even from pre-covid19 days.

I write to you requesting some time if possible to do a podcast of 45 minutes with you over zoom. The science and policy ecosystem in India i think would immensely benefit if you can offer your thoughts on what should be India's 12-month strategy going forward for COVID-19.

We have done some recent podcasts relatedly and they are listed her
(<https://m.soundcloud.com/healthcastbycmhs/>).

If you agree, and we are flexible all of May, my communication head Mr. Deepak marked in the email will arrange the zoom logistics and make it as seamless as possible for you.

We will also go per your time zone conveniences and do this over webex/hangout/skype or phone call if that helps.

It would be a delight Dr. Fauci if you can join us in the conversation, looking forward to hearing from you. Our respectful namaste 🙏 from India for all the brave work you are doing.

My best, Chirantan

Chirantan Chatterjee (PhD, Carnegie Mellon) || Associate Professor (Economics & Business Policy) & ICICI Bank Chair in Strategic Management || Chairperson, Center for Management of Health Services at IIMA || 2019-2020 Visiting Fellow, 2018-2019 Campbell & Edward Teller National Fellow, Hoover Institution, Stanford University || Office Address: Wing 13F, Indian Institute of Management || Ahmedabad, 380 015 Gujarat, India || Skype:

(b) (6) || Email: (b) (6) or (b) (6) || Hoover Institution Website | IIMA Official Website

What is laid down, ordered, factual is never enough to embrace the whole truth: life always spills over the rim of every cup. – Boris Pasternak in *Bridges to Infinity* : The Human Side of Mathematics (1983) by Michael Guillen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 12:08:00 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Haskins, Melinda (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT
Attachments: Dr. Anthony Fauci - Town Hall Invite.pdf

Please take a look at this. We obviously will have to get clearance through HHS and White House Leg. This is for Thursday and so we would need to submit soon.

From: Coney, Lillie (b) (6)>
Sent: Friday, May 1, 2020 11:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Rushing, Glenn (b) (6); Coney, Lillie (b) (6)
Subject: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT

May 1, 2020

Dr. Anthony Fauci, M.D.
Director of the National Institute of Allergy and Infectious Diseases
Department of Health and Human Services
5601 Fishers Lane
Bethesda, MD 20892-9806

Dear Dr. Fauci:

Thank you for your tremendous steadfast leadership during this pandemic and health crisis. Our nation has not faced a crisis of this magnitude since the 1918 Spanish Flu, but we will travel this journey together and defeat this virus. In the end, the nation will become stronger and more prepared.

Your participation is requested in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT. This town hall meeting will focus on testing and guidelines for re-opening our nation. It is scheduled to last an hour with 2 or 3 guests including yourself. Houston is the fourth largest city in the country and your knowledge and expertise would be most helpful in our fight to keep our infection and fatality rates low for this entire region and the State of Texas.

My office has been pushing testing and setting up testing sites since the first notification of the coronavirus. We currently have seven active testing sites and expanding each week to get to the mass testing necessary to flatten the infection rate.

Thank you for your consideration of this request and I look forward to participating with you in the Virtual Town Hall meeting. Again, thank you for your leadership. Please RSVP or if you have questions regarding this request with Glenn Rushing, my Chief of Staff at (b) (6) and Lillie Coney, my Chief Policy Advisor at (b) (6).

Very truly yours,

J

Sheila Jackson Lee
Member of Congress

Regards,
Lillie Coney
Policy Director
Congresswoman Sheila Jackson Lee (TX-18)
2079 Rayburn HOB
Washington, DC 20515

(b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 12:01:04 +0000
To: [REDACTED] (b) (6)
Subject: FW: RE:

Let us try to do this next weekend.

From: Eisinger, Robert (NIH/NIAID) [E] [REDACTED] (b) (6) **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: RE:

Email from Zeke Emanuel.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Emanuel, Ezekiel J [REDACTED] (b) (6) >
Sent: Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: [REDACTED] (b) (6) >
Subject: Re: RE:

Tony

You are national--international --treasure. And we are depending upon your sanity and smarts.

We can have you and [REDACTED] (b) (6) over for dinner on the porch and order in from [REDACTED] (b) (6) or something. Anytime you are ready.

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) v >
Sent: Friday, May 1, 2020 6:55 PM
To: Emanuel, Ezekiel J (b) (6) >
Cc: (b) (6) >
Subject: RE: RE:

Zeke:

Thanks for the note. Indeed, we do agree. (b) (6)

(b) (6) I look forward to chatting with you some time soon.

Best,

Tony

From: Emanuel, Ezekiel J (b) (6) >
Sent: Thursday, April 30, 2020 6:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) >
Subject: Re: RE:

Sorry for misreading what you said—I think maybe I overintepreted—lots of finance people called and seemed like I was a downer compared to you. But I think we agree.

Are you and (b) (6) doing okay?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Sent: Thursday, April 30, 2020 5:33 PM

To: Emanuel, Ezekiel J (b) (6) >

Subject: RE:

Zeke:

I did not "strongly" endorse it. I specifically said that it was not a knockout drug and was only a baby step in the direction of developing more and better drugs. I said that it was important because it proved in a well-powered, randomized, placebo-controlled clinical trial that one can suppress the virus enough to see a clinical effect, as modest as the effect was. I do not think I forced anything.

Happy to chat with you about it.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6)

Sent: Thursday, April 30, 2020 2:12 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject:

Tony,

I hope you and (b) (6) are doing well. You are doing an amazing job under difficult circumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!

I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit forced?

My reading was the data were weak and in normal times for normal disease it is not enough to approve. And very unlikely to really impact COVID-19 disease pattern--regardless of supply issues.

Stay safe

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 02:04:00 +0000
To: Selgrade, Sara (NIH/NIAID) [E]
Cc: NIAID DCGR Leg;Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Requesting your assistance: Draft NIAID Statement for May 12 Senate HELP Hearing
Attachments: 2020.05.12 NIAID Senate HELP testimony COVID 19 - with Fauci tracked changes.docx

I am attaching the document with minor tracked edits. Nice job! Thanks.

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, April 30, 2020 5:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: NIAID DCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Requesting your assistance: Draft NIAID Statement for May 12 Senate HELP Hearing

Dr. Fauci:

In preparation for the upcoming May 12th COVID-19 hearing of the Senate Health, Education, Labor, and Pensions Committee (Chair: Sen. Lamar Alexander, R-TN), we have drafted the attached NIAID testimony, building on your prior testimony on COVID-19. Drs. Giroir, Hahn, and Redfield also have been invited to the hearing.

We expect that your testimony will be included as an insert to an HHS-wide testimony. At the request of NIH OD, we have incorporated into the draft COVID-19 activities across NIH.

The testimony has been reviewed by the Divisions and Drs. Lane, Harper, Marston, and Lerner, as well as Courtney Billet, Greg Folkers, Martin Johnson, and Laurie Doepel.

NIH OLPA has asked to receive your testimony for clearance by tomorrow, if possible.

Thank you for your help.

Sara

Sara Selgrade, Ph.D.

Section Chief for Legislative Activities

Legislative Affairs and Correspondence Management Branch

Office of Communications and Government Relations

NIAID/NIH/DHHS

Bldg. 31, Room 7A17, MSC 2520

Bethesda, MD 20892-2520

Phone: (b) (6)

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 15:28:23 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: clips

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Friday, May 1, 2020 8:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
(b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: RE: clips

Dr. Fauci –

I have requested the full clips from our clipping service. I found the following online in the meantime:

Today Show:

<https://www.today.com/video/dr-anthony-fauci-remdesivir-is-a-very-important-first-step-in-fighting-coronavirus-82800197863>

CNN Town Hall (clip discussing federal "reopening" guidelines):

<https://twitter.com/CNN/status/1256023483638669313>

CNN Town Hall (clip discussing vaccines):

<https://twitter.com/CNN/status/1256044817093558272>

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Friday, May 1, 2020 7:44 AM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Subject: clips

Jen:

Can we please make sure that I get the lips from yesterday from NBC Today Show and CNN Town Hall with Sanjay and Anderson.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:26:55 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: [REDACTED] (b) (4)

Another email from Andre Kalil.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Kalil, Andre C [REDACTED] (b) (6) >
Sent: Thursday, April 30, 2020 8:12 PM
To: Beigel, John (NIH) [E] [REDACTED] (b) (6); Dodd, Lori (NIH/NIAID) [E] [REDACTED] (b) (6);
Davey, Richard (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E]
[REDACTED] (b) (6)>; Proschan, Michael (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary
(NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: RE: [REDACTED] (b) (4)



Thanks,

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

(b) (6) | fax 402.559-5581

(b) (6)

UNMC | Facebook | Twitter | YouTube | Flickr

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

From: Beigel, John (NIH) [E] (b) (6) >

Sent: Thursday, April 30, 2020 5:25 AM

To: Dodd, Lori (NIH/NIAID) [E] (b) (6) >; Kalil, Andre C (b) (6) >; Davey, Richard (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Proschan, Michael (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: Re: (b) (4)

Non-UNMC email

(b) (4)

John Beigel, M.D.

Associate Director for Clinical Research

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

Phone: (b) (6)

email: (b) (6)

From: Lori Dodd (b) (6)>
Date: Thursday, April 30, 2020 at 6:05 AM
To: John Beigel (b) (6)>, Andre Kalil (b) (6)>, Richard Davey (b) (6)>, Cliff Lane <(b) (6)>, Michael Proschan (b) (6)>, Hilary Marston (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: RE: (b) (4)

Andre-

I like what you wrote, and particularly like the first two sentences.

From: Beigel, John (NIH) [E] (b) (6)>
Sent: Thursday, April 30, 2020 5:53 AM
To: Kalil, Andre C (b) (6)>; Davey, Richard (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Dodd, Lori (NIH/NIAID) [E] <(b) (6)>; Proschan, Michael (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: (b) (4)

Andre,

(b) (4)

We too are open for further edits

John

--
John Beigel, M.D.

Associate Director for Clinical Research

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

Phone: (b) (6)

email: (b) (6)

From: Andre Kalil (b) (6) >
Date: Thursday, April 30, 2020 at 3:19 AM
To: John Beigel (b) (6) >, Richard Davey (b) (6) >, Cliff Lane (b) (6), Lori Dodd (b) (6) >, Michael Proschan (b) (6) >, Hilary Marston <(b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: (b) (4)



Please let me know your thoughts and suggestions.

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

(b) (6) | fax 402.559-5581

[UNMC](#) | [Facebook \[facebook.com\]](#) | [Twitter \[twitter.com\]](#) | [YouTube \[youtube.com\]](#) | [Flickr \[flickr.com\]](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:25:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6)
Sent: Thursday, April 30, 2020 8:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: RE:

TX Tony. Nice touch reminding folks of how AZT propelled the pharmas and great to see things moving with this beast!

Sei un campione!

Dani

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, April 30, 2020 7:58 PM
To: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6)
Subject: FW:

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.

Thanks,

Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6) >
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C]
(b) (6) >
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." <(b) (6)>

Date: Monday, April 27, 2020 at 2:53 PM

To: "Matthias Gromeier, M.D." (b) (6)

Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:10:09 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: ACTT publication
Importance: High

Another email from Andre Kalil.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email (b) (6)

From: Kalil, Andre C (b) (6) >
Sent: Friday, May 1, 2020 2:59 AM
To: Beigel, John (NIH) [E] (b) (6) >; Davey, Richard (NIH/NIAID) [E]
(b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6); Dodd, Lori (NIH/NIAID) [E]
(b) (6) >; Proschan, Michael (NIH/NIAID) [E] (b) (6); Marston, Hilary
(NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: ACTT publication
Importance: High

Not my first choice, but I want to share the invitation email below with you.
Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM
Professor
Department of Internal Medicine
Division of Infectious Diseases
Director, Transplant ID Program
Associate Editor, CMI, Official Journal of ESCMID
Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center
985400 Nebraska Medical Center, Omaha, NE 68198-5400
(b) (6) | Fax 402.559-5581
(b) (6)

[UNMC](#) | [Facebook](#) | [Twitter](#) | [YouTube](#) | [Flickr](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."
Robert Ludlum - The Ambler Warning

From: [REDACTED] (b) (4)

Sent: Thursday, April 30, 2020 1:03 PM

To: Kalil, Andre C [REDACTED] (b) (6)

Subject: ACTT publication

Importance: High

Non-UNMC email

Dear Dr. Kalil,

(b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 11:38:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: interview request by Greek newspaper Ethnos

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Γιώργος Σκαφιδάς <gskafidas@ethnos.gr>
Sent: Friday, May 1, 2020 6:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: interview request by Greek newspaper Ethnos

Dear Dr. Fauci,

my name is George Skafidas and I'm a journalist working for the Greek national weekly ETHNOS (www.ethnos.gr).

We would be very much interested in doing an interview with you, to be published in the Sunday edition of the paper, regarding the developments surrounding the COVID-19 pandemic.

Best regards

ΕΘΝΟΣ

George Skafidas

Senior editor, World Affairs

tel: +30 210 6510550

mob: [REDACTED] (b) (6)

Οι πληροφορίες που περιέχονται σε αυτά τα μηνύμα ηλεκτρονικού ταχυδρομείου (e-mail) καθώς και σε τυχόν συντημένα είναι εμπιστευτικές και προορίζονται για χρήση αποκλειστικά από τα συγκεκριμένα παραλήπτη (-ες). Οι πληροφορίες αυτές μπορεί να καλύπτονται από επιχειρησιακά ή άλλα σπέρητα ή άλλους νόμους και δεν επιτρέπεται να ανακοινωθούν σε οποιονδήποτε τρίτο. Σε περίπτωση που δεν είστε ο παραλήπτης του μηνύματος ή το πρόσωπο που είναι αρμόδιο για την παράδοσή του στον παραλήπτη, παρακαλούμε να τα ανακοινώσετε, αντιγράψετε, διανεμήσετε ή διατηρήσετε εν όλων ή εν μέρει.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 11:38:08 +0000
To: (b) (6)
Subject: RE: Coronavirus: Covid 19

Ato:

Thank you for you note. We will know soon whether hydroxychloroquine has any beneficial effects as the results of randomized, controlled trials become available. The pathogenesis of COVID-19 is still an open question. You are correct in that there is a more recent tendency to use ventilators only as a very last resort since oxygenation rather than ventilation appears to be key to recovery.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: gabriel stephens (b) (6)
Sent: Friday, May 1, 2020 4:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus: Covid 19

Hi Dr Fauci,

Please find an audio attached of a doctor describing the experience with regards to covid 19 in the hospital. She seems to suggest covid 19 is a virus that rather attacks the blood cell, leading to respiratory and other organ complications, hence they need to loom at treatment in a different light. In the UK some hospitals have moved away from using ventilators due to the high death rate of those on ventilators, and are rather using ventilators for sleep apnea, as they are less invasive, and the results are much much better compared to invasive ventilators

There are some anecdotal observations I have also made. The infection rate in most African countries seem to be comparatively low, which could possibly due to the rate of testing being conducted. However the death rates are also comparatively very low. From initial information with regards to

hydroxychloroquine and some antimalaria drugs usage, it was suggested that those who were alleged to have had some benefits had mild symptoms of covid 19. I know some clinical trials have shown hydroxychloroquine not to be effective in the treatment of covid 19 in very ill patients. However, my hypothesis is, are the low death rates in Africa linked to the fact that malaria is very prevalent in Africa, and lots of Africans take antimalarial drugs, making them less susceptible to covid 19, hence the low death rate. Is there a similar trend in other countries where malaria is prevalent? Is there an unintended benefit of taking antimalarial drug (or other medication) before covid infection, or at the onset, making people less susceptible to covid19.

As I said, this is based on anecdotal observations.

Yours sincerely

Ato Stephens

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 23:58:07 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Cc: Erbeling, Emily (NIH/NIAID) [E]
Bcc: Dani Bolognesi, Ph.D.
Subject: FW:
Attachments: Brown et al submitted.pdf, NIH Presentation final.pptx, preprints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone (b) (6) 9
Email (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6) >
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6) >
Subject: FW:


Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." [redacted] <[redacted]>
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." [redacted] <[redacted]>
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:35:34 +0000
To: Jeremy Farrar; Dzau, Victor J.; George GAO
Cc: Richard [REDACTED]; Hannon, Emma; Conrad, Patricia (NIH/NIAID) [E]; Teresa Miller de Vega; [REDACTED]; Rebeka Yasmin - CEPI; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com [REDACTED]; McGinnis, J. Michael; Balatbat, Celynne; Mun, Jenny; [REDACTED]; Redfield, Robert R. (CDC/OD)
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Many thanks for the update. Please continue to keep me informed.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED]
FAX: (301) 496-4409
E-mail: [REDACTED]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar [REDACTED]
Sent: Tuesday, April 28, 2020 10:39 AM
To: Fauci, Anthony (NIH/NIAID) [E]; [REDACTED]; Dzau, Victor J. <VDzau@nas.edu>; George GAO [REDACTED]
Cc: Richard Hatchett [REDACTED]; [REDACTED]; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E]; [REDACTED]; Teresa Miller de Vega [REDACTED]; [REDACTED]; Rebeka Yasmin - CEPI [REDACTED]; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; [REDACTED]; McGinnis, J. Michael [REDACTED]; [REDACTED]; Mun, Jenny <JMun@nas.edu> [REDACTED]; Redfield, Robert R. (CDC/OD) [REDACTED]
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Quick update

Update in confidence

European network from this morning:

16 Paris, 2 Geneva, few Madrid last 10 days - nothing like this usually seen even with seasonal KD or TSS

Barcelona have slightly different experience of 6 'Kawasaki' in last 2 weeks - couple now who have large coronary aneurysms, as have one child South London and one in Bristol.

Most UK PICU have 1-2 of these type of cases

Phenotype seems Diarrhoea and abdominal pain, refractory shock then various degrees of heart involvement and inflammation ++ - several have had their normal appendix whipped out

Most negative respiratory and stool PCR for anything, some positive resp PCR COVID - GOSH early case has seroconverted, but had immunoglobulin

We are establishing database UK and Europe and trying to define what the clinician features are and agree investigations.

Notably, none in US reported (just D/W Boston childrens who have been running shared international COVID experience web calls) and none in Rome, unsure about rest of Italy yet

Does seem BAME preponderance -?? immune related or social phenomenon, in terms of deprivation prevalence and ability to isolate

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>

Date: Monday, 27 April 2020 at 12:36

To: Jeremy Farrar <(b) (6)>, Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>

Cc: Richard Hatchett <(b) (6)>

<(b) (6)> "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega <(b) (6)>

<(b) (6)> Rebeka Yasmin - CEPI <(b) (6)>

<(b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>,

"Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>,

"Tia.Miller@turner.com" <Tia.Miller@turner.com>,

<(b) (6)> "McGinnis, J. Michael" <MMcGinnis@nas.edu>,

<(b) (6)>, "Mun, Jenny" <JMun@nas.edu>,

<(b) (6)>, "Redfield, Robert R. (CDC/OD)" <(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2 or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6) >
Sent: Monday, April 27, 2020 7:13 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Dzaou, Victor J. <VDzaou@nas.edu>; George GAO (b) (6) >
Cc: Richard Hatchett (b) (6) >; Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Teresa Miller de Vega <(b) (6)>; (b) (6); Rebeka Yasmin - CEPI (b) (6) >; ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Milner@turner.com; (b) (6) McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6) >; Mun, Jenny <JMun@nas.edu> (b) (6) >
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

<https://www.hsi.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article>

<https://t.co/BJ6YHUJ8zi>

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, 26 April 2020 at 19:52
To: Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>
Cc: Jeremy Farrar <(b) (6)>, Richard Hatchett <(b) (6)>
<(b) (6)>, "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega <(b) (6)>, Rebeka Yasmin - CEPI <(b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda.Scaly@cnn.com" <Amanda.Scaly@cnn.com>, "Neel.Khairzada@turner.com" <Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>, <(b) (6)>, "McGinnis, J. Michael" <MMcGinnis@nas.edu>, <(b) (6)>, "Mun, Jenny" <JMun@nas.edu>, <(b) (6)>
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: <(b) (6)>
FAX: (301) 496-4409
E-mail: <(b) (6)>

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Saturday, April 25, 2020 3:59 PM

To: George GAO (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
(b) (6) Hannon,
Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
(b) (6); rebeka.yasmin@cepi.net; ben.tinker@cnn.com;
Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6)
McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6) >; Mun, Jenny
(b) (6) >; haja.bally@cepi.net
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,
Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.
Hope to see you soon.
Warmest regards,
Victor

On Apr 25, 2020, at 1:22 PM, George GAO (b) (6) wrote:

I am waiting for being connected and will use slides which were sent to your office
George

发自我的iPhone

在 2020年4月24日, 01:49, Dzau, Victor J. <VDzau@nas.edu>
写道:

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, (b) (6), my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Thursday, April 9, 2020 11:01 AM

To: Mun, Jenny <JMun@nas.edu>; (b) (6)

(b) (6)

Cc: (b) (6) Hannon, Emma

<EHannon@nas.edu>; (b) (6)

; 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;

'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>;

'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;

'Tia.Miller@turner.com' <Tia.Miller@turner.com>; (b) (6)

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You

may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM

To: [REDACTED] (b) (6)

Cc: Dzau, Victor J. ; [REDACTED] (b) (6) ; Mun, Jenny ; Hannon, Emma ;

[REDACTED] (b) (6)
[REDACTED] ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com'
'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'

Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, Wellcome Trust

George F. Gao, Director-General, Chinese Center for Disease Control & Prevention

Sanjay Gupta, Chief Medical Correspondent, CNN

Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations

Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

.....

Jenny Mun
Membership Director
National Academy of Sciences

(b) (6)
[Redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:19:19 +0000
To: Alexander Patterson
Subject: RE: [REDACTED] made a Video Game of Yo: "Fauci's Revenge"

Thanks, Alex! Much appreciated.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED]
FAX: (301) 496-4409
E-mail: [REDACTED]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Patterson <alex.patterson@beatthebomb.com>
Sent: Thursday, April 30, 2020 11:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED]
Cc: Daniel Lahart <dlahart@regis.org>
Subject: [REDACTED] made a Video Game of Yo: "Fauci's Revenge"

Dear Dr. Fauci -

My name is Alex Patterson and I'm [REDACTED] I made a video game about you called **Fauci's Revenge**. Link to play: <https://beatthebomb.com/beatthevirus>

We are streaming the Finals of a tournament live tonight at 8 PM EST on Twitch, FB, and YouTube.
Twitch Stream Link (free to watch): <https://www.twitch.tv/beatthebomb1000>

Also available on:

Facebook: <https://www.facebook.com/BeatTheBomb/>

YouTube: <https://www.youtube.com/channel/UCDyh7vo1knuKuaaCKUssAzA>


Please watch the Twitch Stream if you can! Otherwise I will follow up tomorrow with a video!

Media coverage of the Fauci's Revenge in the News:

- [NBC New York](#)
[Spectrum NY1 News](#)
[Timeout New York](#)
[News 12 New York](#)
[Bushwick Daily](#)
[Fox 5 Good Day New York](#)

To date we've raised over \$6,150 for New York City's Public Health System ([NYC Health + Hospitals](#)). We've created limited edition t-shirts (including a Fauci's Revenge one). We've donated 6,150 [Protective Suits](#) and 4,500 [Gloves](#) to the NYC Mayor's Office and face shields to Maimonides Medical Center. Men for others!

Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!

Best,
Alex Patterson 

--

Alex Patterson
CEO BEAT THE BOMB
www.beatthebomb.com
Follow us on instagram: @beatthebomb
247 Water Street, Suite 106, Brooklyn, 11201
work: 718-643-0200 // cell:  (a) (a)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:18:45 +0000
To: [REDACTED] (b) (6)
Subject: FW: [REDACTED] (b) (6) Grad made a Video Game of Yo: "Fauci's Revenge"
Attachments: Fauci's Revenge Game Logo.png

Yikes!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alexander Patterson <alex.patterson@beatthebomb.com>
Sent: Thursday, April 30, 2020 11:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Daniel Lahart <dlahart@regis.org>
Subject: [REDACTED] (b) (6) made a Video Game of Yo: "Fauci's Revenge"

Dear Dr. Fauci -

My name is Alex Patterson and I'm [REDACTED] (b) (6) I made a video game about you called **Fauci's Revenge**. Link to play: <https://beatthebomb.com/beatthevirus>

We are streaming the Finals of a tournament live tonight at 8 PM EST on Twitch, FB, and YouTube.
Twitch Stream Link (free to watch): <https://www.twitch.tv/beatthebomb1000>

Also available on:

Facebook: <https://www.facebook.com/BeatTheBomb/>

YouTube: <https://www.youtube.com/channel/UCDyh7vo1knuKuaaCKUssAzA>

Please watch the Twitch Stream if you can! Otherwise I will follow up tomorrow with a video!

Media coverage of the Fauci's Revenge in the News:

- NBC New York
Spectrum NY1 News
Timeout New York
News 12 New York
Bushwick Daily
Fox 5 Good Day New York

To date we've raised over \$6,150 for New York City's Public Health System (NYC Health + Hospitals). We've created limited edition t-shirts (including a Fauci's Revenge one). We've donated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields to Maimonides Medical Center. Men for others!

Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!

Best,
Alex Patterson (b) (6)

--

Alex Patterson
CEO BEAT THE BOMB
www.beatthebomb.com
Follow us on instagram: @beatthebomb
247 Water Street, Suite 106, Brooklyn, 11201
work: 718-643-0200 // cell: (b) (6)





BEAT THE BOMB

PRESENTS

FAUCI'S REVENGE

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:14:57 +0000
To: (b) (6)
Cc: Tromberg, Bruce (NIH/NIBIB) [E]; Sharpless, Norman (NIH/NCI) [E]; Birx, Deborah L. EOP/NSC; Redfield, Robert R. (CDC/OD); Collins, Francis (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Stanford National Daily Health Survey for COVID - "Open Up America Again"
Attachments: 4.28.20 NDHS Overview Slides-Rusty-Fauci _ 1.pptx

Rod:

Great to hear from you. Thanks very much for sending this. Very impressive! I will forward this to Bruce Tromberg and Ned Sharpless who have been working on COVID-related apts. In addition, I have cc'd Deb Birx (Coordinator of the White House COVID-19 Task Force) as well as CDC Director Bob Redfield and Francis Collins. I hope that all is well with you. Stay well and safe,

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pettigrew, Roderic I
Sent: Thursday, April 30, 2020 4:20 AM
To: Anthony S. Fauci (NIH/NIAID) (b) (6)
Subject: Stanford National Daily Health Survey for COVID - "Open Up America Again"

Hi Tony,

Greetings from Houston, where the number of cases peaked ~2 weeks ago, dropped 35-40% and seemed to have plateaued since. Great to see you on TV and see the nation (including Brad

Pitt☺) get to know the rigorously informed, keenly rationale and consistently clear Tony your colleagues have long known.

(b) (4), (b) (5)

Thank you, Tony. Very proud to know you. Kind regards to (b) (6).

Rod

Roderic I Pettigrew, PhD, MD

CEO EnHealth | Health Science Center and College of Engineering

Robert A Welch Professor and Executive Dean EnMed | Colleges of Medicine, Engineering and Houston Methodist Hospital

Texas A&M University ALKEK Building|Suite 1103

2121 W Holcombe Blvd | Houston, TX 77030

www.enmed.tamu.edu

Ph: (b) (6) | (b) (6)

MAKING WHAT IF POSSIBLE | whatif.tamu.edu

From: Hofmann, Lawrence, M.D. <[REDACTED] (b) (6)>

Sent: Tuesday, April 28, 2020 11:19 AM

To: Pettigrew, Roderic I [REDACTED] (b) (6)

Cc: Pelc, Norbert J [REDACTED] (b) (6)

Subject: [EXTERNAL]National Daily Health Survey for COVID - "Open Up America Again"

(b) (4), (b) (5)

Best,

R

Lawrence "Rusty" Hofmann, MD

Professor and Chief, Interventional Radiology

Medical Director, Digital Health Integration

Medical Director, Cardiac and Interventional Services

@rustyhofmannMD

(m) [REDACTED] (b) (6)

Assistant: [REDACTED] (b) (6)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:05:19 +0000
To: Barillas, Carolina (NIH/NIAID) [E]
Cc: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (5)

Carolina:

Thanks for sending this [REDACTED] (b) (5)

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barillas, Carolina (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Thursday, April 30, 2020 11:25 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Auchincloss, Hugh (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: [REDACTED] (b) (5)

Dear Tony,

[REDACTED] (b) (5)

All the best,
Carolina

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 21:47:05 +0000
To: (b) (6)
Subject: FW: Autopsy data supporting Remdesivir trial
Attachments: (b) (4)

Take a look at the Figures in the manuscript. (b) (7)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Timothy Schacker (b) (6)
Sent: Thursday, April 30, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Autopsy data supporting Remdesivir trial

Tony,

(b) (4)

Stay well (please) and thank you for all you are doing!

Tim
Timothy Schacker, M.D.
Vice Dean for Research, Medical School
Director, Program in HIV Medicine
University of Minnesota

Mail:
MMC 250
420 Delaware Street SE
Minneapolis, MN 55455

FedEx/UPS:
Mayo C688
420 Delaware Street SE
Minneapolis, MN 55455

Phone: (b) (6)
Fax: 612-626-5599
email: (b) (6)





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 14:17:43 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: May the Official Nobel documentary program at Swedish Television get an interview with you Dr Fauci about Covid-19 before May 7th please?

Please get clearance and set it up if possible.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johan Bergendorff <johan.bergendorff@svt.se>
Sent: Thursday, April 30, 2020 9:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: May the Official Nobel documentary program at Swedish Television get an interview with you Dr Fauci about Covid-19 before May 7th please?

Dear Dr. Fauci,

I had the honor to interview you in april 2016 about the zika epidemic at your office for a program for national Swedish radio as their global health correspondent. I hope I may have the honor again now Sir?

I am now working as science correspondent for the national Swedish Television (non commercial public service, half the population as daily viewers) in our official Nobel prize laureate documentary program "Vetenskapens Värld" (the World of Science) and wonder if you have any chance to give us a 10 minute interview by web video before May 7th please?

I would like to ask you two questions: What is most crucial now to succeed with an covid-19 pandemic exit in the US? How do you find the Swedish strategy against Covid-19 so far (Dr. Mike Ryan praised it yesterday at the WHO press conference as a model for an exit strategy, what is your view)?

In this one hour program aired on May 11th we will have other prominent scientists as well talking about exit strategies, among others Nobel prize winner prof. Paul Krugman, prof. Bengt Holmström MIT, prof. Angus Deaton Princeton, as well as Prof Gabriel Leung Dean University Hongkong etc.

Here you can see the reports I did from my earlier interview with you about the zika epidemic in 2016 (in Swedish). News report: <https://sverigesradio.se/artikel/6420891> 20 min
documentary: <https://sverigesradio.se/avsnitt/712016>

One option is that I send you a link for a web video Conference call. Another option is that I call you on the phone and your media department may have the opportunity to record a video of your answers with HD quality that is better to air.

Please let me know if you are available and when.

Best regards,

Johan Bergendorff
Science correspondent, Swedish Television

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 13:31:50 +0000
To: Julie.Steenhuysen@thomsonreuters.com
Cc: Greg Folkers (b) (6)
Subject: FW: Fauci says leak concerns fueled his White House revelation of Gilead drug results

Julie:

You did a good job in reporting our conversation last night. Thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, April 30, 2020 8:59 AM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Fauci says leak concerns fueled his White House revelation of Gilead drug results

[Health News](#)

April 30, 2020 / 1:07 AM / Updated 4 hours ago

Fauci says leak concerns fueled his White House revelation of Gilead drug results

[Julie Steenhuysen](#)

5 Min Read

CHICAGO (Reuters) - Concerns over leaks compelled the top U.S. infectious disease official to reveal data on Gilead Sciences Inc's experimental drug remdesivir, the first in a scientifically rigorous clinical trial to show benefit in treating COVID-19.



National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci attends a coronavirus response meeting between U.S. President Donald Trump and Louisiana Governor John Bel Edwards in the Oval Office at the White House in Washington, U.S., April 29, 2020. REUTERS/Carlos Barria
The dramatic announcement by Dr Anthony Fauci in the Oval Office on Wednesday prompted concerns among scientists that the Trump administration was raising hopes about a coronavirus treatment before sharing the full data with researchers.

As a cautionary example of inflating the potential value of a therapy, some pointed to President Donald Trump's repeated endorsements of malaria drug hydroxychloroquine as a treatment, with no evidence that it works.

Newer data suggests the malaria treatments may carry significant risks for some sufferers of the respiratory disease caused by the virus.

Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is running the trial, said he took the first opportunity to get the word out that patients taking a dummy treatment or placebo should be switched to remdesivir in hopes of benefiting from it.

He expressed concern that leaks of partial information would lead to confusion. Since the White House was not planning a daily virus briefing, Fauci said he was invited to release the news at a news conference with Louisiana Gov. John Bel Edwards(D). "It was purely driven by ethical concerns," Fauci told Reuters in a telephone interview.

"I would love to wait to present it at a scientific meeting, but it's just not in the cards when you have a situation where the ethical concern about getting the drug to people on placebo dominates the conversation."

An independent data safety and monitoring board, which had looked at the preliminary results of the NIAID trial, determined it had met its primary goal of reducing hospital stays.

On Tuesday evening, that information was conveyed in a conference call to scientists studying the drug globally.

"There are literally dozens and dozens of investigators around the world," Fauci said. "People were starting to leak it." But he did not give details of where the unreported data was being shared.

Several scientists interviewed by Reuters felt the White House setting seemed inappropriate for the release of highly anticipated government-funded trial data on the Gilead therapy.

They had expected it to be presented simultaneously in a detailed news release, a briefing at a medical meeting or in a scientific journal, allowing researchers to review the data.

Information from various trials of remdesivir has been leaked to media in recent weeks. In a statement on Wednesday, Gilead said the NIAID's much anticipated trial had met its primary goal, but gave no details.

Data in a separate NIAID statement after Fauci spoke detailed preliminary results showing that patients who got the drug had a 31 percent faster time to recovery than those who got a placebo, cutting hospital stays by four days.

The trial also came close to showing the drug helped people survive the disease, but the data fell just short of statistical significance.

"I want to see the full data. I want to understand the statistics. I want to understand the benefit and risk. I want to understand the structure of the study, and all of it," said Dr. Steven Nissen, the chief academic officer at the Cleveland Clinic.

"Am I encouraged from what I've heard? Yes, I'm encouraged. But I want to get a full understanding of what happened here, and not get it via a photo opportunity from the Oval Office."

Data Gilead released on its own trial of remdesivir drew less attention, as it did not compare outcomes between those receiving therapy and those who did not.

Results from a third study in China suggesting remdesivir failed to help COVID-19 patients were released in the British medical journal the Lancet after review by a peer group of scientists.

"That's the only thing I'll hang my hat on, and that was negative," said Dr. Eric Topol, director and founder of the Scripps Research Translational Institute in La Jolla, California.

He was unimpressed by remdesivir's modest benefit.

"It was expected to be a whopping effect," Topol added. "It clearly does not have that."

At the Oval Office news conference, Fauci compared the study findings to AZT, the first drug to show any benefit against HIV, decades ago.

"We know that was an imperfect drug. It was the first step," Fauci said in the interview.

"Similar to AZT, it's (remdesivir) the first baby step towards what hopefully will be a number of better drugs that will come in and be able to treat people with COVID-19."

(This story has been refiled to correct spelling of "clinical" in paragraph one)

Reporting by Julie Steenhuisen; Editing by Michele Gershberg and Clarence Fernandez

Our Standards: [The Thomson Reuters Trust Principles.](#)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 10:20:32 +0000
To: STEWART SIMONSON (b) (6)
Cc: Masur, Henry (NIH/CC/CCMD) [E]; STEWART SIMONSON
Subject: RE: COVID-19 and Haiti

Bill:

(b) (6) Work with him. As per our prior conversation and as you know better than anyone, Haiti is struggling and I know that Stewart will do whatever he can to assist you.

Warm regards,

Tony

From: STEWART SIMONSON (b) (6)
Sent: Thursday, April 30, 2020 5:44 AM
To: (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E]; (b) (6); Masur, Henry (NIH/CC/CCMD) [E]; (b) (6); STEWART SIMONSON (b) (6)
Subject: COVID-19 and Haiti

Dear Dr. Pape:

I lead the World Health Organization (WHO) delegation to the United Nations and know of you through Tony Fauci and Henry Masur, (b) (6). For nearly 5 years immediately preceding my appointment at WHO, I was a technical advisor at Hôpital Sacré-Cœur in Milot and remain in close contact with institution. Because of this, PAHO leadership asked me to join their COVID-19 planning discussions related to Haiti. I understand from Henry that you have been appointed by MSPP to coordinate COVID-19 preparedness and response activities. If you have some time available on Friday, it would be good to talk via Zoom or Webex. I can arrange this and would plan to have the PAHO deputy director as well as other PAHO officials on the line. Would you be available Friday afternoon for such a discussion? If not Friday, anytime over the weekend would also likely work on our end.

Thanks so much for considering this.

With best regards,

Stewart Simonson

STEWART SIMONSON
Washington, DC/New York
(b) (6) or
(b) (6)
(b) (6) (S)
(S)
(Switzerland)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 01:24:46 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Has anyone tried palivizumab (Synagis)

Please respond.

From: Rich May (b) (6)
Sent: Wednesday, April 29, 2020 10:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Has anyone tried palivizumab (Synagis)

Good morning Dr. Fauci,

Has anyone tried palivizumab (Synagis) on any new COVID-19 patients?

Thank you for your time,
Richard May, MD, PhD, D.H.Sc (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 22:42:24 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: NAD repletion for Covid-19

Please take a look and respond if appropriate

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mel Cohen (b) (6)
Sent: Wednesday, April 29, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: NAD repletion for Covid-19
Importance: High

Dear Dr. Fauci,

Recent research has shown that SARS-CoV-2 plays havoc with NAD function within cells.

Coronavirus Infection and PARP Expression Dysregulate the NAD Metabolome: A Potentially Actionable Component of Innate Immunity:

<https://www.biorxiv.org/content/10.1101/2020.04.17.047480v3>

The Molecular Story of COVID-19; NAD+ Depletion Addresses All Questions in this Infection:

<https://www.preprints.org/manuscript/202003.0346/v1>

Other research has shown that NAD+ levels decline from aging and obesity, both significant factors in Covid-19 severity. But it has also been demonstrated that NAD levels can be replenished through oral administration of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NR in particular has had several human studies demonstrating its safety and efficacy, and roughly 50 human studies listed on clinicaltrials.gov for all manner of disorders.

There is at least one anecdotal report of dramatic improvement in a Covid-19 patient after

administration of NMN.

NMN shows great promise in case studies of humans with COVID-19:

https://alivebynature.com/nmn-shows-promise-for-treatment-of-covid-19-in-case-studies/?utm_campaign=NMN%20for%20covid%20%28TqFTyz%29&utm_medium=email&utm_source=Main%20List&_ke=eyJrbF9lbWFpbCI6ICJtZWxhZGlzdHJpYnV0ZWwuY2EiLCJka2xY29tcGFueV9pZCI6ICJibWROWFoifQ%3D%3D

That article begins with the disclaimer, "*There are no human trials that prove effectiveness of any NAD+ boosting supplements for preventing or curing COVID-19.*"

That is a problem. When I see the resources that have been wasted pursuing hydroxychloroquine, I am saddened to learn that there are no clinical trials of nicotinamide riboside as part of a treatment regimen for Covid-19. Can you do anything about getting such a study done?

Regards,
Mel Cohen

Disclaimer: [REDACTED] (b) (5)

[REDACTED]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 22:01:22 +0000
To: Folkers, Greg (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD

Now FINAL in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, April 29, 2020 5:03 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD

- This is a zoom call.
- I think you will be able to use slides.
- I have put in OD a draft "curtain-raiser" set that you could show to kick things off – or use them as TPs if you prefer.
- I will update any epi or other numbers tomorrow night
- The "ask" is below

From: Silverberg, Kristen <KSilverberg@brt.org>
Sent: Tuesday, April 14, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: invitation from BRT

Dr. Fauci,

First, thank you for everything you are doing. I have always been grateful for your public service, but feel particularly indebted to you these days.

To add to the debt...Josh and I wanted to see if you would be willing to join a call with Business Roundtable CEOs. We have been doing COVID-19 calls with them every Friday at 1:30pm. Typically, about 100-125 CEOs of large, U.S.-based firms will join. They are all managing and planning for difficult issues around employee and customer safety. They would love to hear from you directly and to ask a few questions. It might also be a good place to deliver any messages you want them to hear.

We completely understand if it isn't doable, of course. If you are able, we would love to host you sometime between 1:30pm-2:30pm this Friday (or any Friday on which your schedule would allow it).

Best,

Kristen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 15:09:44 +0000
To: Anthony Fauci
Subject: FW: Potential slides for Remdesivir presentation
Attachments: Remdesivir bullet slides - FAUCI - FINAL.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, April 29, 2020 11:02 AM
To: Short, Marc T. EOP/OVP (b) (6); 'Miller, Katie R. EOP/OVP'
(b) (6) >
Subject: Potential slides for Remdesivir presentation

Marc/Katie:

Here are 3 slides that I might use in the press briefing. If necessary, I could make the presentation without them, but it might be clearer to have them just in case.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 14:18:44 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: RE: two things

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, April 29, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: two things

Talked to FDA. They have written (and cleared with Gilead) a new sentence in place of what we had in there about an EUA. Our release has been updated (attached) with the sentence highlighted below.

ALSO: Bill Hall called me to ask if you had alerted the Secretary to this (so the press release clearance process isn't the way he first learns of it). I told him I wasn't sure. If you haven't done so, perhaps you wish to now?

As part of the U.S. Food and Drug Administration's commitment to expediting the development and availability of potential COVID-19 treatments, the agency has been engaged in sustained and ongoing discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible, as appropriate.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 10:45:24 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Erbeling, Emily (NIH/NIAID) [E]
Subject: RE: please read, Gilead statement

Looks fine. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>
Sent: Wednesday, April 29, 2020 6:43 AM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Cc: Folkers, Greg (NIH/NIAID) [E] <gfolkers@niaid.nih.gov>; Conrad, Patricia (NIH/NIAID) [E] <conradpa@niaid.nih.gov>; Marston, Hilary (NIH/NIAID) [E] <hilary.marston@nih.gov>; Routh, Jennifer (NIH/NIAID) [E] <jennifer.routh@nih.gov>; Stover, Kathy (NIH/NIAID) [E] <kathy.stover@nih.gov>; Lane, Cliff (NIH/NIAID) [E] <clane@niaid.nih.gov>; Erbeling, Emily (NIH/NIAID) [E] <emily.erbeling@nih.gov>
Subject: ASF: please read, Gilead statement

FYI – this will go out before markets open this morning:

GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGING FROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES' STUDY OF REMDESIVIR

Foster City, Calif., April 29, 2020 – Gilead Sciences, Inc. (Nasdaq: GILD) is aware of the positive data emerging from the National Institute of Allergy and Infectious Diseases' (NIAID) study of remdesivir. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.

In addition to the NIAID trial, Gilead expects to share additional remdesivir data from the company's open-label Phase 3 SIMPLE trial in patients with severe COVID-19 disease shortly. This study will provide information on whether a shorter, 5-day duration of therapy may have similar efficacy and safety as the 10-day treatment course evaluated in the NIAID trial and other ongoing trials. Gilead expects data at the end of May from the second SIMPLE study evaluating the 5- and 10-day dosing durations of remdesivir in patients with moderate COVID-19 disease.

Gilead will continue to discuss with regulatory authorities the growing data set regarding remdesivir as a potential treatment for COVID-19.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 03:09:03 +0000
To: Berkowitz, Avrahm J. EOP/WHO
Subject: RE: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top Coronavirus Task Force Expert

Thanks, Avi.

-----Original Message-----

From: Berkowitz, Avrahm J. EOP/WHO (b) (6)
Sent: Tuesday, April 28, 2020 10:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises Top Coronavirus Task Force Expert

Just wanted to share an article- all the best!
Avi

<https://www.newsweek.com/jared-kushner-defends-dr-fauci-fox-news-host-little-tough-1500339>

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 03:08:36 +0000
To: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: SHORTENED NIAID statement NEW NEW - with Fauci edits.docx

See my minor edits. [REDACTED] (b) (5)

From: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Tuesday, April 28, 2020 10:40 PM
To: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

OK – here's a re-do. [REDACTED] (b) (5)
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 28, 2020 10:02 PM
To: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

(not sure what happened with spacing). Cliff – I got your suggestion too. I'll blend yours, mine, and Gregs and send a clean new one shortly.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Tuesday, April 28, 2020 10:01 PM
To: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)

Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

I took a crack at a revision as well. We can blend these.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)

Sent: Tuesday, April 28, 2020 9:57 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E]

(b) (6)>; Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily

(NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston,

Hilary (NIH/NIAID) [E] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2

Here is my suggested edit to the short version.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Sent: Tuesday, April 28, 2020 9:21 PM

To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E]

(b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily

(NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston,

Hilary (NIH/NIAID) [E] <(b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2

Importance: High

Thanks for all your work. (b) (5)

(b) (5)

(b) (5). Please change

this.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)

Sent: Tuesday, April 28, 2020 7:29 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E]

(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg

(NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>;

Lane, Cliff (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E]

(b) (6)

Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2

Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:53:28 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: Bullets
Attachments: Rendesivir bullet slides - FAUCI.pptx

I added another bullet.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 28, 2020 9:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Bullets

Graph inserted.

From: Anthony Fauci (b) (6) >
Date: Tuesday, April 28, 2020 at 9:47 PM
To: "Lane, Cliff (NIH/NIAID) [E]" (b) (6) >
Subject: RE: Bullets

I made some minor changes

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, April 28, 2020 9:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Bullets

For comment

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:50:16 +0000
To: Lane, Cliff (NIH/NIAID) [E]
Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KS EE HM HCL1 - with minor edits.docx

(b) (5) I made some minor edits.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: DRAFT NIAID statement on remdesivir, ACTT 2

Attached for consideration.

From: Anthony Fauci (b) (6)>
Date: Tuesday, April 28, 2020 at 9:21 PM
To: "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>, "Folkers, Greg (NIH/NIAID) [E]" (b) (6), "Erbelding, Emily (NIH/NIAID) [E]" (b) (6), "Lane, Cliff (NIH/NIAID) [E]" (b) (6)>, Hilary Marston (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2

Thanks for all your work. (b) (5)

(b) (5)
(b) (5). Please change this.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:21:27 +0000
To: Routh, Jennifer (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Greg Folkers (GFOLKERS@niaid.nih.gov);Erbelding, Emily (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2
Attachments: ACTT 2 NIAID statement CB KS EE HM.docx, SHORTENED NIAID statement.docx

Thanks for all your work. However, [REDACTED] (b) (5)
[REDACTED] (b) (5)
[REDACTED] (b) (5). Please change
this.

From: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Tuesday, April 28, 2020 7:29 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [REDACTED] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2
Importance: High

There are two versions for your consideration here, as discussed.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 00:56:02 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus info about a program that can help.
Attachments: BCA_id_V1 (wecompress.com).pdf

Please take a look and respond if appropriate

-----Original Message-----

From: Alex Holbus [REDACTED] (b) (6)
Sent: Tuesday, April 28, 2020 6:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Coronavirus info about a program that can help.

Dear Dr Fauci

It's a pleasure to send you this email my name is Alex Holbus I am from the UK I currently live in Serbia or ex Yugoslavia.
I am a Economist and Humanitarian. I can talk about my Biography but at this time the subject I want to share with you I much more important.

In January 2016 I sent a letter to Mr Trump [REDACTED] (b) (6) telling him that I was happy that he will bring change to America and the world and that if he needed my expertise that I would help your country and the world. As I have not got any responses from him nor his people I can see that he might not be interested. But as I have been following you over the media and be reading about your carrier as a Doctor I believe you know what your doing and would like to take this opportunity to help you and your country at this time when it's the worst then ever before in the modern world. I have a program that can help with the coronavirus in the way of identifying people and following there movement that can help you collect data faster and more sufficient. The program is based on an app so every one can use it. Countries in Europe are starting to use it by the end of May the Europe Union has made it mandatory that all member states need to use it and the future members like Serbia. So you will see attached a presentation about the program and if you or your country is interested please let me know and I will put you in contact with the company making this program. I did not send this email to you so we make money on people it's to help I just wanted to help. I will be contacting my contacts in the USA from Thursday morning but first I wanted to talk with you and give you the opportunity to see if Mr Trump would interested in this program for your country. If nothing comes back from you anyway my friend and contact in the USA will talk with the white house but I wanted to do it the proper way by talking to you as you are the main medical person in the USA for the coronavirus.

Anyway wish you and your country all the best and that the world will become a better place after this epidemic is over.

It's one life one world one human we are all one on this planet no one is bigger or better the all of us as humanity as one.

Kind regards

Alex Holbus

Director at Real Five Company.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 17:41:52 +0000
To: [REDACTED] (b) (6)
Subject: RE: worrisome

Yes. Please call to their attention. [REDACTED] (b) (6) It is merely a nasal swab

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6)
Sent: Tuesday, April 28, 2020 10:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: worrisome

From today's Medscape.

https://www.medscape.com/viewarticle/929407?nlid=135287_5653&src=wnl_newsairt_daily_200427_MSCPEDIT&uac=71367AK&impID=2361940&faf=1

Older adults with COVID-19, the illness caused by the coronavirus, have several "atypical" symptoms, complicating efforts to ensure they get timely and appropriate treatment, according to physicians. COVID-19 is typically signaled by three symptoms: a fever, an insistent cough and shortness of breath. But older adults — the age group most at risk of severe complications or death from this condition — may have none of these characteristics.

Instead, seniors may seem "off" — not acting like themselves — early on after being infected by the coronavirus. They may sleep more than usual or stop eating. They may seem unusually apathetic or confused, losing orientation to their surroundings. They may become dizzy and fall. Sometimes, seniors stop speaking or simply collapse.

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 17:39:34 +0000
To: Janet Tobias; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Riding along tomorrow am

OK

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Janet Tobias <janet@ikanamedia.com>
Sent: Tuesday, April 28, 2020 12:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: Riding along tomorrow am

Hi Tony and Patty:

Would it be ok to do the 6:45 am ride to NIH tomorrow? We would also get there early to do one more paper throw. And last night was great!

Janet

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, April 26, 2020 at 4:30 PM
To: Janet Tobias <janet@ikanamedia.com>
Subject: RE: Quick question

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would

encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 15:50:24 +0000
To: NIAID OD AM
Subject: FW: Invitation from the Investment Community
Attachments: Letter of invitation_Dr. Anthony Fauci from UBS Investment Bank (1).pdf

I don't think so.

From: Elizabeth Haenle [REDACTED] (b) (6) >
Sent: Tuesday, April 28, 2020 11:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Invitation from the Investment Community

Dear Dr. Fauci,

I am the co-founder of SAGE Worldwide, a global speaker and consulting company. I am reaching out on behalf of one of my partners, Robert Karofsky, Co-President of UBS Investment Bank, with an invitation to join the UBS Global response to Covid-19 in a live streaming moderated discussion on May 18. Alternatively your conversation could be pre-recorded to accommodate your busy schedule. At this critically important time in our nation's history, the investment community wants to help our nation fight Covid-19 and use our country's economic engine to find a cure and solutions for Covid-19. They also are thinking through how to help our nation's businesses going forward. Your expertise is important to this conversation.

By way of background, I served in the White House for eight years in the Bush Administration as the Social Secretary to Vice President Cheney. In that capacity, I had the privilege of curating a range of discussions with global thinkers and thought leaders on the world's most pressing topics. At SAGE, we bring that level of excellence to our business partners as we help curate discussions that have an impact on public awareness and investor sentiment, which is particularly important as the U.S. responds to Covid-19.

Additionally, [REDACTED] (b) (6)

Participants at the UBS Global Healthcare Conference provide critical funding to pharmaceuticals and healthcare research and are the businesses on the frontline of the Covid-19 healthcare response.

Attached please find an invitation from UBS with further details of the event. I welcome the opportunity to hear from you at your earliest convenience, and thank you for your important work and dedication to our country's well being over the course of your distinguished career and service at NIAID.

Warmest regards,
Elizabeth Haenle
Co-Founder, SAGE Worldwide
Phone: [REDACTED] (b) (6)
Attachment 1

Elizabeth Haenle 戴丽翠

Co-founder and President

M: [REDACTED] (b) (6)

E: [REDACTED] (b) (6)

W: SAGEworldwide.com



This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager. This message contains confidential information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this e-mail by mistake and delete this e-mail from your system. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 14:46:56 +0000
To: NIAID OD AM
Subject: FW: HIGH SCHOOL MUN CONFERENCE

For discussion

From: Dane Cohn [REDACTED] (b) (6) >
Sent: Tuesday, April 28, 2020 10:44 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] [REDACTED] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6) >; Fauci, Anthony (NIH/NIAID) [F] [REDACTED] (b) (6) >
Subject: HIGH SCHOOL MUN CONFERENCE

Dear Dr. Anthony Fauci,

My name is Dane Cohn, and I am an [REDACTED] (b) (6). I have often listened to your inspiring words on the news and followed your assiduous work to help us through this pandemic. Our school participates in Model UN, an event in which high school students represent various countries in debates on international issues from the past and present. Colorado's final Model UN conference was canceled, so our school [REDACTED] (b) (6) decided to host an online conference for the whole state of Colorado and beyond. Our team would like to formally invite you to give a short address (be it pre-recorded or live online) to the students during our opening ceremony.

We hope that our conference will inspire the youth of our nation and the world to stand up and fight for our future rather than resign their aspirations to lockdown. We host this conference because we see the importance of keeping our academic passions going while staying safe within the confines of our homes. We host this conference because we want to contribute to the fight against COVID-19 — money raised from our conference will go towards buying masks, food, and other resources for those who need it most.

This is why we ask you, a hero during this troubling time, to speak to the students of our conference, who not only include the youth of Colorado, but also the youth of our country and world. Any type of address would be greatly and wholeheartedly appreciated. If your address is pre-recorded, we would appreciate it if we could receive it by May 1st, as our conference is the morning of May 2nd. We believe you can bring true inspiration into our hearts and minds. We know you are very busy, but if it were at all possible to share with us even a short 2-3 minute pre-recorded greeting and message to the students participating in this Model UN conference, it would be truly inspirational. Thank you so much for your time, we hope to hear from you soon.

Most Respectfully,
Dane Cohn and the entire [REDACTED] (b) (6) Model UN Team

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 11:25:09 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

8:30 AM would be good. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 28, 2020 7:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Let me know when you'd like me to call please.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, April 28, 2020 7:04 AM
To: Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Re: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6

Let us chat by phone this morning

On Apr 28, 2020, at 5:51 AM, Haskins, Melinda (NIH/NIAID) [E] <(b) (6)> wrote:

We do not know if the DeLauro hearing would be remote. The Senate HELP one would be in person with some form of social distancing.

Sent from my iPhone

On Apr 27, 2020, at 10:36 PM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6) > wrote:

E should make sure that we schedule it at a time of day that does not conflict with the COS visit.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 27, 2020 8:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 5

This is the day of the VIP visit—whoever it is. VP or COS. Pls advise. And not sure if these are 1 person or not. I suspect remote right??

Sent from my iPhone

Begin forwarded message:

From: "Haskins, Melinda (NIH/NIAID) [E]"
(b) (6)
Date: April 27, 2020 at 8:10:52 PM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]"
(b) (6) >
Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b) (6) >, "Harper, Jill (NIH/NIAID) [E]" (b) (6)
Subject: Please advise LHHS Hearing w/ Dr. Fauci --
Wednesday, May 5

Patty,

See below. Another hearing.

Thank you,
Melinda

Sent from my iPhone

Begin forwarded message:

From: "Hallett, Adrienne (NIH/OD) [E]"
(b) (6)
Date: April 27, 2020 at 7:57:36 PM EDT
To: "Haskins, Melinda (NIH/NIAID) [E]"

(b) (6)>, "Selgrade, Sara
(NIH/NIAID) [E]" <(b) (6)>,
"LaMontagne, Karen (NIH/OD) [E]"
(b) (6)>, "Higgins, Lauren
(NIH/OD) [E]" (b) (6)>
**Subject: Fwd: LHHS Hearing w/ Dr. Fauci --
Wednesday, May 6**

Guess they really are coming back.

Begin forwarded message:

From: "Steigleder, Stephen"
(b) (6)
>
Date: April 27, 2020 at 7:41:56 PM
EDT
To: "Hallett, Adrienne (NIH/OD) [E]"
(b) (6)>
**Subject: LHHS Hearing w/ Dr. Fauci -
- Wednesday, May 6**

Hi Adrienne,

I hope you're doing well.

I'm reaching out because Chair DeLauro would like to invite Dr. Fauci to a hearing next Wednesday, May 6, with the House LHHS appropriations subcommittee. The focus of the hearing, not surprisingly, would be COVID-19. Members of the subcommittee would very much like to hear from Dr. Fauci on anything related to COVID-19, but I think the main topics would be:

- Mitigation and Testing; and
- Progress on vaccines, therapeutics, and diagnostics, as well as necessary preparations to manufacture and disseminate a vaccine once it is ready.

Chair DeLauro is flexible about a starting time for the hearing on Wednesday, so she would be happy to accommodate a time that works for Dr. Fauci's schedule.

Please let me know as soon as possible, so we can plan accordingly.

Thanks so much,

Stephen

.....
Stephen Steigleder
House Appropriations Committee
Labor/HHS/Education Subcommittee

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Apr 2020 00:22:50 +0000
To: (b) (6)
Subject: FW: Remdesivir--good news
Attachments: 20-0006_DSMB_primary_analysis_report_for_DMID.pdf

From: Erbeiding, Emily (NIH/NIAID) [E] (b) (6) >
Sent: Monday, April 27, 2020 8:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Remdesivir--good news

Tony,

(b) (5)

Emily

Emily Erbeiding, M.D., M.P.H.
Director, Division of Microbiology and Infectious Diseases
NIAID/NIH
5601 Fishers Lane
Rockville, MD 20852
Tel: (b) (6)

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:56:59 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW:
Attachments: Brown et al submitted.pdf, NIH Presentation final.pptx, preprints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdf

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6)>
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." (b) (6) >

Date: Monday, April 27, 2020 at 2:53 PM

To: "Matthias Gromeier, M.D." (b) (6)

Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:17:19 +0000
To: Folkers, Greg (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: COVID/Transportation Impacts

Ok. Let us discuss forwarding to CDC>

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 6:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: RE: COVID/Transportation Impacts

this seems like CDC issue

They address some of the issues here:

What Rideshare, Taxi, Limo, and other Passenger Drivers-for-Hire Need to Know about COVID-19
<https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/rideshare-drivers-for-hire.html>

Communication Toolkit for Transportation Partners to Inform Road Travelers Monday, April 27, 2020
<https://www.cdc.gov/coronavirus/2019-ncov/travelers/transportation-toolkit.html>

Cleaning and Disinfection for Non-emergency Transport Vehicles Tuesday, April 14, 2020
<https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/disinfecting-transport-vehicles.html>

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) > On Behalf Of Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:05 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: COVID/Transportation Impacts

-----Original Message-----

From: Anthony Foxx [REDACTED] (b) (6)>
Sent: Monday, April 27, 2020 4:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: COVID/Transportation Impacts

Dr. Fauci,

This is Anthony Foxx, immediate former US Transportation Secretary, and I greatly enjoyed our interactions (brief thoughts they were) during my time in the last Administration.

I write to request your help in advising the transportation community about how to manage through the present crisis, particularly as some areas are easing restrictions. I would welcome an opportunity to join you in a Q/A, which could be valuable for rideshare companies [REDACTED] (b) (6), transit agencies, airlines etc. I would think that a 10-15 minute chat would do wonders. That said, I know you are terribly busy and have so many things to do but would appreciate any opportunity to help you get important information out.

This could be pulled together rapidly and done within the next week or so.

Thanks for your attention to this matter. All my best,

Anthony,
Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 22:00:13 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Update - White House Coronavirus Task Force Meeting - 4.28.20

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(3) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:57:57 +0000
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: RE: Covid thrombi

Thanks, Paolo.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lusso, Paolo (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 12:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Kovacs, Joseph (NIH/CC/CCMD) [E] (b) (6); Masur, Henry (NIH/CC/CCMD) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Subject: Re: Covid thrombi

Dear Tony,

I talked with Dr. Viecca this morning who shared additional information about his protocol. They started from the pathological observation that all patients dying of Covid-19 pneumonia had diffuse pulmonary microthrombosis. Since they detected almost exclusively white thrombi, they reasoned that they had to block platelet activation/aggregation, while heparin would be ineffective at that stage. Thus, they treated a first group of five critical patients with potent anti-aggregant therapy (Tirofiban/Aggrastat) and apparently in all of them the pO2 started to rise within less than 2 hours, they got off the ventilators and went on to full recovery. Viecca is an interventional cardiologist (b) (4)

(b) (6) I sent copy of his protocol and contact information to Joe.

Let me know if I can be of any further help. All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: [REDACTED] (b) (6) (personal)

[REDACTED] (b) (6) (lab)

Fax: (301) 480-5291

E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:57:23 +0000
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Mascola, John (NIH/VRC) [E]
Subject: FW: Revised Slides
Attachments: Vaccine Development Slides Revised Draft 042720.pptx

Pleas respond for both of us. I already cc'd you on an email that I sent to John with a minor comment about slide #2.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marks, Peter (b) (6)
Sent: Monday, April 27, 2020 1:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Mascola, John (NIH/VRC) [E] (b) (6)>
Subject: Revised Slides

Dear Francis and Tony,

Apologize that the prior slides were too busy. John conveyed that message. Please see these versions that may be more along the lines that you are looking for. (b) (5)

Best Regards,
Peter

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:54:37 +0000
To: Schwetz, Tara (NIH/OD) [E]
Subject: RE: Flagging NIH Media Product for Release Tomorrow

You could play the role in the movie of my medical school girl friend, which would give you the possibility of working with Brad Pitt 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] (b) (6)
Sent: Monday, April 27, 2020 5:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Flagging NIH Media Product for Release Tomorrow

Now, you also have the answer to who would play you in a movie! 😊

Tara A. Schwetz, PhD
Acting Director, NINR
Associate Deputy Director, NIH
A: Building 1, Room 138
P: (b) (6) | M: (b) (6)

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Monday, April 27, 2020 at 5:46 PM
To: Tara Schwetz (b) (6)
Subject: RE: Flagging NIH Media Product for Release Tomorrow

Thanks, Tara. Pitt was amazing. One reviewer of the SNL show said that Pitt looked "exactly like me". That statement made my year. 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Schwetz, Tara (NIH/OD) [E] (b) (6) >
Sent: Monday, April 27, 2020 5:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C] (b) (6) Myles, Renate (NIH/OD) [E] (b) (6); Walsh, Elizabeth (NIH/OD) [E] (b) (6)
Subject: Flagging NIH Media Product for Release Tomorrow

Tony,

Please see below and attached a time-sensitive COVID-19 item for your awareness and sharing with the remainder of the Task Force, as appropriate. The plan is to release this tomorrow.

Item 1: Title: Rapid Acceleration of Diagnostics (RADx) Initiative

Activity Type: Funding of new research program

Summary: With a (b) (5) investment from federal stimulus funding, RADx initiative will infuse funding into early innovation technologies to speed development of rapid and widely accessible COVID-19 testing. At the same time, NIH will seek opportunities to move more advanced diagnostic technologies swiftly through the development pipeline toward commercialization and broad availability. As part of the initiative, NIH is urging scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to \$500 million over all phases for further development. The goal is to add tens of millions per month of accurate and easy-to-use tests to all Americans by Fall 2020.

Impact on COVID-19 Pandemic Response: RADx will accelerate the development, validation, and commercialization of innovative new testing methods that can be deployed in point-of-care and home settings. These technologies are urgently needed to guide and inform safe return to work, school, and life activities.

Office: National Institute of Biomedical Imaging and Bioengineering

Action Date: Solicitation announcement April 28, 2020

Type of Action: Research Program Award

Potential for Press Coverage: Mainstream Press

Press Release in Development?: Yes

Do let me know if you have any questions.

(Also, Brad Pitt?! Wow, that was a really nice shout out/thank you.)

Best,

Tara A. Schwetz, PhD

Acting Director, NINR

Associate Deputy Director, NIH

A: Building 1, Room 138

P: (b) (6) | M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:48:46 +0000
To: Birx, Deborah L. EOP/NSC
Cc: Redd, Stephen (CDC/DDPHSIS/OD); Hahn, Stephen
Subject: Flagging NIH Media Product for Release Tomorrow
Attachments: 2020-04-27_COVID-19WeeklyReport_NIBIB OD_tas.docx

Deb:

As an FYI. This is an initiative from NBIB/NIH on development of POC diagnostics for SARS-CoV-2.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:39:57 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in children

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Sent: Monday, April 27, 2020 4:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in children

Hi Dr. Fauci,

Please find attached for your review a draft release about the launch of the Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, which is intended to help determine the percentage of children infected with SARS-CoV-2 and the percentage of infected children who develop COVID. In addition, the study will examine whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not. Your draft quote is as follows:

“One interesting feature of this novel coronavirus pandemic is that very few children have become sick with COVID-19 compared to adults,” said NIAID Director Anthony S. Fauci, M.D. “Is this because children are resistant to infection with SARS-CoV-2, or because they are

infected but do not develop symptoms? The HEROS study will help us begin to answer these and other key questions.”

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 21:04:24 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]; Jean W Pape
Subject: (b) (4)
Attachments: (b) (4)

Hugh:
(b) (6), (b) (4)

(b) (6) Please take care of it.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Monday, April 27, 2020 3:01 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: (b) (4)

Tony,

(b) (4), (b) (6)

Best,

Bill

JEAN WILLIAM PAPE, MD

Howard and Carol Holtzmann Professor of Clinical Medicine,
Center for Global Health, Division of Infectious Diseases, Department of Medicine,
Weill Cornell Medical College, New York, New York, USA
402 East 67th Street, New York, NY 10065
Tel (Office) [REDACTED] (b) (6)

Director,
Les Centres GHESKIO,
33, Blvd. Harry Truman, Port-au-Prince, Haïti.
Tel (Office): [REDACTED] (b) (6)
Voip: [REDACTED] (b) (6)

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 16:09:04 +0000
To: NIAID OD AM
Subject: FW: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview Request

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor Taglianetti <taylor@noiaft.org>
Sent: Monday, April 27, 2020 12:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: The National Organization of Italian Americans in Film & Television (NOIAFT) - Interview Request

Dear Dr. Fauci,

I hope this email finds you well. My name is Taylor Taglianetti and I am the founder of the National Organization of Italian Americans in Film & Television (NOIAFT).

Our organization is so very proud of the work you are doing for our country and sends tremendous thanks for the hope and reassurance you have instilled during these trying times.

It would be an honor to conduct a short interview with you. Our organization includes many young Italian Americans breaking into the entertainment industry and with the coronavirus dramatically impacting our field, I'd love to ask you a few questions about what the future of the entertainment business looks like. We'd be happy to send the questions in advance for your approval. If you don't have time for a phone call, the questions can be answered via email at your leisure.

Thank you for your time and consideration.

Sincerely,

Taylor Taglianetti

Founder, *The National Organization of Italian Americans in Film & Television (NOIAFT)*


(347) 686-4968


www.noiaft.org

taylor@noiaft.org









From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:19:38 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Media query: CNN, re: ASF's NAS web briefing on Saturday

I was referring only to animal (macaque) models. I never said that it looked good in humans. Human clinical trials are ongoing to answer that question. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 9:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: Media query: CNN, re: ASF's NAS web briefing on Saturday

Pls advise

Sent from my iPhone

Begin forwarded message:

From: "Leifman, Laura (NIH/NIAID) [E]" (b) (6)>
Date: April 27, 2020 at 9:27:13 AM EDT
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, NIAID FOG
<fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquiries
<mediainquiries@niaid.nih.gov>
Subject: Media query: CNN, re: ASF's NAS web briefing on Saturday

Elizabeth Cohen

CNN

Elizabeth.Cohen@turner.com

Topic: Statement by ASF during Saturday NAS web briefing

Deadline: urgent

Hi Patty,

Elizabeth would like to clarify something that Dr. Fauci apparently said about remdesivir during his NAS web briefing on Saturday. The transcribed segment of the talk that she is focused on says:

"Remdesivir is the one that's gotten the most publicity. It is interesting that if you look at it in a prophylactic therapeutic model in MERS coronavirus infection, it looked pretty good. There was clinical benefits just reported a couple of weeks ago of SARS coronavirus 2 in rhesus macaques."

She wants to clarify what Dr. Fauci meant by looking at remdesivir "in a prophylactic therapeutic model in MERS"—whether this means in an animal model or something else. It sounds like that phrase is referring to the RML study in which remdesivir successfully prevented disease in MERS-infected rhesus macaques, as reported in the Feb. 13 NIAID media availability pasted below. Is that correct?

Best,

Laura

Remdesivir Prevents MERS Coronavirus Disease in Monkeys

Results Support Testing Antiviral Against 2019 Novel Coronavirus

February 13, 2020

The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to a new study from National Institutes of Health scientists. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.

The new report from NIH's National Institute of Allergy and Infectious Diseases (NIAID) appears in the *Proceedings of the National Academy of Sciences*.

MERS-CoV is closely related to the 2019 novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV) that has grown to be a global public health emergency since cases were first detected in Wuhan, China, in December.

Remdesivir has previously protected animals against a variety of viruses in lab experiments. The drug has been shown experimentally to effectively treat monkeys infected with Ebola and Nipah viruses. Remdesivir also has been investigated as a treatment for Ebola virus disease in people.

The current study was conducted at NIAID's Rocky Mountain Laboratories in Hamilton, Montana. The work involved three groups of animals: those treated with remdesivir 24

hours before infection with MERS-CoV; those treated 12 hours after infection (close to the peak time for MERS-CoV replication in these animals); and untreated control animals. The scientists observed the animals for six days. All control animals showed signs of respiratory disease. Animals treated before infection fared well; no signs of respiratory disease, significantly lower levels of virus replication in the lungs compared to control animals, and no lung damage. Animals treated after infection fared significantly better than the control animals: disease was less severe than in control animals, their lungs had lower levels of virus than the control animals, and the damage to the lungs was less severe.

The scientists indicate that the promising study results support additional clinical trials of remdesivir for MERS-CoV and COVID-19, the disease that SARS-CoV-2 causes. Several clinical trials of remdesivir for COVID-19 are under way in China, and other patients with COVID-19 have received the drug under a compassionate use protocol.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also provided support for this study. Gilead Sciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in the research.

MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World Health Organization had confirmed 2,499 MERS-CoV cases and 861 deaths (or about 1 in 3). Because about one-third of MERS-CoV cases spread from infected people being treated in healthcare settings, the scientists suggest that remdesivir could effectively prevent disease in other patients, contacts of patients, and healthcare workers. They also note the drug might help patients who are diagnosed with MERS or COVID-19 if given soon after symptoms start.

ARTICLE:

E de Wit *et al.* Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *PNAS* DOI: 10.1073/pnas.1922083117.

WHO:

NIAID Director Anthony S. Fauci, M.D., and Emmie de Wit, Ph.D., a principal investigator in NIAID's Laboratory of Virology, are available to comment on this study.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:11:59 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Coronavirus Antigen Microarray

Please take a look and handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Anderson, Cassandra (NIH/NIDDK) [E] (b) (6)>
Sent: Monday, April 27, 2020 8:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: Coronavirus Antigen Microarray

Good morning Dr. Fauci,

I work in NIDDK in bldg. 50 in the Laboratory Endocrinology and Receptor Biology.

Thank you for all the information you have provided to our nation. I also want to say you are doing a terrific job in handling the COVID-19 virus, without you and your staff I don't know where our country would be.

I received the email below this morning from Jiang Yufei from Sino Biological. Not sure why I was sent this email, but I thought of you and your staff. Please see the email below.

Thank you again for all that you are doing to help keep us safe!

Stay safe!

Cassandra Anderson
Administrative Professional
Bldg. 50 Room 4133
301-402-7845

From: Yufei Jiang <yufei.jiang@sinobiological.info>
Sent: Monday, April 27, 2020 8:04 AM
To: Anderson, Cassandra (NIH/NIDDK) [E] (b) (6) >
Subject: Coronavirus Antigen Microarray

Hi Cassandra,

Happy Day! I am excited to let you know that Sino Biological just released Coronavirus antigen Microarray (CoVAM) which belongs to our Sinomune™ Multiplex Antigen Microarray product line. You may get more details from the following link:

<https://www.sinobiological.com/research/virus/coronavirus-array>

Currently the standard pre-printed CoVAM array is sold in the unit of slide, 16 arrays/slide. In each array there are 65 antigens related to the viruses that can cause upper respiratory tract infections including the most recent SARS-CoV-2. The list price is \$3,200/slide. Please contact me for how to place the order if you are interested or need more information.

So far, this array has mainly been used for two purposes: 1) Sero-surveillance studies of COVID-19 infection, and 2) Evaluating antibody reactivity in animals (monkeys and mice) after vaccination. Please be advised that our array is for research use only (RUO), not for the diagnostic purpose which needs the FDA approval.

After you run the samples on the slide, you may read the slide on the following compatible machines:

<https://www.innopsys.com/en/lifesciences-products/microarrays/innoscan>

<https://www.moleculardevices.com/products/additional-products/genepix-microarray-systems-scanners#gref>

<https://www.agilent.com/en/product/cgh-cgh-snp-microarray-platform/cgh-cgh-snp-microarray-scanners-equipment/surescan-microarray-scanner-228493>

Thanks.

-Yufei

Yufei Jiang, PhD
Manager, NY, MD, DC, VA
Sales & Business Development
Sino Biological US Inc.
1400 Liberty Ridge Dr., Suite 101
Wayne, PA 19087
Cell: (b) (6)
Email: yufei.jiang@sinobiological.com
www.sinobiological.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:11:06 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Otto e Mezzo - Italian Show

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Torchia Patrizia <Patrizia.Torchia@la7.it>
Sent: Monday, April 27, 2020 8:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Otto e Mezzo - Italian Show

Dear Mr. Fauci,

I'm Patrizia Torchia, I'm a journalist and I am a member of the team on the Italian show *Otto e Mezzo*, hosted daily by journalist Lilli Gruber on La7 channel.

I'm reaching out to invite you in our show. Mrs. Gruber would be honored to have you, Dr. Fauci explore in more depth the challenges Coronavirus has forced the world to face. Can make this happen?

Below is Lilli Gruber's bio and a brief description of the show.

WHO:

Lilli Gruber is the editor-in-chief and host of Italy's most influential political daily talk show, "Otto e mezzo", airing on prime-time on La7 TV. She's received Italy's most prestigious journalism awards for her work and was the first woman to ever conduct the prime-time News broadcast in Italy (RAI TV, 1987). As a foreign correspondent she covered most of last 30 years' major world events, from the fall of the Berlin wall to 9/11 to the Iraq war. Beside her television work, Ms. Gruber wrote eleven bestseller books including "Eredità", which was top seller for 20 weeks and ran 14 reprints. In 2004, Ms. Gruber

won a head-to-head campaign against Silvio Berlusconi by a large margin of votes and was elected to the European Parliament. There, among other appointments, she was the Head of the EU Delegation to the Gulf States and Yemen and a member of the EU Delegation to Iran.

"Otto e mezzo"

Italy's most influential political daily talk show shown on prime-time on La7 TV. Through interviews with elected political figures and candidates for office, commentators, and journalists, the show focuses on international political news and economy with a special focus on Italy and Europe. Beginning in 2008 "Otto e Mezzo" became Lilli Gruber's way to keep her commitment to holding those in power accountable by asking questions and touching on topics citizens are curious about. **Otto e Mezzo** airs Monday to Saturday from 8:35pm to 9:10pm. Within this time-frame Paolo Pagliaro's news column "Il Punto" stands out for accuracy and thoughtfulness by pulling the thread on the highest rated issues in an agenda. During the current season Otto e Mezzo has become Italy's most watched political talk show reaching an average of 7.3% of share with 2.5 million viewers per day.

Production location(s): La7 studios, via Umberto Novaro 32, Rome, Italy

Presented by: Lilli Gruber

Original network: La7

Executive producers: Stefania Bucciarelli

Directed by: Lorenzo Fontana

www.live.la7.it

www.ottoemezzo.la7.it

Twitter: @OttoemezzoTW)

Facebook: OttoemezzoLa7)

Thank you in advance for the considering. Looking forward to hearing from you.

Patty Torchia

Otto e Mezzo

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:08:24 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Fauci and PayPal

Not really.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Monday, April 27, 2020 9:54 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Fauci and PayPal

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fetalvo, Ninio J. EOP/OVP [REDACTED] (b) (6)
Sent: Monday, April 27, 2020 9:51 AM
To: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: Fauci and PayPal

FYI—Defer to you on this.

From: Miller, Amanda <amanmiller@paypal.com>
Sent: Monday, April 27, 2020 9:18 AM
To: Fetalvo, Ninio J. EOP/OVP [REDACTED] (b) (6)
Cc: Walters, Lindsay <Lindsay.Walters@edelman.com>
Subject: [EXTERNAL] Re: Fauci and PayPal

Hi Ninio,

We are wondering if Dr. Fauci would like to have a taped Skype conversation with PayPal CEO and President Dan Schulman to talk about safety measures, health and science tied to COVID-19. We would air the conversation during a global employee all hands to our 23,000 employees and then we could syndicate parts of it externally on our social channels.

Thanks for any help in reaching Fauci's team.

Thanks,
Amanda

Amanda Christine Miller
Senior Director, Corporate Communications
408.219.0563
[@PayPalNews](#)


From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:07:40 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (4)

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Monday, April 27, 2020 10:05 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: [REDACTED] (b) (4)

I will make sure they get a response!

From: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)>
Date: Sunday, April 26, 2020 at 8:43 PM
To: "Lerner, Andrea (NIH/NIAID) [E]" [REDACTED] (b) (6)>
Subject: FW: Update: [REDACTED] (b) (4)

Please respond to this person. Thanks.

From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Sent: Wednesday, April 22, 2020 9:41 AM
To: Coomes, Stephanie (NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: [REDACTED] (b) (6); Kircheis Dr. Ralf <RKircheis@syntacoll.de>
Subject: Update: [REDACTED] (b) (4)
Importance: High

Dear Dr. Fauci,
dear Dr. Coomes,

thank you for your reply from 13. April with the notice that the information has been shared with NIAID's COVID-19 research team.

Has the project already been initially evaluated by the team?

Are there any questions or need for additional information?



Looking forward to hearing from you.

Kind regards,

Ralf

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis
Director R&D
Research & Development

Mail: RKircheis@syntacoll.de
Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Dornaustrasse 24, D-93042 Saarn, D. Dornau
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 178538705

Geschäftsführer: Dr. Alexandra Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter:
www.syntacoll.de/de/datenschutz

Von: Coomes, Stephanie (NIH/NIAID) [E] [REDACTED] (b) (6)]

Gesendet: Montag, 13. April 2020 02:37

An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Betreff: RE: [REDACTED] (b) (4), (b) (5)

Dear Dr. Kircheis,

Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleased to respond.

I want to thank you for reaching out to share this information and let you know that your message has been shared with NIAID's COVID-19 research team.

Sincerely,
Stephanie

Stephanie M. Coomes, Ph.D.
Health Scientist Administrator
Office of Scientific Coordination and Program Operations
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 7G68
Rockville, MD 20892

[REDACTED] (b) (6)

[REDACTED] (b) (6)

Disclaimer: The information in this email and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the originally intended recipient. If you have received this email in error, please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of NIAID by one of its representatives.

From: Kircheis Dr. Ralf <[REDACTED] (b) (6)>

Sent: Wednesday, April 8, 2020 2:49 AM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Billet, Courtney (NIH/NIAID) [E]

[REDACTED] (b) (6)>; NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>

Cc: Fischer, Elizabeth (NIH/NIAID) [E] [REDACTED] (b) (6)>; Foster, Erin (NIH/NIAID) [E]

[REDACTED] (b) (6) Foster, Sarah (NIH/NIAID) [E] [REDACTED] (b) (6)>; Vasilenko, Olga

(NIH/NIAID) [E] [REDACTED] (b) (6)>; Vasquez, Aurelio (NIH/NIAID) [E]

[REDACTED] (b) (6)>; Vostal, Alexander (NIH/VRC) [F] [REDACTED] (b) (6)>; Vazquez-

Maldonado, Nancy (NIH/NIAID) [E] [REDACTED] (b) (6)>; Austin, James (NIH/NIAID) [E]

[REDACTED] (b) (6)>; Agulto, Liane (NIH/NIAID) [E] [REDACTED] (b) (6)>; Deckhut, Alison

(NIH/NIAID) [E] [REDACTED] (b) (6) Kircheis Dr. Ralf <RKircheis@syntacoll.de>

Subject: WG: [REDACTED] (b) (4), (b) (5)

Importance: High

[REDACTED] (b) (4), (b) (5)

Dear Dr. Fauci,
dear Madams/Sirs,

I want to bring to your attension some potentially important experimental data and a new proposal for treatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry for the broad distribution but I wanted to make sure that my message reaches you.

[REDACTED] (b) (4), (b) (5)

Please forward this mail to the colleagues you consider relevant for evaluation, discussion and consideration for your clinical strategy for COVID-19.

Please let me know if additional informations are necessary.

To my person: I have MD PhD degree and have many years experience in pharmaceutical development (Boehringer Ingelheim), Biotech (Igeneon, Apton, Virologik GmbH) (for reference see also PubMed Kircheis r) currently leading R&D activities at Syntacoll (part of Innocoll). I am providing this information personally in order to help to find a treatment for COVID-19 patients.

Looking forward to getting feedback from you,

With kind regards,

Ralf Kircheis (MD PhD)

(b) (6)

rkircheis@syntacoll.de

(b) (6)

Mit freundlichen Grüßen / Kind regards

Dr. Ralf Kircheis
Director R&D
Research & Development

Mail: RKircheis@syntacoll.de
Phone: +49 9441 686048

syntacoll

Syntacoll GmbH, Dornstrasse 24, D-93342 Seelitz, DE, Dornitz
Tel: +49 9441 / 68 60 0, Fax: +49 9441 / 68 60 30
Handelsregister: Amtsgericht Regensburg - HRB 1612
USt-IdNr. DE 12960296

Geschäftsführerin: Dr. Anke-Kristina Dietrich

Unsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unter:
www.syntacoll.de/datenschutz



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 12:33:44 +0000
To: Jeremy Farrar
Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Thanks, Jeremy. I saw the report in the Post from Saturday. These children had mostly respiratory disease and diarrhea. I will check with the docs at DC Children's Hospital about the presence of "multisystem inflammatory state". This could just be the advanced stage of their disease compatible with advanced SARS-COV-2

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)
Sent: Monday, April 27, 2020 7:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Dzau, Victor J. <VDzau@nas.edu>; George GAO (b) (6)>
Cc: Richard Hatchett (b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Teresa Miller de Vega (b) (6); (b) (6); Rebeka Yasmin - CEPI (b) (6); ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6) McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6) Mun, Jenny <JMun@nas.edu>; (b) (6) Redfield, Robert R. (CDC/OD) (b) (6)>
Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Thanks Tony – have asked for that and will share as soon as I can.

I believe there have been reports in the Washington Post.

https://www.washingtonpost.com/local/new-dc-hospital-numbers-suggest-kids-do-face-some-risk-of-coronavirus-hospitalization/2020/04/25/5e78c268-86fe-11ea-878a-85477a724bdb_story.html

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>

Date: Monday, 27 April 2020 at 12:36

To: Jeremy Farrar <(b) (6)>, Victor Dzau <VDzau@nas.edu>, George Gao <(b) (6)>

Cc: Richard Hatchett <(b) (6)>

"Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, Teresa de Vega

<(b) (6)>, Rebeka Yasmin - CEPI

<(b) (6) "ben.tinker@cnn.com" <ben.tinker@cnn.com>,

"Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com"

<Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>,

<(b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>,

<(b) (6) "Mun, Jenny" <JMun@nas.edu>,

<(b) (6) "Redfield, Robert R. (CDC/OD)"

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2 or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: <(b) (6)>

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)>

Sent: Monday, April 27, 2020 7:13 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Dzaou, Victor J. <VDzau@nas.edu>; George GAO (b) (6)>

Cc: Richard Hatchett (b) (6)

(b) (6) Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) Teresa Miller de Vega (b) (6);

(b) (6); Rebeka Yasmin - CEPI (b) (6)> <ben.tinker@cnn.com>;

<Amanda.Sealy@cnn.com>; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6);

McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6); Mun, Jenny <JMun@nas.edu>; (b) (6)

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

<https://www.hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article>

<https://t.co/BJ6YHLJ8zi>

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>

Date: Sunday, 26 April 2020 at 19:52

To: Victor Dzaou <VDzau@nas.edu>, George Gao (b) (6)>

Cc: Jeremy Farrar (b) (6)>, Richard Hatchett (b) (6)

(b) (6) "Hannon, Emma" <EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>,

Teresa de Vega (b) (6)>, Rebeka Yasmin - CEPI (b) (6)>, "ben.tinker@cnn.com" <ben.tinker@cnn.com>,

"Amanda.Sealy@cnn.com" <Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com"

<Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>,

(b) (6) "McGinnis, J. Michael" <MMcGinnis@nas.edu>,

(b) (6)>, "Mun, Jenny" <JMun@nas.edu>,
(b) (6)>

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Saturday, April 25, 2020 3:59 PM
To: George GAO (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6);
(b) (6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b) (6);
(b) (6) ben.tinker@cnn.com;
Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6)
McGinnis, J. Michael <MMcGinnis@nas.edu>; (b) (6); Mun, Jenny
(b) (6); haja.bally@cepi.net

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,
Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.
Hope to see you soon.
Warmest regards,
Victor

On Apr 25, 2020, at 1:22 PM, George GAO [REDACTED] (b) (6) wrote:

I am waiting for being connected and will use slides which were sent to your office
George

发自我的iPhone

在 2020年4月24日, 01:49, Dzau, Victor J. <VDzau@nas.edu>
写道 :

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,
Victor

PS, [REDACTED] (b) (6) my special assistant, will be sending you additional information about the session logistics shortly.

From: Dzau, Victor J. <VDzau@nas.edu>

Sent: Thursday, April 9, 2020 11:01 AM

To: Mun, Jenny <JMun@nas.edu>; [REDACTED] (b) (6)

[REDACTED]

Cc: [REDACTED] (b) (6) Hannon, Emma

<EHannon@nas.edu>; [REDACTED] (b) (6)

[REDACTED]

(b) (6); 'ben.tinker@cnn.com' <ben.tinker@cnn.com>;
'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com>;
'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;
'Tia.Miller@turner.com' <Tia.Miller@turner.com>; 'hujr@chinacdc.cn'

(b) (6)

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his experience as a global leader, the chair of the Scientific Advisory Group for the WHO's R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019-20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2, insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best,
Victor

From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM

To: [REDACTED] (b) (6)

Cc: Dzau, Victor J. ; [REDACTED] (b) (6) ; Mun, Jenny ; Hannon, Emma ;

[REDACTED] (b) (6)
[REDACTED] 'ben.tinker@cnn.com' ; 'Amanda.Sealy@cnn.com'
'Neel.Khairzada@turner.com' ; 'Tia.Miller@turner.com'

Subject: NAS Annual Meeting Session on COVID-19 – Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (<https://www.youtube.com/user/theNASciences>) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. **Please return the signed speaker release form by Monday, April 13.**

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, Wellcome Trust

George F. Gao, Director-General, Chinese Center for Disease Control & Prevention

Sanjay Gupta, Chief Medical Correspondent, CNN

Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations

Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings – such as “sharing your screen” (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun
Membership Director
National Academy of Sciences

jmun@nas.edu

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:45:27 +0000
To: [REDACTED] (b) (6)
Subject: SNL review

OKAY, so here is something even better than having Brad Pitt portray me on SNL. It is a recent review of Pitt's performance in which the TV reviewer said :

"Kicking things off, the Oscar winner dropped jaws during the cold open with his monologue about President Donald Trump's recent (and concerning) comments about COVID-19.

"Good evening, I'm Dr. Anthony Fauci," Pitt began his monologue and looked nearly identical to the director of the National Institute of Allergy and Infectious Diseases."

Someone said Pitt looked "nearly identical" to me. Yikes!! 😊

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:37:57 +0000
To: Barnes, Freddie
Subject: RE: Appreciation

Freddie:

Many thanks for your kind note. It is much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barnes, Freddie <freddie.barnes@ncdps.gov>
Sent: Sunday, April 26, 2020 10:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Appreciation

Dr. Fauci I just wanted to express my profound appreciation to you for your work during this COVID-19 pandemic. I especially appreciate how you have spent considerable time and capital reaching out to the Black and brown communities. I saw excerpts of your snapchat with Will Smith and saw nearly all of your interview on the Breakfast Club. I regret I have to send an email to you re this matter. But this is the day we live in. Minority communities continue to be over-looked in crises and the impact of such crises on their respective communities. For you to be intentional about keeping the minority communities in the loop is commendable, especially since these communities will be absorbing the disproportionate share of the sicknesses and deaths coming from COVID-19.

Thanks for all of what your are doing in keeping the nation informed. Thanks for informing based on the facts, data, and truth.

Take care and "Cover your six."

Email correspondence to and from this address may be subject to the North Carolina Public Records Law and may be disclosed to third parties by an authorized state official.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 13:29:53 +0000
To: Adams, Jerome (HHS/OASH) [REDACTED]; Giroir, Brett (HHS/OASH)
Cc: [REDACTED]
Subject: RE: High touch points

[REDACTED] (b) (5)

From: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 7:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; [REDACTED] (b) (6); Giroir, Brett (HHS/OASH) [REDACTED] (b) (6) >
Cc: [REDACTED] (b) (6)
Subject: Fwd: High touch points

Please see short thread below. Senator Young reached out to me about this and I forwarded to CDC. As I mention [REDACTED] (b) (5)

[REDACTED] Thoughts?

Jerome

VADM Jerome Adams
20th US Surgeon General

Begin forwarded message:

From: "Adams, Jerome (HHS/OASH)" [REDACTED] (b) (6) >
Date: May 3, 2020 at 7:32:46 AM EDT
To: "Jernigan, Daniel B. (CDC/DDID/NCIRD/ID)" [REDACTED] (b) (6) >
Cc: "Schuchat, Anne MD (CDC/OD)" [REDACTED] (b) (6)
Subject: Re: High touch points

Thank you. [REDACTED] (b) (5)

Please keep me posted. And should I refer the senator to you or someone at CDC to close the loop?

Thanks!

J

VADM Jerome Adams
20th US Surgeon General

On May 2, 2020, at 7:08 PM, Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <(b) (6)> wrote:

ADM Adams:

Thanks for sending this. There has been a lot of guidance on disinfection and cleaning, notably some very recent collaborative work we have done with EPA (<https://www.cdc.gov/coronavirus/2019-ncov/community/reopen-guidance.html>). Attached are two documents focused on re-opening America with emphasis on cleaning and disinfection, including high-touch surfaces. Also below are a number of websites that address cleaning and disinfection which point out the importance of disinfecting high-touch locations like doorknobs. They give guidance how to clean them, but they don't address methods for using a paper towel or Kleenex to first turn the knob and then discard the towel. (b) (6)

Thanks
Dan.

Daniel B. Jernigan, MD MPH
Director, Influenza Division; HHS CDC Lead, FEMA-HHS COVID-19 Response
Captain, USPHS (RET)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd NE, Atlanta, GA 30329
Phone (b) (6), Cell (b) (6)
(b) (6) www.cdc.gov/flu

<https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility.html>

<https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/disinfecting-your-home.html>

<https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility-H.pdf>

From: Adams, Jerome (HHS/OASH) <(b) (6)>
Sent: Friday, May 1, 2020 5:35 PM
To: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <(b) (6)>
Cc: Schuchat, Anne MD (CDC/OD) <(b) (6)>
Subject: High touch points

Dr. Jernigan,

I got a message from a Senator asking why we didn't have specific reopening recommendations for "high touch" points like door knobs/ handles/ elevator buttons. The Senator stated that (b) (5)

[Redacted]

[Redacted] I told him I'd follow up with CDC, (b) (5)

[Redacted] Would appreciate your feedback on this.

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

<Reopening_America_Guidance.pdf>

<ReOpening_America_Cleaning_Disinfection_Decision_Tool.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:37:05 +0000
To: Hahn, Stephen;Debi Birx;Redfield, Robert R. (CDC/OD);Verma, Seema (CMS/OA)
Subject: RE: Serology Studies in Germany

Thanks, Steve!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hahn, Stephen (b) (6)>
Sent: Thursday, April 30, 2020 6:34 PM
To: Debi Birx (b) (6)>; Redfield, Robert R. (CDC/OD) (b) (6),
Seema (CMS/OA) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Fwd: Serology Studies in Germany

Interesting information from Germany

From: Shuren, Jeff <(b) (6)>
Date: April 30, 2020 at 5:46:27 PM EDT
To: Hahn, Stephen <(b) (6)>, Shah, Anand (b) (6)>, Lenihan, Keagan
(b) (6)>, Guram, Jeet <(b) (6)>, Rom, Colin
(b) (6)>
Subject: Serology Studies in Germany

FYSA regarding serology studies being conducted in Germany, including status of tests to be used for those studies. This is the follow up to what I sent you last week. (b) (6)

(b) (6)

(b) (6)

From: Hoshi, Ryan <[REDACTED]> (b) (6)

Sent: Thursday, April 30, 2020 3:17 PM

To: Shuren, Jeff [REDACTED] (b) (6)


Cc: Nalubola, Ritu [REDACTED] (b) (6); Louati, Claudia (FSN)* [REDACTED] (b) (6);

O'Leary, Brendan [REDACTED] (b) (6); Torres, Melissa A [REDACTED] (b) (6);

Stenzel, Timothy [REDACTED] (b) (6)

Subject: FW: PLEASE REVIEW >> Meeting Notes - Call with [REDACTED] (b) (5)

(b) (5)





Thank you,
Ryan

Ryan A. Hoshi, Ph.D.

International Policy Analyst | Center for Devices and Radiological Health | (b) (6) | phone

(b) (6) | mobile (b) (6)



Excellent customer service is important to us.

Please take a moment to provide feedback regarding the customer service you have received.

[click here for survey](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 14:14:36 +0000
To: Halkovich, Townshend Connie
Subject: RE: Appreciation to my hero--Dr. Fauci--our country's voice of reason in these unsettling, uncertain times--We NEED YOU!!!! Please don't leave us now when we need you most!!!

Connie:

Many thanks for your kind note. Much appreciated.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Halkovich, Townshend Connie <(b) (6)>
Sent: Monday, April 27, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Halkovich, Townshend Connie (FDA/OC) <(b) (6)>
Subject: RE: Appreciation to my hero--Dr. Fauci--our country's voice of reason in these unsettling, uncertain times--We NEED YOU!!!! Please don't leave us now when we need you most!!!

Where is Dr. Fauci?

I know where Dr. Fauci is—I saw him on SNL—remarkably he looked like Brad Pitt—except [to many of us] Dr. Fauci is better looking. Smile, wink *Why? We look with our hearts*
I remember someone asked Dr. Fauci [in jest] who would he like to represent him in a movie...Dr. F. said Brad Pitt. Well—Dr. F. Your dream suggestion came true. But, in many of our hearts—NO ONE can take the place of our beloved, well respected, honored Dr. Anthony Fauci!!!!

God Bless America, God Bless Dr. Fauci !!!

From: Halkovich, Townshend Connie <(b) (6)>
Sent: Friday, March 13, 2020 11:06 AM

To: 'anthony.fauci@nih.gov' (b) (6)
Cc: Halkovich, Townshend Connie <Constance.Halkovich@fda.hhs.gov>
Subject: Appreciation

Dear Dr. Fauci:

1st & foremost—please keep yourself healthy....get more rest than 3 hrs/night. 😊 Why? We need you!
THANK YOU for all your very informative updates. YOU are voice of reason...in time of coronavirus
fear...you give us hope...saying that action is what is needed...not fear!
You are someone we can be proud of...you provide service we can count on!!!!
God bless You & Your Family!!!

Warmest Regards from:

Connie Leigh Townshend Halkovich, Management Analyst, 410-867-0878,

#FDA/OIMT/DIO Proud: People & Service you can count on! 😊

(b) (6)

*My Wish 4 U: Peace, Love, Laughter — blessed 2 work with U ALL! Abe Lincoln: "Folks are as happy as they choose 2 be" —
happy all circumstances—hope all well with you, yours—if not, pretend it is.*

FDA Mission: Responsible for protecting public health by ensuring safety, efficacy/security of human & vet. drugs, biol. products, med.
devices, our nation's food supply, cosmetics, & products that emit radiation.

DIO Mission: Provide excellent implementation, operation, maintenance of IT (equipment, services) to promote FDA's Public
Health Mission.

DIO Vision: Provide state-of-the-art IT services-inclusive of surrounding policy, planning, customer service, integration, &
oversight necessary to make the mission successful & sustainable.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:26:27 +0000
To: Folkers, Greg (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject: RE: ASF RE: Dr. Fauci video request: Public Service Recognition Week
Attachments: ASF public service recognition - with tracked edits -05-05-2020.docx



See minor tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 6:16 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Awwad, David (NIH/NIAID) [C] (b) (6) >
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF RE: Dr. Fauci video request: Public Service Recognition Week

ASF –

Here is a short script for Public Service Recognition Week. We agreed to do a short video
ASF – can u tweak as needed?
David, could u record in some format that is easy? Cell phone or other I just learned they want by COB tomorrow

<< File: ASF public service recognition.docx >>

From: Seigfreid, Kim (NIH/OD) [E] (b) (6)>
Sent: Monday, April 27, 2020 4:30 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] (b) (6)>; Polimeni, Lydia (NIH/OD) [E] (b) (6)
Subject: Dr. Fauci video request: Public Service Recognition Week

Hi there,

Please see below. HHS is taking over the Partnership for Public Service IG account next week for Public Service Recognition Week. They asked if Dr. Fauci would be willing to do a short 30-second or less pre-recorded video thanking public servants for their work. It would be featured during the takeover, and also on NIH's other sm handles next week. It can be taken on a cell phone as sm does not require higher resolution. Let me know if you would like to accept or decline the request.

Many thanks,
Kim

Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: (b) (6)
(b) (6)

From: Muhammad, Janell (HHS/ASPA) <(b) (6)>
Sent: Monday, April 27, 2020 4:10 PM
To: Seigfreid, Kim (NIH/OD) [E] (b) (6)>; Channer, Amber (OS/OASH) (b) (6)>; Foster, Timothy (OS/ASPA) (b) (6)>
Cc: Palczewski, Andrew (HHS/ASPA) <(b) (6)>; Pratt, Michael (OS/ASPA) <(b) (6)>; Sherman, Jennifer (HHS/OASH) (b) (6)
Wilker, Michael (HHS/ASPA) (b) (6); Dine, Brooke (HHS/ASPA) (b) (6)
Subject: Public Service Recognition Week

Hello All,

Hope everyone is holding up well!

OHR is taking over the Partnership for Public Service (PPS) Instagram account during Public Service Recognition Week (May 3-9, 2020). The OHR team has reached out about wanting to develop a senior leader "mashup" video —perhaps including the DepSec. T

They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and the SG doing a pre-recorded video thanking public servants for their work.

I wanted to gather the troops so we can identify what all is being planned for this week of recognition and provide a POC for OHR if the request is feasible.

Happy to set up a call, if that is needed to discuss further.

Thanks,
Janell

Janell Muhammad

ASPA Digital Engagement (Team Lead)

U.S. Department of Health and Human Services

Email: (b) (6)

Office: (b) (6)

iPhone: (b) (6)

[HHS on Facebook](#) | [HHS on Twitter](#) | [HHS Latino](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 21:58:55 +0000
To: Adams, Jerome (HHS/OASH)
Subject: RE: Update on Sara Alert

What do you mean by [REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6)>
Sent: Tuesday, May 5, 2020 2:49 PM
To: Birx, Deborah L. EOP/NSC <[REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: Update on Sara Alert
Importance: High

Jerome

VADM Jerome Adams, MD, MPH
20th U.S. Surgeon General

From: Jarris, Paul [REDACTED] (b) (6)>
Sent: Friday, May 1, 2020 7:29 PM
To: Adams, Jerome (HHS/OASH) [REDACTED] (b) (6)>
Cc: Wright, Janet (HHS/OASH) [REDACTED] (b) (6)

Subject: Update on Sara Alert

Importance: High

Dear Jerome,

I hope you are well. Thank you for all you are doing to represent public health and our nation. It is very comforting knowing you are informing the nations COVID-19 response.

I wanted to give you an update on called Sara Alert, the software program I am leading at MITRE. Sara Alert is being provided free of any costs and deployed in state, tribal, and local health departments to support public health in contact tracing and active monitoring of individuals in isolation and quarantine. We are engaged with ASTHO, NACCHO, CSTE, and the application is hosted live on APHL's AIMS platform. Sara Alert officially launched on April 3 and is currently supporting multiple jurisdictions including Commonwealth of the Northern Mariana Islands, Danbury, CT, and the State of Arkansas. It is also being rolled out in Washington, Arizona, Pennsylvania, Virginia, Maine and Vermont. We are getting ready to launch in additional jurisdictions over the next couple of weeks.

We have recently responded to questions we were told came from the White House so I wanted to make sure you have background materials. I imagine you are the person that the President and Vice President would turn to for information. I am happy to arrange any briefing materials or demo that would be helpful for you to respond.

As I mentioned previously, Sara Alert is a standards-based, open source tool that automates the process of monitoring individuals exposed to or infected with COVID-19 (or any disease, it's configurable) – and will serve as an enduring national resource to contain disease. Sara Alert is free for use by public health organizations.

Best wishes to you. Stay healthy for all of us.

Paul

ABOUT SARA ALERT

In response to the COVID-19 pandemic, the MITRE Corporation, a not-for-profit that works in the public interest, developed Sara Alert, a standards-based, open source tool in partnership with national public health organizations. Sara Alert **automates the process of monitoring** individuals exposed to or infected with COVID-19 (or any disease, it's configurable) – and will serve as an **enduring national resource** to contain disease. **Sara Alert is free for use by public health organizations.**

- Sara Alert allows public health officials to import and enroll individuals (or households) at risk of developing or infected with COVID-19.
- Individuals enter their symptoms daily via web, text, email or phone, allowing public health officials to focus on high risk and non-reporting individuals.
- The web-based tool enables increased efficiency in tracking cases, leading to earlier containment of the virus and reduction of burden on public health resources.
- Sara Alert is a national system and allows transferal of monitorees across jurisdictions for tighter contact tracing.

Sara Alert launched on April 3 and **is now supporting multiple jurisdictions.**

Sara Alert YouTube Video: <https://youtu.be/!QxAuNsg-RA>

Paul E. Jarris, MD, MBA
Chief Medical Advisor
Health Transformation Center
MITRE Corporation

(b) (6)

(b) (6) Office

(b) (6) Mobile

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:45:26 +0000
To: Lane, Cliff (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]
Cc: Lowy, Douglas (NIH/NCI) [E]; Mascola, John (NIH/VRC) [E]
Subject: RE: Gallo and OPV

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, May 3, 2020 1:22 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>
Cc: Lowy, Douglas (NIH/NCI) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6)>
Subject: Re: Gallo and OPV

Francis,

(b) (5)

Cliff

On May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Hi all,

I'm a bit at a loss to know how to respond to Bob Gallo. [REDACTED] (b) (5)

Francis

From: Gallo, Robert [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 12:07 PM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)
Subject: RE: Your query to Dr. Kadlec

Dear Francis,

It was a pleasure to hear from you, and yes, it has been a long time since we met or even spoke. Moons ago I was set to write to you after reading your wonderful book, but I ended up instead speaking with others about it. I should add at this point that I did not quickly respond to your email of a few days ago because I simply missed it.

It is true that I strongly suggest that OPV be quickly (already it is not quickly) brought forward for induction of a strong innate immune response to prevent or markedly reduce SARS-CoV-2 infection and/or severity until the field obtains a proven safe and efficacious vaccine producing a long lasting, adaptive immunity. OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use and completely safe in a vaccinated population), simple, cheap, rather obvious, yet unique among the massive number of vaccines many (maybe most) of which are the same or at least if not exactly the same aiming at the same mechanism (targeting the spike and searching for the putative correlate of neutralizing Abs.).

OPV should work for a few months and possibly longer. Also it should be working multiple times so I think could cover more than a few months, giving us time for a proven vaccine of adaptive immunity, which might be very long lasting as is hoped.

In the main the WHO comments are correct. Of course we sought and have letters of support from them as well as from many others. Though they are again supportive in their notes to you, there is one item that surprises me. They add that there was no clinical efficacy results as yet. They know or certainly should know that there is plenty of clinical data for this concept with BCG, OPV, and live Measles vaccine. Needless to say this is what turned me on during our regular Global Virus Network (GVN) conference calls. (Incidentally GVN is an organization I have thought of bringing to your attention. I think you would find it impressive and useful). I would be happy to share with you the clinical observations with OPV if you wish.

I would like to take a small diversion, but I suspect you are aware of these things. My colleagues and I respect the WHO because of its representation and because we have colleagues/friends there as well. However, sometimes bureaucracy of a massive degree leads to inaction or even much worse— political expediency. I won't bother you with details of these unless you ask, but I had such experiences with HTLV-1 which we discovered in 1980 as the 1st human retrovirus and which cause not only the highest incidence of cancer (% of infections) of any virus and other fatal diseases as well but mainly in less developed countries (plus Japan) and again with HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in the future because a few at WHO took a position to remove OPV (Sabin) in favor of IPV (Salk) in their polio eradication scheme. It was a huge failure. As my FDA collaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he saved OPV and saved the day and in so doing has produced a still better OPV.

There is indeed data also for BCG as well as live Measles though I know less of the latter. BCG is less available, requires injection, harder to make, not as safe, and we think unlikely to be as effective as OPV. Nonetheless, we favor its use too. The mechanisms will be similar.

You asked whether monkey trials are planned. For several reasons definitely not -- though we are planning some monkey experiments, but not large enough for "clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousands or millions have received OPV safely and in our collective view (and we know the studies pretty well) protection has been clinically shown; 3) In a pandemic we wished to move quickly (so far we must say that has not been achieved). A typical monkey vaccine study will take time, but 4) in this case it would be a huge amount of lost time as monkeys require great doses of polio for infection and monkeys have to be trained to drink their orange juice. It would be hard to imagine that such studies would even give us useful information.

On a final digression Francis I have had 36 years of on/off experiences with glycosylated spike proteins—their analyses immunologically and especially regarding use in vaccines and developing neutralizing Abs. I believe it will be a mistake to put most eggs in that basket. The risks: shortened antibody half life; 2) protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them. Admittedly, they might work, but I trust and hope that not everything is going in this bag. If you wish to discuss this again I will be available.

Finally, I had no idea you were into vaccines or SARS-2 nor any part of CoVID-19 disease, but I am very happy to learn this.

Thanks.

Bob Gallo

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Thursday, April 30, 2020 5:00 PM
To: Gallo, Robert (b) (6) >
Cc: Disbrow, Gary (OS/ASPR/BARDA) <(b) (6)>; Kadlec, Robert (OS/ASPR/IO) (b) (6) >; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6) >; Johnson, Robert (OS/ASPR/BARDA) (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Subject: Your query to Dr. Kadlec

CAUTION: This message originated from a non UMB, UMSON, FPI, or UMMS email system. Whether the sender is known or not known, hover over any links before clicking and use caution opening attachments.

Dear Bob,

It's been quite a while since we've chatted. Bob Kadlec asked me to respond to your query about the possible use of OPV to activate innate immunity and provide COVID-19 protection. Has this been tested in a non-human primate model? I note the recommendation below that says a clinical trial is planned – can you tell me more about that?

As you can imagine, we are all flat out on the vaccine development pathway!

Francis

The use of oral polio vaccine (OPV) to prevent SARS-CoV2 (Polio Eradication Campaign)

There is no evidence that oral poliovirus vaccine (OPV) protects people against infection with COVID-19 virus.

A clinical trial addressing this question is planned in the USA, and WHO will evaluate the evidence when it is available.

In the absence of evidence, WHO does not recommend OPV vaccination for the prevention of COVID-19. WHO continues to recommend OPV as part of essential immunization services to prevent poliomyelitis and as part of global polio eradication efforts.

There are experimental signals from various studies over the years that OPV has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance is unknown. Such non-specific effects may

not be limited to OPV, as other live vaccines have also been associated with non-specific protective effects (such as BCG vaccine against tuberculosis). Nonlive vaccines in contrast do not seem to have the same effects.

The exact mechanism of non-specific protection induced by live vaccines needs to be elucidated further. Clinical studies could begin immediately because the vaccines in question are licensed and have an excellent safety record. Clinical trials involving off-label use of various drugs licensed for other indications are currently underway. The existing scientific rationale suggests that the same should be done for OPV and other live vaccines. A study is currently being discussed with various partners and vaccine manufacturers, including the US FDA, the outcomes of which will be carefully assessed to determine potential use in the context of the spread of SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.

From: Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)
Sent: Thursday, April 30, 2020 10:28 AM
To: Gallo, Robert [redacted] (b) (6); Collins, Francis (NIH/OD) [E]
<[redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Shuy, Bryan (OS/ASPR/IO) [redacted] (b) (6)>
Subject: Re: Response

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

On Apr 30, 2020, at 10:02 AM, Gallo, Robert [redacted] (b) (6)> wrote:

Dear Dr. Kadlec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks, which can be given a second or third time, and with a historical track record of

preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoV-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,

And
Co-founder and International Science Advisor of the Global Virus
Network (GVN)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 15:17:01 +0000
To: Collins, Francis (NIH/OD) [E]; Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Tabak, Lawrence (NIH/DD) [E]
Subject: RE: Response

Francis:

Thanks for the note. I will let Cliff speak for himself, [REDACTED] (b) (5)

[REDACTED] (b) (5)

[REDACTED] (b) (5) but I will let him speak for himself. We can discuss further if you wish.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Thursday, April 30, 2020 10:58 AM
To: Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Subject: FW: Response

Hi John, Cliff, and Tony,

Ignore the silly part of the message below, where (b) (5)
(b) (5). But let me ask you guys whether (b) (5)
(b) (5)
(b) (5)

Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, April 30, 2020 10:55 AM
To: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6); Disbrow, Gary (OS/ASPR/BARDA) (b) (6) >; Johnson, Alfred (NIH/OD) [E] (b) (6)
Subject: RE: Response

Bob,

Dropping Bob Gallo from the thread, but adding Gary and Robert. (b) (5)
(b) (5)
(b) (5)
(b) (5) Please advise.

Francis

From: Kadlec, Robert (OS/ASPR/IO) (b) (6)
Sent: Thursday, April 30, 2020 10:28 AM
To: Gallo, Robert (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6) >; Shuy, Bryan (OS/ASPR/IO) (b) (6)
Subject: Re: Response

Dr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins and Dr Tabak to consider the ACTIV forum they have created to bring industry academia and government to consider scientific base approaches That you have described. Dr Collins has organized a vaccine group and I assess could be the best and fastest place to discuss your concept. I am sure they will connect with you soonest

Best

Bob Kadlec.

Sent from my iPhone

On Apr 30, 2020, at 10:02 AM, Gallo, Robert [REDACTED] <[REDACTED]> wrote:

Dear Dr. Kadlec,

I have not heard from you in over a week. You mentioned getting back to me in a day or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as a bivalent, completely safe vaccine with powerful stimulation of innate immunity lasting several weeks, which can be given a second or third time, and with a historical track record of preventing other infections from entirely different RNA viruses (such as protecting against influenza). Therefore, it should be really helpful for some months, and I think get us past a second wave of SARS-CoV-2, and help people return to work safely. I don't understand delays or apparent lack of interest. Who can possibly be against this? If you hear of hypothetical problems we can show you that these are false. Just ask the questions, and we can give you the evidence.

However, no answer from you suggests no interest and must quickly make alternative pathways. I am though quite surprised and fear you are receiving "fake news" if you will pardon the expression. Some have been against this who defend their old and failed position on polio eradication with their promotion of the use of the inactivated polio virus vaccine. Please note that in the US between 1962 and 1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated already there has not been a single case of a complication and BILLIONS have received it. No it will not last long as innate immunity is short lived, but we strongly believe that we can break the back of the SARS-CoVID-2 spread. Also note that this is what Bill Gates is doing now in India and much of the Eastern hemisphere.

There are countries outside the US wanting to move fast on this. We are waiting for your reply.

Robert Gallo
Director, Institute of Human Virology,
Professor of Medicine and Professor of Microbiology,
UMB, School of Medicine, Baltimore,

And

Co-founder and International Science Advisor of the Global Virus Network (GVN)

From: (b) (6)
Sent: Wed, 29 Apr 2020 13:39:44 -0400
To: Billet, Courtney (NIH/NIAID) [E]
Subject: Fwd: ASF: For review ASAP: draft Sec. Azar Remdesivir statement
Attachments: 4 29 20 remdesivir.docx, ATT00001.htm

Cannot do right now. Go without me

Begin forwarded message:

From: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)
Date: April 29, 2020 at 1:11:19 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Cc: "Routh, Jennifer (NIH/NIAID) [E]" <(b) (6)>, "Stover, Kathy (NIH/NIAID) [E]" (b) (6), "Lane, Cliff (NIH/NIAID) [E]" (b) (6), "Marston, Hilary (NIH/NIAID) [E]" (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Folkers, Greg (NIH/NIAID) [E]" (b) (6)>
Subject: ASF: For review ASAP: draft Sec. Azar Remdesivir statement

From: Fritz, Craig (NIH/OD) [E] (b) (6)
Sent: Wednesday, April 29, 2020 10:38 AM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)
(b) (6) Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] (b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Fine, Amanda (NIH/OD) [E] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] (b) (6)>; NIH News Clearance (NIH/OD) <NIHNewsClearance@mail.nih.gov>
Subject: FW: For review ASAP: draft Sec. Azar Remdesivir statement
Importance: High

Hi all – please let us know if you have any comments to the attached.


Thanks!
Craig

From: Brennan, Patrick (OS/ASPA) (b) (6)>
Sent: Wednesday, April 29, 2020 10:33 AM
To: Fritz, Craig (NIH/OD) [E] (b) (6)>; Burklow, John (NIH/OD) [E] (b) (6)>; Myles, Renate (NIH/OD) [E] (b) (6)>; Fine, Amanda (NIH/OD) [E] (b) (6)>; Wojtowicz, Emma (NIH/OD) [E] (b) (6)>; Charrow, Robert (HHS/OGC) (b) (6)
Cc: Pence, Laura (HHS/ASL) (b) (6)>; Hall, Bill (HHS/ASPA) (b) (6)>; Pratt, Michael (OS/ASPA) (b) (6)>; Blakeman, Scott (OS/ASPA) <(b) (6)>
Subject: For review ASAP: draft Sec. Azar Remdesivir statement

NIH and Mr. Charrow,

Below and in the attached is a draft statement from the Secretary regarding the Remdesivir trial – please let me know as soon as you can if this looks OK. (I pulled the frontmatter from the NIH press release.) Thank you!

- Patrick



Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: (b) (6) | Cell (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Apr 2020 01:56:42 +0000
To: (b) (6)v
Subject: FW: DRAFT document for WH Briefing Tomorrow
Attachments: Development-Medical-Countermeasures-WH-Briefing 29 April.pptx

Here it is.

From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Tuesday, April 28, 2020 8:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: DRAFT document for WH Briefing Tomorrow

Hi Tony,

I called Paul to (b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)

Francis

From: Mango, Paul (HHS/IOS) <(b) (6)>
Sent: Tuesday, April 28, 2020 7:26 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Marks, Peter (FDA/CBER) (b) (6); Woodcock, Janet (FDA/CDER) (b) (6)>; Tromberg, Bruce (NIH/NIBIB) [E] (b) (6)
Subject: DRAFT document for WH Briefing Tomorrow

Thank you all for your timely responses for contributions to this today. Please give this a look and let us know if there is anything glaringly out of place. We will have time to address edits during and after our 930am check in tomorrow. The Secretary may or may not use page 1 during his introductory remarks.



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 18:14:04 +0000
To: Gibbons, Gary (NIH/NHLBI) [E]
Cc: Koroshetz, Walter (NIH/NINDS) [E]; (b) (6); Auchincloss, Hugh (NIH/NIAID) [C]; (b) (6); Collins, Francis (NIH/OD) [E]; (b) (6); Tabak, Lawrence (NIH/OD) [E]; Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: Thrombotic phenomena in COVID-19

Gary:

In follow-up of our recent conversation regarding the growing evidence that the extremely catastrophic course of many patients with COVID-19 seems to be pathogenically associated with the findings of microthrombi in the lungs and often a multisystem process resembling DIC. In addition, there have been growing numbers of cases of individuals (some young and otherwise healthy) who have had unexplained strokes, only to find out that they actually have COVID-19. (b) (6)

(b) (6)

(b) (6) Thanks.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 17:42:12 +0000
To: NIAID OD AM
Subject: FW: Invitation to Webinar as keynote speaker.

I wouldn't think so.

From: Secretary ARP [REDACTED] (b) (6)>
Sent: Saturday, April 25, 2020 2:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Invitation to Webinar as keynote speaker.

To,
Anthony S. Fauci,
Office of the Director,
National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 9000 Rockville Pike, Bldg 31, Room 7A03,
Bethesda MD 20892

Subject: Invitation to Webinar as keynote speaker.

Dear Sir,

On behalf of ASSOCIATION OF REGISTERED PHARMACIST (An association working for Pharmacy Profession and having more than 2000 members) in collaboration with Divine International, Gwalior (A Pioneer Pharmacy Institute) I am pleased to invite you to our Webinar having THEME "CHALLENGES AND OPPORTUNITIES FOR PHARMACIST IN THE PRESENT EPIDEMIC COVID-19" that will be held from 2nd May 2020 to 3rd May 2020. This Webinar is the get together of Pharma professionals through the web. The vision of this Webinar is to Aware, Prepare and strengthen our Pharmacy professionals in our country to this epidemic COVID-19 for present and future aspect and exports more realistic ideas and present scenario of this epidemic COVID-19.

You are one of the legends of Pharma Expert of our country, it is a great privilege for us to see if you share your experience with us, we really expect and want that you join our Webinar and share with us the great experience of your life, we want to learn something from you so that we can create a great ideas, opportunity, and roll of Pharma professional for our country in the present scenario.

We would be pleased to have you present at this point at this webinar to listen to what the role and importance in the Pharmacist advancement and their impact on our society and daily life we would also love to hear your thoughts and opinion about the Pharma professional that is a dream of our pharmacy fraternity.

Therefore you are requested to send your recorded Lecture/presentation of 30-40 min

Sincerely,

—
Thanks

Rajesh Singh Jadon
Secretary (National)
Association of Registered Pharmacists
Gwalior MP
Mob: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 15:43:25 +0000
To: [REDACTED] (b) (6)
Subject: RE [REDACTED] (b) (6), (b) (4)
Attachments: [REDACTED] (b) (6), (b) (4)

From: [REDACTED] (b) (6) >
Sent: Sunday, April 26, 2020 11:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: [REDACTED] (b) (6), (b) (4)

To work on at home

From: Ulrich, Connie M [REDACTED] (b) (6)
Sent: Saturday, April 25, 2020 2:35 PM
To: Cynda Rushton [REDACTED] (b) (6) >; [REDACTED] (b) (6)
Subject: [REDACTED] (b) (6), (b) (4)

Hi Christine and Cynda,

I finished my section and unfortunately have to keep changing the COVID numbers! I will add some thoughts to the last section. Not sure how much we can add there but maybe some reflections would be helpful. Enjoy the sunshine today!!

Best,
Connie

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 02:57:31 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Bcc: Mascola, John (NIH/VRC) [E] (b) (6)
Subject: RE: agenda for Kadlec et al., Sun noon meeting

Francis:

Sorry that I took so long to respond.

(b) (5)

(b) (5)

(b) (5) Let us connect

by phone first thing in the AM>

Thanks,

Tony

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Saturday, April 25, 2020 2:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>
Subject: RE: agenda for Kadlec et al., Sun noon meeting

(b) (5)

From: Collins, Francis (NIH/OD) [E]
Sent: Saturday, April 25, 2020 2:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>
Subject: agenda for Kadlec et al., Sun noon meeting

Hi Tony and Larry,

For the meeting tomorrow at noon (currently invitees are Kadlec, Disbrow, Johnson, Woodcock, Marks, and us three), I would propose the following framework:

(b) (5)



(b) (5)

Thoughts? Tony, should

(b) (5)

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Apr 2020 01:22:21 +0000
To: Corey MD, Larry
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (6)

Let us talk tomorrow (Sunday). I am sorry that I did not get back to you today.

From: Corey MD, Larry [REDACTED] (b) (6)
Sent: Saturday, April 25, 2020 5:36 PM
To: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6); Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)
Subject: Re: [REDACTED] (b) (6)

Agree. [REDACTED] (b) (6)

Sent from my iPhone

On Apr 25, 2020, at 1:59 PM, Mascola, John (NIH/VRC) [E] <[REDACTED] (b) (6)> wrote:

[REDACTED] (b) (6) seem reasonable

Sent from my iPhone

On Apr 25, 2020, at 15:54, Corey MD, Larry [REDACTED] (b) (6) wrote:

A do have to say I am surprised . but ok

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Saturday, April 25, 2020 12:53 PM
To: Corey MD, Larry [REDACTED] (b) (6); Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6) >
Cc: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >
Subject: Fwd: New England Journal of Medicine 20-13479

Let us discuss next steps

Begin forwarded message:



(b) (6)

From: (b) (6)
Sent: Sat, 25 Apr 2020 13:05:04 -0400
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]
Subject: Re: White House Task Force Briefing Monday

(b) (5)

On Apr 25, 2020, at 11:42 AM, Collins, Francis (NIH/OD) [E]

<(b) (6)>

Judy Stecker called. Said there's a separate (b)(5) - PCP

(b) (7)
(b) (7)
(b) (7)

FC

From: Collins, Francis (NIH/OD) [E]
Sent: Saturday, April 25, 2020 10:36 AM
To: (b) (6)(OS/IOS) (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Pence, Laura (HHS/ASL) <(b) (6)>; Harrison, Brian (HHS/IOS) (b) (6)>; Wood, Gretchen (NIH/OD) [E] (b) (6) McManus, Ayanna (NIH/OD) [E] (b) (6)
Subject: FW: White House Task Force Briefing Monday

Hi Mr. Secretary,


Please see below for a (b)(5) - PCP
(b) (7) Glad to speak with you about how best to handle, if
you have advice. (b) (6)

Francis

(b)(5) - PCP







From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 14:25:16 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Italy Covid-19

La Stampa is one of the two most important newspapers in Italy.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mastrolilli Paolo <Paolo.MASTROLILLI@lastampa.it>
Sent: Friday, April 24, 2020 10:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Italy Covid-19

Dear Doctor Fauci,

My name is Paolo Mastrolilli, I am the US Bureau Chief for the Italian daily La Stampa. I am writing because we would appreciate very much the opportunity to have a phone or written Q&As interview with you to discuss the Covid 19 pandemic. Considering the difficult situation Italy is experiencing, the help President Trump is sending to Italy, and the plan to open America again, it would be very helpful for Italy to hear from your experience and competence to address the Covid 19. We think that your advices would be very helpful to help our country and our citizens in dealing with the pandemic.

We understand that you are very busy and this request has no deadline.

La Stampa is a leading Italian daily, it is owned by the Agnelli Elkann family, owner of Fiat Chrysler as well.

I am also a contributor for the Vatican Radio and the official news portal of the Holy See, I would share the interview with them as well, if you like.

My cellphone number is (b) (6)

Please let me know if you need any further information.

Best regards

Paolo Mastrolilli

Il presente messaggio (inclusi gli allegati) contiene informazioni riservate esclusivamente al destinatario/ai destinatari indicato/i nel messaggio, ed è protetto dalla legge. La diffusione, distribuzione e/o la copia del contenuto del presente messaggio da parte di qualsiasi soggetto diverso dal destinatario è severamente vietata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei dati personali. Se non siete i destinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immediata comunicazione inviando un messaggio di ritorno all'indirizzo e-mail del mittente.

This message (including any attachments) contains confidential information intended only for the recipient(s) named above, and is protected by law. Any disclosure, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art. 616 c.p. and to the applicable data protection laws. If you are not the intended recipient, please delete this message and inform us immediately about the deletion by sending a message to the sender's e-mail address.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 10:33:49 +0000
To: Holland, Steven (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Successful Submission of a Manuscript to Science (abc4208)

Thanks, Steve.

-----Original Message-----

From: Holland, Steven (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 23, 2020 11:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: FW: Successful Submission of a Manuscript to Science (abc4208)

This is the acalabrutinib paper today submitted to Science. NEJM was interested but wanted a month delay to be sure about the results but some of the authors (Not the NIAID one) balked and have gone elsewhere. Just keeping you in the loop.

Steve

--

Director, Division of Intramural Research National Institute of Allergy and Infectious Diseases National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960
(b) (6) voice
301-480-4507 fax
(b) (6)

Assistant lab: Eva Portillo
(b) (6)
(b) (6) voice

Assistant to SD: Beth Schmidt
(b) (6)
(b) (6) voice

On 4/23/20, 1:59 PM, "Lionakis, Michail (NIH/NIAID) [E]" (b) (6) > wrote:

Attached the submitted paper, which will be deposited to MedRxiv.org today I think.
Mihalis

On 4/23/20, 1:34 PM, "science_editors@aaas.org" <science_editors@aaas.org> wrote:

Manuscript Title: Inhibition of Bruton Tyrosine Kinase in Patients with Severe Covid-19
Author: Lionakis
Manuscript Number: abc4208

Dear Dr. Lionakis:

You are listed as a coauthor on the above manuscript, which has recently been submitted to Science.

According to Science policy, all authors must have seen and approved the submission of their manuscript. If you have seen the manuscript and approved its submission, no action is necessary.

If you have not read this paper or do not approve its submission to Science, please let us know as soon as possible. Please refer to the manuscript number listed above in any correspondence (you can just reply to this message).

You can see the status of your manuscript at any time by logging into your account at the Science Journals Submission and Information Portal at <https://cts.sciencemag.org>.

If you do not yet have an account, please go to <https://cts.sciencemag.org/scc/#/forgot-password> and use the email at which you received this correspondence because that is linked to your manuscript. Then, follow the prompts to set your password and login. After login, you can access your manuscript and monitor its status.

Once you are registered, we encourage you to link your account to your ORCID ID, an identifier that facilitates the correct attribution of your publications to you. To learn more about ORCID or to obtain an ORCID ID, visit their site at: <http://orcid.org>.

Your manuscript is now undergoing an initial screening to determine whether it will be sent for in-depth review. If the manuscript is sent to review, its status will change to "To Review".

Sincerely,
The Editors
Science

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:58:36 +0000
To: Greg Folkers (b) (6)
Subject: FW: HIVR4P postponed to 17-21 January 2021

FYI. See yellow highlighted request.

From: HIVR4P - Secretariat <secretariat@hivr4p.org>
Sent: Thursday, April 23, 2020 11:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] (b) (6) >
Subject: HIVR4P postponed to 17-21 January 2021



Dear Dr. Fauci,

As the research community responds to the global challenges of the COVID-19 pandemic, HIV prevention science matters as much as ever. Our priority as organizers of the HIV Research for Prevention (HIVR4P) conference remains the safety and wellbeing of all participants.

After careful consideration, we have decided to postpone the HIVR4P conference to **17-21 January 2021**. Updated details for the session(s) are listed below:

Session title:	HIV prevention 2020 – Where are we now and where are we going?
Session type:	Opening plenary
Suggested presentation title/topic:	Much accomplished; Much to do – An overview on HIV prevention research
Session description:	Today's plenary sets the stage for the conference week ahead, outlining the big-picture challenges we face in research, product development and access to prevention. Speakers will provide diverse perspectives on the state of the field today, the opportunities and obstacles ahead and priorities for action moving forward.
Session date and time:	Monday, 18 January 2021 - 16:00-18:00

Meet the Experts lunches

We invite you to host an informal table discussion at a Meet the Experts lunch on **20 January 2021, 12:00-13:00**. Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges and HIV-affected communities.

Please reply to this email by Wednesday, 6 May if you are still available to deliver this important presentation and, if so, please also include a photo and a brief biography.

We are acutely aware many researchers and research organizations with critical studies and submissions to HIVR4P are now also heavily engaged in the COVID-19 response. Our hope is that postponing the conference, rather than presenting it virtually in October, will allow for the broadest participation to foster knowledge-exchange, debate and direction-setting in the field of HIV prevention research that HIVR4P is known for.

Thank you for your consideration.

Sincerely,

HIVR4P - Secretariat
HIV Research for Prevention

W: (b) (6)
Avenue de France 23 | CH-1202 Geneva | Switzerland

HIVR4P Conference | 17-21 January 2021 | Cape Town, South Africa



HIVR4P.org



[@HIVR4Px](https://twitter.com/HIVR4Px)



[/HIVR4P](https://www.facebook.com/HIVR4P)

From: HIVR4P - Secretariat
Sent: 21 February 2020 16:57
To: (b) (6)
Cc: Bargavi Thyagarajan (b) (6)
Subject: HIVR4P 2020 - Invitation to present



HIV RESEARCH
FOR PREVENTION

CAPE TOWN, SOUTH AFRICA - 11-15 OCTOBER 2020

Dear Dr. Fauci,

We are writing with great pleasure to invite you to present at the 4th HIV Research for Prevention Conference ([HIVR4P 2020](#)) in Cape Town, South Africa, from 11-15 October 2020. HIV Research for Prevention is the only global scientific conference focused exclusively on the challenging and fast-growing field of HIV prevention research. HIVR4P fosters interdisciplinary knowledge-exchange on HIV vaccines, microbicides, PrEP, treatment as prevention and biomedical interventions as well as their related social and behavioural implications.

Details for the session(s) are listed below:

Session title:	HIV prevention 2020 – Where are we now and where are we going?
Session type:	Opening plenary
Suggested presentation title/topic:	Much accomplished; Much to do – An overview on HIV prevention research
Session description:	Today's plenary sets the stage for the conference week ahead, outlining the big-picture challenges we face in research, product development and access to prevention. Speakers will provide diverse perspectives on the state of the field today, the opportunities and obstacles ahead and priorities for action moving forward.
Session date and time:	Monday, 12 October 2020 - 16:00-18:00

Meet the Experts lunches

We invite you to host an informal table discussion at a Meet the Experts lunch on **14 October 2020, 12:00-13:00**. Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges and HIV-affected communities.

As an invited-speaker, you would be eligible to receive:

- Complimentary conference registration;
- Roundtrip economy airfare arranged through the HIVR4P travel agency; and
- Accommodation at one of the hotels pre-blocked by the conference secretariat.

To accept this invitation, please reply to this email by **Thursday, 27 February** and include a photo and a brief biography. Please find also attached for your record the official invitation signed by the HIVR4P 2020 Co-Chairs.

We ask that you please send any questions to the HIVR4P Secretariat at secretariat@hivr4p.org.

Thank you for your consideration. We look forward to you joining us in Cape Town!

Sincerely,

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 01:30:49 +0000
To: blonda quirico
Subject: RE: estimation of dynamics of COVID-19 in USA new simulations at 23 April 2020

Thanks.

From: blonda quirico <(b) (6)>
Sent: Thursday, April 23, 2020 5:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; COPPIETERS' WALLANT Yves (b) (6)>
Subject: estimation of dynamics of COVID-19 in USA new simulations at 23 April 2020

Tony,

We send you our simulations.

Best regards.

Quirico

Le mercredi 22 avril 2020 à 00:09:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> a écrit :

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: blonda quirico (b) (6)
Sent: Tuesday, April 21, 2020 11:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); COPPIETERST WALLANT Yves (b) (6)>
Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 21 April 2020

Tony,

Professor COPPIETERS and I, we send you our new simulations :

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = more than 850610 people infected and detected;
- date of epidemic peak = +/- 7 April 2020 with theoretical new cases - in one day during this peak - about +/- 35520;
- end of epidemic = +/- 19-28 June 2020 (we use two methods);
- mortality at the end of epidemic :
- ** if death rate 5% = +/- 42.530 deceased people (for the moment the death rate = 5%)
- ** if death rate 10% = +/- 85.060 deceased people

You reached 91,1 % of the theoretical logistic curve.

Best regards.

Quirico

00 32 475 48 68 42

Le dimanche 19 avril 2020 à 15:57:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> a écrit :

Quirico:

Thanks again! Please keep this information coming to me.

Best regards,

Tony

From: blonda quirico (b) (6) >
Sent: Sunday, April 19, 2020 5:04 AM
To: Fauci, Anthony (NIH/NIAID) (E) (b) (6) >; COPPIETERS'T WALLANT Yves (b) (6)
Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 18 April 2020

Tony,

We send you our new simulations.

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = more than 779000 people infected and detected;
- date of epidemic peak = +/- 7 April 2020 with theoretical new cases - in one day during this peak - about +/- 35063;
- end of epidemic = +/- 4-13 June 2020 (we use two methods);

- mortality at the end of epidemic :

** if dead rate 5% = +/- 40000 deceased people

** if dead rate 10% = +/- 80.000 deceased people

You reached 87.5 % of the theoretical logistic curve.

Best regards.

Quirico

00 32 475 48 68 42

Le lundi 6 avril 2020 à 03:32:35 UTC+2, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> a écrit :

Dr. Blonda:

Thank you for sending me this information. I appreciate it.

Best regards,

Tony

From: blonda quirico (b) (6)
Sent: Sunday, April 5, 2020 9:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; COPPIETERST WALLANT Yves (b) (6)>
Subject: estimation of dynamics of COVID-19 in USA

Professor Anthony FAUCY,

Sorry to disturb during the COVID-19 in USA.

But I would you inform about the COVID-19 in USA.

I'm medical doctor in Belgium.

With my teacher Professor Yves COPPIETERS (Ecole de santé publique - ULB - Brussels), we make simulations about the COVID-19 for many countries.

In summary, the USA COVID-19 epidemic model says :

- the final size of epidemic = +/- 462760 people infected and detected;
- date of epidemic peak = +/- 1- 2 April 2020 with theoretical new cases - in one day during this peak - about +/- 28390;
- end of epidemic = +/- 15 May 2020;
- mortality :
- ** if dead rate 5% = +/- 23140 deceased people
- ** if dead rate 10% = +/- 46275 deceased people

If you are interested by our simulations, you can contact us.

Best regards.

Dr Quirico BLONDA

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Apr 2020 00:50:12 +0000
To: [REDACTED] (b) (6)
Subject: FW: The Tablet I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

You have got to read this!!!

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Thursday, April 23, 2020 7:21 PM
To: NIAID COG CORE <COG CORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: The Tablet I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

<https://thetablet.org/only-in-print-dr-faucis-roots-in-dyker-heights/>

ADVERTISE / CLASSIFIEDS / CONTACT US

THE TABLET

Search GO

NEWS

OPINION

PAPERS

SCHOOLS

SPORTS

AROUND THE EPISCOPY

CLASSIFIEDS

COVID-19

Only in Print: Dr. Fauci's Roots in Dyker Heights

April 8, 2020



Dr. Anthony Fauci meets with Regis High School students and the school's president, Father Daniel Lahart (r.), in 2019. Fauci (whose family owned a neighborhood pharmacy in Dyker Heights) is a 1950 graduate of the Jesuit school. (Photo: courtesy of Fauci family)

CATHOLIC NEWS SERVICE

Religious education continues in different format during pandemic

Bishops in Atlanta urge Pelosi to guard indigenous lands during pandemic

April 15, 2020
Volume 15

From the Neighborhood by Frank DeRosa

Frank DeRosa retired as Associate Publisher of The Tablet and director of the Diocesan Public Information Office in 2008

When I see Dr. Anthony Fauci on the TV screen explaining expertly everything we need to know about the coronavirus pandemic, I find myself thinking back to his father, Stephen Fauci, whose drugstore our family relied on back in the 1950s.

Steve Fauci was the neighborhood pharmacist.

The Fauci Pharmacy stood on the southwest corner of 13 th Ave. and 83 rd St., in the Dyker Heights section of Brooklyn, diagonally across from the Shrine Church of St. Bernadette. We lived two blocks away on 85 th .

Long ago parishioners like me remember what the store looked like, the soda fountain that ran along the right wall, the telephone booths at the left close to the entrance and the counter straight ahead down the center.

Whenever my mother sent me there, Mr. Fauci would be behind the counter, but it was a family enterprise. They lived in an apartment above the store, and if the patriarch wasn't serving you, his wife, Eugenia, or daughter, Denise, was there. Young Anthony, I've since learned, pitched in too, his father sending him out on his bike to deliver items to customers.

I've never met the man who has become the most important medical voice in the country. Nor have former parishioners that I've spoken to about him in recent days, like boyhood pals Anthony LoFrisco, from 80th St., now in Connecticut, and Bob Orlando, who lived on 84th, now a New Jersey resident, as well as Bishop Gerald Barbarito of the Palm Beach Diocese, from 11th Ave. But each remembers the pharmacy as a Dyker Heights institution.

While we don't know him personally, in a sense he's become everyone's friend. With his steady television presence, he's imparted his vast knowledge and straightforward advice in a trademark, sometimes gravelly or raspy, Brooklyn accent that has endeared him to people far and wide. You can't be anything but proud of someone of his prominence who came from the parish.

Anthony became known as Tony, as he tells it, when Father Flanagan, principal of Regis High School, decided to call him that on his first day as a freshman. The name stuck.

Tony took buses and trains to the Jesuit school in Manhattan, including the old Sea Beach Express. He traveled 70 minutes each way, did three hours of homework, captained the basketball team and excelled in the classroom.

I remember hearing that when Tony was a high schooler, he had a part-time job working in St. Bernadette's rectory, answering the phone and doing whatever else parishioners wanted him to do to put them in touch with one of the parish priests. In those days, the rectory had a priestly bonanza. There

were four of them.

Because St. Bernadette's School had not yet been established, Tony went to Our Lady of Guadalupe School, where he was taught by Dominican Sisters. It was, and is, St. Bernadette's neighboring parish.

Like most kids, he loved sports. He played CYO baseball and basketball. At Dyker Park on 86th St., he and his friends developed skills in imitation of their heroes. A Yankee follower living in the midst of Brooklyn Dodgers fans who adored The Boys of Summer, he's said his favorite players were Joe DiMaggio and Mickey Mantle.

Tony's father and mother married at 18, after they graduated from New Utrecht High School. Steve went on to Columbia to study pharmacy.

Sometime after he opened his pharmacy, he became friends with Father Al Varriale, one of St. Bernadette's beloved parish priests. At one point, Steve, as a parent, and the priest known as Father V, who directed the parish's robust CYO sports program for youths, shared a concern. It was the easy availability of indecent

and immoral publications that they knew was a threat to the moral development of young people.

So, with the approval and support of the Diocese of Brooklyn, together they formed a diocesan commission against pornography. Both men are now long gone, and so is the commission, but it was a good idea, though it did not survive them.

Remarkably, just a few houses up the block from where Steve established his pharmacy, lived the Pellegrinos, another family of St. Bernadette's parishioners that produced a renowned medical professional. The eldest son, Edmund, became a bioethicist, a "preeminent" one, as one newspaper described him after he died. But he was more. He helped develop medical programs at Kentucky, Stony Brook and Tennessee Universities. Later, he took on the presidency of The Catholic University of America. Then, after completing his tenure there, he became, as physician and philosopher, the director of the Kennedy Institute of Ethics at Georgetown University.

Though years apart in age, both Dr. Fauci and Dr. Pellegrino became Hippocratic stars, nurtured on the same block.

Only in Brooklyn, I say, not without bias.

Steve Fauci was known by members of his extended family and friends for his personality, kindness, sense of humor and wit, and for telling good stories. So they said in comments after he died in 2008.

Tony appears to have inherited Steve's gene for lightheartedness. His daughter once told the Washington Post that her dad could be a "goofball. . .he works hard and does his thing, but he comes home and he's singing opera in the kitchen and dancing around."

That kind of calm can help a man maintain his balance as he deals with the pressure of talking to millions of people every day about the complexity of a global pandemic.

As one newsman said, "When Fauci appears on the screen, you turn up the volume."

He once said the Jesuits at Regis and Holy Cross College taught him the importance of "precision of thought and economy of expression."